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ABSTRACT 
Cysteine proteinase inhibitors have shown potential as biocontrol agents for the protection of plants against 
insect and pathogen attack. With the advent of protein and genetic engineering such inhibitors can now be 
modified in order to improve their effectiveness. Because cystatins have already been isolated from plants. 
they provide a good starting point for developing modifications which may improve their function as 
biocontrol agents. The purpose of this project, therefore, was to design a potentially improved analogue of the 
rice cysteine proteinase inhibitor, oryzacystatin I, through molecular modelling studies. The gene sequence for 
this modified protein was then synthesised and expressed for kinetic analysis and insect trial assays. 
A prediction of the oryzacystatin I (OC I) tertiary structure was made using Biograf software on an Evans and 
Sutherland workstation. This structure was based on the known structures of stefin B and chicken cystatin 
\\·hose co-ordinates are published in the Brookhaven data files . Chicken cystatin is one of the most potent 
inhibitors of papain in the cystatin superfamily. This is believed to be due, in part, to an increased binding of 
the cystatin to papain through its amino-terminal region with the residues Leu7 to Gly9 playing a particularly 
important role. 
In order to determine whether the chicken cystatin N-terminal sequence could enhance the binding of OC I to 
papain, the amino-terminus of chicken cystatin was substituted for the OC IN-terminus. Such manipulations 
of the protein structure. it was hoped, would give some insight into the interactions of cystatins in the amino-
terminus . The rest of the OC I sequence remained wunodified and three models suggesting possible structures 
fo r this ' hybrid ' inhibitor were designed. 
For synthesis of the gene, the amino acid sequence of this ' hybrid ' inhibitor was back translated to a 282-bp 
gene sequence using E. coli codon usage. Since this gene was too long to be synthesised in a single step on an 
automatic DNA synthesiser, the gene sequence was scanned for unique restriction sites or these were generated 
by modifications of the codon usage. This enabled division of the gene into smaller sections. Cloning of this 
gene proved problematic as a result of errors in the sequence that arose as a result of inefficient DNA 
synthesis. A number of methods were therefore explored to purify the full length DNA sequences from the 
truncated sequences. These methods included HPLC purification and the use of biotin-labelled primers for 
purification using streptavidin Dynabeads. These techniques, as well as the use of larger controlled pore glass 
columns for synthesis and a division of the gene into four parts, resulted in the successful synthesis of this gene 
which was then cloned into pUC18. 
Protein expression of the hybrid oryzacystatin (HO) gene was achieved using the pMAL vector system. In 
these vectors, the gene is cloned 3' to the sequence which codes for the E. coli maltose binding protein (MBP). 
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CHAPTER 1 
Literature Review: Cysteine Proteinases and their Inhibitors 
1.1 Introduction 
Proteases and their inhibitors are a widespread group of proteins which occur naturally in many different 
physiological systems. These include digestion, blood clotting, fertilisation and seed germination. These 
proteins have also been implicated in the processing and inactivation of peptide hormones, in tumour 
metastasis and in cellular invasion (Polgar et al., 1986). 
Proteases or proteinases act by cleaving peptide bonds. Because of the large number of enzymes that function 
in this way, there has often been some confusion in the terms used to describe them. Barrett & McDonald 
( 1986) have provided the following clarifying definition: 
The term protease is used to describe a peptide bond hydrolase that may be either an endopeptidase or 
an exopeptidase . The term 'proteinase,' on the other hand, refers exclusively to the endopeptidases. 
The relationship between these terms is illustrated below: 
I 




Endo-acting peptide bond hydrolase 
Endopeptidase 
( =Proteinase) 
(from Barrett & McDonald, 1986) 
I 
Exo-acting peptide bond hydrolase 
Exopeptidase 
This review will focus on the endopeptidases since firstly, the large majority of proteases are endo-acting 
peptidases and secondly this project deals with a cysteine endopeptidase inhibitor from rice seeds, namely 
oryzacystatin I. Hence the term 'proteinase' will be used. This review will also discuss very briefly the 
various characteristics of the different classes of proteinases. Emphasis will be placed on the cysteine 
proteinases and their inhibitors since the oryzacystatin inhibitor used in this study belongs to this class. 
Furthermore, with the advent of protein engineering, it is possible to modify the structures of protein inhibitors 
to improve their inhibitory capabilities against target enzymes. This review will thus discuss the potential of 
cysteine proteinase inhibitors (cystatins) to act as agents against viruses and human parasites, and to serve as 
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1.2 Classification of Proteinases into their Different Mechanistic 
Classes 
Proteinases can be classified according to: 
( 1) their catalytic mechanisms 
(2) the pH range over which they are active (i.e. acid, neutral or alkaline) 
(3) their ability to hydrolyse specific proteins (keratinase, elastase, collagenase etc.) 
( 4) their sensitivity to specific inhibitors (North, 1982; Barrett, 1986). 
Based on these criteria, several mechanistic classes of proteinases have been recognised. These include the 
serine. cysteine, aspartic and metallo-proteinases whose different characteristics and properties are shown in 
Table 1.1. 
Table 1.1: The four classes of proteinases and their different properties (adapted from North, 1982 and Barrett 
et al. , 1986) 
Proteinase Example Active Site Residue 
Serine Chymotrypsin Serine 
(EC 3.4.21) Trypsin Histidine 
Elastase 
Cysteine Pa pain Cysteine 
(EC 3.4.22) Cathepsins L, B, H, Histidine 
and S 
Cal pain 
Aspartic Cathepsin D Two Aspartic Acid 
(EC 3.4.23) Penicillopepsin Residues 
Metallo Thermolysin Metal , usually Zinc 
(EC 3.4.24) Collagenases 
3L-trans-epoxysuccinyl-leucylamido( 4-guanidino )butane 
bethylenediaminetetra-acetic acid 
pH Range Inhibitors 
7.0 - 10.0 Bowman-Birk 
Kunitz 
Lima bean 
5.0 - 7.0 Cystatins 
E-643 
Iodoacetate 
Below 4.5 Pepstatin 
7.0 EDTA0 
This table shows that each class of proteinase has distinct characteristics and is inhibited by a number of class 
specific inhibitors. In general proteinase inhibitors act by binding to the active site of the proteinase to inhibit 
proteolytic activity. The inhibitors achieve this by preventing access of substrates to the proteinase catalytic 
site through steric hindrance. Only a small portion of the inhibitor ' s structure, the 'inhibitory' site, is involved 
in binding directly to the proteinase (Creighton & Darby, 1989). 
Some proteinase inhibitors, however, are able to act on more than one type of proteinase, i.e. they have 'dual ' 
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well as many cysteine proteinases (Bode & Huber, 1992a). The Streptomyces subtilisin inhibitor has also been 
shown to inhibit not only subtilisin, but also a metallo endopeptidase (Kajiwara et al., 1991). Similarly, an 
inhibitor from potato was shown to inhibit the aspartyl proteinase, cathepsin D, as well as the serine proteinase, 
trypsin (Bode & Huber, 1992a). 
Thus it appears that proteinases (and their inhibitors) are an extremely diverse group, each with a number of 
different characteristics. Since the cysteine proteinases are of particular relevance to this study they will be 
discussed more fully in the following section. 
1.3 The Cysteine Proteinases 
The cysteine proteinases (as shown in Table 1.1) generally show maximal activity, on either synthetic 
substrates or proteins, at slightly acidic or neutral pH (Barrett, 1986) and all require activation by thiol reagents 
(North, 1982). The catalytic mechanisms which involve the active site residues Cys25 and His 159 (papain 
numbering), will be discussed in more detail in Chapter 2. This section will deal mainly with the types of 
cysteine proteinases, their occurrence and their possible functions. 
Cysteine proteinases are a diverse group of proteins and are found in most living organisms (Barrett, 1986). 
Most cysteine proteinases belong to the large papain superfamily. This includes papain, (isolated from the 
latex of Carica papaya, Drenth et al., 1971 ), many cysteine proteinases, with properties similar to pa pain, from 
the protozoa and higher plants (North, 1982), the lysosomal cathepsins, B, H, L and S, and the calcium-
dependent cysteine proteinases, the calpains. These latter enzymes are generally found in solution in the 
cytoplasmic fraction of the cells and require Ca2+ for activation (Barrett, 1986). 
These above-mentioned proteinases are considered to fall into a single evolutionary superfamily (Barrett, 
1986) while bacterial and viral cysteine proteinases have evolved independently. Two examples of bacterial 
cysteine proteinases are the proteinase from Streptococcus species (Tai et al., 1976) and clostripain from 
Clostridium histolyticum (Siffert, 1976). Viruses known to contain cysteine proteinases include the polio virus 
(Argos e~ al., 1984) and many plant viruses such as the plum pox potyvirus (Garcia et al., 1993). These 
proteinases are responsible for cleaving viral polyprotein precursors into their functional units (Argos et al., 
1984; Garcia et al., 1993). 
The two largest groups of cysteine proteinases i.e. those found in plants and mammals, are considered in more 
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1.3.1 Plant Cysteine Proteinases of the Papa in Superfamily 
All four mechanistic classes of proteinases have been found to occur in plants, particularly in the seeds and 
tubers (Ryan, 1973). However, since this review focuses on the cysteine proteinases, only the properties of 
this class of enzymes in plants will be discussed. Furthermore, as this project deals with a cysteine proteinase 
inhibitor isolated from rice plants ( oryzacystatin I) , it seems pertinent to discuss the possible roles that cysteine 
proteinases might play in plants. 
Examples of some of the cysteine proteinases found in plants include papain, aleurain, ficin, actinidin, 
bromelains and oryzain (Koizumi et al. , 1993). It is known that during germination there is a marked specific 
increase in the activity of cysteine proteinases. These function to digest the reserve protein and to provide 
amino acids for the developing seedlings (Cervantes et al., 1994; Watanabe et al., 1991). Cysteine proteinases 
may also be involved in the degradation of proteins stored in vacuoles, thus releasing products for the synthesis 
of new proteins during stress or for osmotic adjustment (Guerrero et al. , 1990). 
Plant cysteine proteinases are often induced in plants in response to hormones. The transcription of barley 
aleurain and rice oryzains, for example, is activated by gibberellic acid and repressed by abscisic acid (Rogers 
et al. , 1985; Watanabe et al., 1991). Furthermore, the production of ethylene by plants has also been shown to 
regulate the expression of cysteine proteinase genes during the germination of chickpea (Cervantes et al., 
1994). 
Environmental stresses such as cold or water deficiency have also been shown to affect the regulation of 
cysteine proteinase genes (Bond & Butler, 1987). The functions of proteinases induced by these adverse 
conditions have not, however, been fully elucidated. During cold or desiccation stress, conformational 
changes in the proteins may occur and the breakdown of cellular structures and leakage of solutes and 
electrolytes may lead to the denaturation of polypeptides (Guerrero et al. , 1990). Researchers have postulated, 
therefore, that cysteine proteinases may be involved in the degradation of proteins that have been denatured by 
dehydration or cold stress. Thus, activation of cysteine proteinases may influence biochemical pathways by 
increasing the rates of protein turnover. 
The cysteine proteinases therefore appear to play a physiological role in plants. One might assume that this 
could have important implications for biocontrol strategies that involve cloning of cysteine proteinase 
inhibitors into plants. However, transgenic plants producing high levels of cysteine proteinase inhibitors have 
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1.3.2 The Mammalian Cysteine Proteinases, the Cathepsins and Calpains 
The cathepsins are foW1d mainly in the lysosomes in the cells of higher animals. The name 'cathepsin ' is 
derived from the Greek word meaning. ' to digest ' (Bond & Butler, 1987), and these proteinases are believed to 
be responsible for much of the bulk turnover of proteins in the cell. They are essentially small proteins, which 
differ from one another in pH optima and substrate specificity. Some of them are true endopeptidases (such as 
cathepsins L and S; Bond & Butler, 1987), while others exhibit aminopeptidase ( cathepsin H; Jerala et al., 
1994) or carboxypeptidase ( cathepsin B) activity (Musil et al. , 1991 ). Besides the endopeptidases, lysosomes 
also contain the cysteine exopeptidases such as dipeptidyl peptidase I (cathepsin C; Barrett, 1987). These 
proteinases complete the degradation of proteins by their rapid action on oligopeptides. A brief summary of 
the lysosomal proteinases and their properties is given in Table 1.2. 
The cathepsins have also become important in the development and progression of a variety of human diseases 
(KatW1uma & Kominami , 1986). For example, the two most commonly s~died lysosomal cysteine 
proteinases, cathepsins L and B, have been shown to degrade components of the extracellular matrix in 
diseased states such as muscular dystrophy (Moreau et al. , 1990) and osteoporosis (Abrahamson et al., 1987). 
Furthermore, malignant tissues have also been shown to secrete a ' cathepsin B-like ' cysteine proteinase that is 
thought to be involved in the destruction of the extracellular matrix as well as facilitating the detachment of 
metastatic cells from primary tumour masses (KatW1urna & Kominami, 1986). 
Table 1.2: The properties of lysosomal cysteine proteinases. 
Examples Activity Activity Location pH- Optima Inhibitors References 
Requirements 
Cathepsin H Endo- SH-reducing Lysosomes 5.0 Alkylating reagents, Bond & Butler, 1987 
(EC 3.4.22 .16) Peptidase agent Cystatin inhibitors 
Cathepsin B Endo- SH-reducing Lysosomes 5.0 Alkylating reagents, Bond & Butler, 1987 
(EC 3.4 .22 .1) Peptidase agent Cystatin inhibitors 
Cathepsin L Endo- SH-reducing Lysosomes 5.0 Alkylating reagents, Bond & Butler, 1987 
(EC 3.4.22 .15) Peptidase agent Cystatin inhibitors 
Cathepsin S Endo- SH-reducing Lysosomes 3.5 Alkylating reagents, Isemura et al., 1991 
(EC 3.4.22.27) Peptidase agent Cystatin inhibitors 
Cathepsin C Exo- SH-reducing Lysosomes 7.0 Alkylating reagents, Barrett, 1987 
(EC 3.4.14.1) Peptidase agent Cystatin inhibitors 
Cal pains Endo- Ca2+, SH- Cytosol 7.0 - 8.5 Calpastatin, Bond & Butler, 1987;· 
(EC 3.4.22.17) peptidase reducing agent Kininogens, E-64 Murachi, 1983 
Other mammalian cysteine proteinases include the calpains. These are a group of cysteine endopeptidases 
which require calcium ions for activity (Murachi , 1983). They are heterodimers of 110 kDa and are composed 
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cysteine residue shows 33% homology with papain. These inhibitors have been identified in most tissues and 
all have similar properties. Some of the properties of the calpains are shown in Table 1.2. 
1.4 The Cystatin Superfamily 
Cysteine proteinase inhibitors or cystatins, are very tight-binding, non-covalent inhibitors of the cysteine 
proteinases (Turk & Bode, 1991 ). Crystal and solution structures of native and recombinant forms of cystatins 
have been elucidated (Bode et al., 1988; Stubbs et al. , 1990; Diekmann et al. , 1993 ; Engh et al. , 1993 ; Martin 
er al. , 1995 ; Tate et al., 1995). From these models and from primary structure sequence homology, it is 
apparent that the cystatins have a very similar basic structure. Interaction of the enzyme and the inhibitor 
occurs mainly through hydrophobic interactions between the inhibitor and the complementary active-site cleft 
of the enzyme. The inhibitor forms three distinct binding loops which form the contact regions with the 
enzyme. These are the amino terminus, a first hairpin loop and a second hairpin loop. Machleidt et al. ( 1995) 








Figure 1.1: The 'elephant-trunk model' which depicts the three binding areas of contact of the 
inhibitor with the cysteine proteinase (from Machleidt et al., 1995). 
The significance of these three binding areas, and especially that of the amino terminus of cystatins, has long 
been debated. Since this issue is considered in greater detail in Chapter 2, this section rather gives an overview 
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Members of the cystatin superfamily have been subdivided into a number of families based on: 
1. sequence identity or primary structure characteristics 
2. the number of disulphide bonds present 
3. the molecular mass of the protein (Barrett, 1986). 
By these criteria, four families were defined which, with the discovery of cystatins in plants, have been 
extended to include a fifth family, known as the "phytocystatins" (Kondo et al., 1991 ). The five cystatin 
families are: 
• Stefins (family I) 
• Cystatins (family II) 
• Kininogens (family III) 
• The non-inhibitory proteins of human histidine-rich glycoproteins and a-2-HS-glycoproteins (family IV) 
• Phytocystatins (plant cystatins; family V) 
A number of hypotheses have been put forward as to how the different cystatins diverged during evolution. 
Rawlings and Barrett ( 1990) suggested that: 
• the archetype cystatin, like current members of family I, had no disulphide bonds 
• the family II cystatins came into existence with the introduction of disulphide bridges into the secondary 
structure 
• a gene duplication produced the family IV cystatins 
• a divergence, followed by a second gene duplication gave rise to the family III cystatins 
Abe et al. (1987) suggested that the plant and the animal cystatins evolved from a cognate ancestral gene. 
The main characteristics of each of the cystatin families are described below. 
1.4.1 Family I (Stefins) 
This family contains the proteins which lack disulphide bonds (Abrahamson et al., 1986; Turk et al., 1995). 
They are small, acidic proteins consisting of approximately 100 amino acid residues and are mainly involved 
in the regulation of protein degradation. They are generally found intracellularly, although there are some 
indications that they may function extracellularly. In terms of activity the stefins are potent inhibitors of 
papain and the cathepsins H and L (Turk et al., 1986). 
Stefins characterised at the molecular level include stefins A, B, C (Jarvinen, 1978; Green et al., 1984) and 
PLCPI (pig leukocyte cysteine proteinase inhibitor; LenarCic et al., 1993) which has now been designated 
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two rodent counterparts of stefins A and B called rat cystatins a and 13. Ste fins A, C and D 1 contain no 
cysteine residues. Stefin B contains one cysteine residue which can form intermolecular disulphide bridges 
and is thought to be responsible for the observed formation of dimeric complexes (Barrett, 1987). 
The stefins have been isolated from a number of different sources and all have many sequence similarities. 
Stefin A, for example, has been found in high concentrations in various types of epithelial cells (Rinne et al. , 
1985; Hopsu-Havu, et al. , 1985; Takeda et al. , 1989), in polymorphonuclear leukocytes (Brzin et al. , 1983) 
and in lymphoid follicular dendric cells (Alavaikko et al., 1985). This association with epithelial barriers to 
microbial invasion and with cells involved in protection against infective agents has led to the suggestion that 
stefin A may be involved in the defense mechanism (Katunuma & Kominami, 1986). Furthermore, since 
stefin A has been detected in squamous cell carcinomas of the lung, skin, vulva, cervix and oesophagus, it may 
also play a role in tumour invasion (Rinne et al., 1980; Lah et al. , 1990). 
In contrast to stefin A, stefin B is uniformly distributed among various cell and .tissue types (Barrett et al. , 
1986). The most likely role of stefin B is in the regulation of proteolysis in the cytoplasm following rupture of 
lysosomes (Barrett et al. , 1986). It could also play a role in the control of intracellular and extracellular 
breakdown (Stubbs et al., 1990). 
1.4.2 Family II (Cystatins) 
This group contains the proteins with disulphide bonds and is slightly larger than the stefins, consisting of 
approximately 115 amino acid residues (Barrett et al. , 1986). They occur in high concentrations in human 
seminal plasma, in saliva and chicken egg white. Examples include chicken cystatin, human cystatin C, the 
human salivary cystatins and beef colostrum cystatin. A further member of this family, cystatin M, has been 
isolated from human mammary cells and tissues (Sotiropoulou et al., 1997). 
Of the family II cystatins, chicken cystatin is the best known representative and its X-ray crystal structure has 
been determined (Bode et al., 1988). It is a tight binding inhibitor of the cysteine proteinases ficin, papain, 
cathepsin B and dipeptidyl peptidase I. Chicken cystatin can be purified as two major isoforms (Turk et al. , 
1983 ; Anastasi et al., 1983): a phosphorylated (pl 5.6) and unphosphorylated form (pl 6.5; Laber et al. , 1989). 
This latter, more basic form lacks eight residues on its N-terminus (Curin et al., 1986). · Chicken cystatin has 
no free thiol group and contains four cysteine residues in the C-terminal segment. These form two successive 
disulphide bridges (Grubb et al., 1984). Because it occurs in such high concentrations in chicken egg white, 
chicken cystatin is thought to play a role as a defensive agent against pathogens (Barrett et al., 1986). 
Three cysteine proteinase inhibitors of this family have also been isolated from saliva, namely cystatin S, 
cystatin SA and cystatin SN (Isemura et al. , 1991 ). In addition to these S-type cystatins, human saliva also 
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et al. , 1986). Cystatin C, like chicken cystatin, is one of the more potent inhibitors of papain and lysosomal 
cysteine proteinases. It appears to be expressed in all tissues (Abrahamson et al., 1990; Dickinson et al. , 1993) 
with the highest concentrations being found in seminal plasma and cerebral spinal fluid (Abrahamson et al. , 
1986). Cystatin C is thought to play a role in physiological control. 
1.4.3 Family Ill (Kininogens) 
This family contains the plasma kininogens. These are well known for their involvement in inflammation 
(Sharma & Mohsin, 1990; Stewart, 1993), in the blood coagulation cascade (Kato et al. , 1981 ; Turk & Bode, 
1991) and for the inhibition of pa pain-like cysteine proteinases (Milller-Esterl et al. , 1985). Members of this 
group have large molecular weights - usually above 65 k.Da (Turk et al., 1986) - and typically up to nine 
disulphide bonds. They are acidic glycoproteins and occur in multiple isoforms with pl values ranging from 
4.0 to 5.2 (Auerswald et al., 1993). They have been found in plasma and other mammalian secretions (Turk & 
Bode, 1991 ). In mammals, three types of kininogens have been found differing in size, structure and function. 
They are: 
• H-kininogen (M, 80 - 120 k.Da) 
• L-Kininogen (M, 56 - 68 k.Da) 
• Rat T-kininogen (M, 68 k.Da) (Milller-Esterl et al., 1986). 
Human plasma contains H-kininogen (high molecular weight form) with M, of 83.5 k.Da (Turk et al., 1996), 
and L-kininogen (low molecular weight form) with M, of 50 - 68 k.Da (Okamoto & Greenbaum, 1983). 
Human kininogens H and L are single-chain plasma glycoproteins each composed of an amino-terminal heavy 
chain, the kinin segment and a C-terminal light chain. The heavy chains can be divided into three segments, 
DI , D2 and D3 with the kinin segment making up D4. The light chains of both kininogens differ from one 
another, and can be divided into domains D5 (LK) and D5 and D6 (HK). All eighteen cysteine residues of 
LMW kininogen form disulphide bonds. The disulphide bonds are intra-domain with the exception of a link 
between domain 1 and the light chain (Milller-Esterl et al., 1986; Salvesen et al., 1986). The structure of the H 
and L-kininogens are shown in Figure 1.2. 
Salvesen et al. (1986) showed that domains D2 and D3 of the kininogens are potent inhibitors of papain and 
cathepsin L but poor inhibitors of cathepsin B. Domain D2 differs from other cysteine proteinase inhibitors in 
that it can inhibit chicken calpain - no other cystatin is known to inhibit the cal pains. Domain D 1, on the other 
hand, has proven ineffective against any protease tested so far (Bradford et al., 1993; Turk & Bode, 1991). 
Turk et al. (1995) showed that intact human L-kininogen could bind two molecules of papain-like cysteine 
proteinases with high affinity and more recently that H-kininogen can also bind two molecules of cathepsin S, 













Figure 1.2: The general structure of human kininogens is represented as comprising multiple 
domains. (A) HMW kininogen has six domains (DJ - D6) and (B) LMW kininogen has.five domains 
(DJ - D5) 
symbols: * -putative reactive site p_ -potential disulphide loop 
? -carbohydrate attachment site ED - histidine-rich region 











Figure 1.3: The phylogeny of the cystatin domains of the kininogens and a-2-HS generated by the 
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1.4.4 Family IV (a-1-HS and a-2-HS-glycoproteins) 
In discussing the evolution of the cystatins Calkins & Sloane (1995) suggested that, despite their similarities to 
the kininogens, the a-1-HS-glycoprotein (a-1-HS; Ohkubo et al. , 1984) and the a-2-HS-glycoprotein (a-2-
HS; Elzanowski et al., 1988) should be included as a separate family. These two proteins consist of two 
repeated patterns of a single cystatin-like molecule (Rawlings and Barrett, 1990; Elzanowski et al., 1988). 
They occur in very high levels in the matrix of bone and dentine. This association with mineralised tissues and 
the affinity for calcium and barium ions suggests that these proteins play a role in mineral balance (Elzanowski 
et al. , 1988). Figure 1.3. shows the phylogeny of the cystatin domains of the kininogens and a-2-HS as 
suggested by Hunt et al. (1985). 
1.4.5 Family V (Phytocystatins) 
The discovery of cystatins in plants added a further group to the cystatin superfamily. This group, which 
contains all the plant cystatins, has become known as the Phytocystatins. Despite being placed in a family on 
their own, plant cystatins are similar to the family I cystatins in that they lack disulphide bonds and to the 
family II cystatins in their overall amino acid homology (Abe et al., 1987b ). Some authors suggest that many 
of these plant cystatins such as oryzacystatin, should be included in the stefin family as the phytostefins (Turk 
& Bode, 1991 ), since they contain no disulphide bonds and are more similar in amino acid composition to the 
stefins. 
Table 1.3: Cysteine proteinase inhibitors isolated from plants 
Plant · Reference- '"" . . ,._ '/;/if -, 
"' ' ", ·'' Potato Rodis et al., 1974 
Pineapple stem Perlstein & Kezdy, 1973; Hatano et al., 1995 
Cowpeas Rele et al., 1980; Fernandes et al., 1993, Valevski et al., 1991 
Mung beans Baumgarner & Chrispeels, 1976 
Seeds oftlie legwninous Bauhinia tree Goldstein et al. , 1973 
Pumpkin seeds Zimacheva et al., 1988 
Maize Abe et al., 1980; Abe et al., 1992; Abe et al., 1994 
Rice Abe & Arai, 1985; Kondo et al., 1990 
Brazilian beans Olivia et al., 1988 
Soybean Brzin et al., 1990; Hines et al., 1991 
Chinese cabbage Lim et al., 1986 
Wisteriajloribunda seeds Hirashiki et al., 1990 
Wheat, Barley, Rye Fossom, 1970 
Papaya Song et al. , 1986 
Tomato Akers & Hoff, 1980 











Chapter 1 Page 12 
Com cystatin, isolated from maize, was one of the first cystatins to be discovered in plants (Abe & Arai, 1980). 
Subsequently, however, cystatins were found in rice (Oryzacystatins I and II, Abe & Arai, 1985; Kondo et al., 
1990) and cysteine proteinase inhibitors in a number of other plant species (Table 1.3). 
1.5 The Phytocystatins 
In the plant kingdom, cysteine proteinase inhibitors are usually found in seeds and tubers and are particularly 
prevalent in the families Graminacae, Leguminacae and Solanaceae (Ryan, 1973). However, their role in 
plants has not been fully elucidated. 
The following sub-sections describe two cystatins that have been thoroughly investigated. 
1.5.1 The Oryzacystatins 
Oryzacystatin I (OC I), was first isolated from rice endosperm by Abe & Arai , (1985). This cystatin contains 
102 amino acids, has no disulphide bonds and shares sequence homology with other members of the cystatin 
superfamily, particularly the family I cystatins (Kondo et al., 1990; Abe et al., 1987b). 
Following the isolation of the OC I inhibitor from rice, a second cystatin in rice was discovered. This was 
named oryzacystatin II (OC II; Kondo et al., 1990). This inhibitor is composed of 107 amino acid residues 
and shows 55% identity in its amino acid sequence to OC I (Kondo et al., 1990). Figure 1.4 shows an amino 

















Figure 1.4: Sequences of oryzacystatin I (OC I) and oryzacystatin II (OC II) . Commonly conserved 
amino acid residues are shown in bold with underlining (from Kondo et al. , 1990). 
Despite their similarities these two rice cystatins have slightly different expression patterns and perhaps 
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that the mRNA of OC II is expressed constantly throughout the maturation stages of rice and has even been 
detected in mature seeds. OC I m.RNA, on the other hand, was found to reach a maximum level two weeks 
after flowering and then gradually decreased to an undetectable level at ten weeks. By this time the ripening of 
the seeds was complete. OC I m.RNA was not detected in mature seeds. 
The two rice cystatins have also shown differences in their specificity to different proteinases. For example, 
OC I has been shown to inhibit papain more efficiently than OC II, while OC II inhibits cathepsin H more 
efficiently than OC I. The inhibitory characteristics of OC I and II are shown in Table 1.4. 
Table 1.4: Inhibitory characteristics of OC I and OC II (from Kondo et al., 1990) 
Oryzacystatin II 0.79 x 10- M 1.00 x 10- M 
*The above kinetic studies were carried out using BANA (N-Benzoyl-DL-arginine-2-
naphthylamide) as the substrate (Kondo et al., 1990). 
In rice, oryzains a and ~ are believed to be the two proteinases analogous to papain. These proteinases are 
therefore inhibited more efficiently by OC I. Another rice cysteine proteinase oryzain y, on the other hand, is 
similar to cathepsin H and this proteinase is thus considered to be the natural target of OC II in rice seeds (Abe 
et al., 1987b; Watanabe et al., 1991). Investigations into the pattern of m.RNA expression of oryzacystatin 
have also led to the deduction of possible functions of these inhibitors in plants. As mentioned previously, the 
mRNA of the cystatins accumulates in seeds before germination. They are not, however, expressed at 
germination, which is the time at which the oryzains are expressed (Watanabe et al., 1991). Thus, the presence 
of oryzacystatins before germination may prevent the degradation of seed storage proteins by the exogenous 
proteinases of destructive insects or the premature breakdown of the protein by the oryzains. The 
disappearance of oryzacystatins at the time of germination would then release proteolytic activity for the 
digestion of storage proteins. 
1.5.2 Plant 'Multicystatins' 
Besides the single cystatins, other types of cysteine proteinase inhibitors have been found in plants. One of 
these, the 'multicystatin' was first observed in potato by Rodis (1974). Potato multicystatin (PMC) is quite 
unique amongst the plant cystatins in that it is able to form crystal-like units at alkali pH. It consists of eight 
tandem cystatin-like domains (of approximately 10 kDa), which are linked by proteolytically sensitive 
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Despite its unique features, PMC is 43 - 50% identical to the rice and com cystatins, suggesting that all plant 
cystatin genes may be derived from a common ancestor (Waldron et al., 1993). 
PMC has been shown to be active against the cysteine proteinases papain, chymopapain and ficin (Rodis & 
Hoff, 1984; Krizaj et al., 1993). These crystals occur in the subphellogen layer of potato tubers as well as 
throughout the tuber and are considered to be the first line of defence against insect attack. The crystals can be 
solubilised at low pH (Rodis & Hoff, 1984) and by proteinase treatment (Walsh & Strickland, 1993). Since the 
pH of the midgut of insects using cysteine proteinases for digestion is typically acidic (Murdock et al., 1987), 
ingested crystals would thus be solubilised and the multicystatin broken up into its inhibitory cystatin units 
(Walsh & Strickland, 1993). 
1. 6 The Functions of Cystatins 
As can be seen from the previous sections, cystatins have been isolated from numerous sources. Experimental 
evidence suggests that cystatins not only play important roles in the protection of cells from unfavourable 
proteolysis by cysteine proteinases, but also in biological defence systems against invaders (Bieth, 1986). An 
example of such protection is provided by the cysteine proteinase inhibitor stored in the large granuies of 
horseshoe crab hematocytes. This cystatin serves as a defence against invading microbes and, together with 
other defence molecules, is released in response to external stimuli (Agarwala et al., 1996). Similarly, many 
insects have also been shown to contain proteinase inhibitors that protect against proteases from invading fungi 
and microorganisms (Eguchi, 1993). 
Thus, these proteinase inhibitors could show potential as a means of controlling the proteinases of human and 
plant parasites and viruses. Cystatins could also be used as biocontrol agents to protect plants from insect 
attack through inhibition of the insect digestive proteinases. These potential applications of the cystatins in the 
pharmaceutical and agricultural fields have been made more attractive by the development of techniques to 
improve the capabilities of inhibitors through modelling studies and site-directed mutagenesis, thus making 
them more specific for their target enzymes. 
The following subsections discuss examples from the literature where cystatins have shown potential in the 
area of host protection. 
1.6.1 Cystatins and Control of Human Parasites 
Cysteine proteinases have been isolated from the lysates of many different parasitic protozoa and nematodes 
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contortus (Pratt et al., 1990; Cox et al., 1990); Trypanosoma brucei (Lonsdale-Eccles & Grab, 1986); 
Leishmania mexicana mexicana (North, 1992) and Toxoplasma gondii (Irvine et al., 1992). 
Many parasites depend on proteolysis for nutrition, for entry into tissues or cells or to counteract, directly or 
indirectly, the host' s defence mechanisms (Irvine et al. , 1992). Furthermore, parasites often have complex 
life-cycles and proteinases are important in protein turnover during cell differentiation and in the 
transformation from one stage to another. For these reasons, it may be beneficial to identify functional 
differences between the proteinases of the host and those of the parasite that might be exploited by 
appropriately tailored inhibitors. 
Proof of the potential for proteinase inhibitors in host protection can be seen from the work of Silva et al. 
( 1995), who showed that on infection by Trypanosoma cruzi, cystatin S was induced in rats as a defence 
mechanism. They suggested that this increase in cystatin S on infection may be related to the presence of T 
cruzi proteinases acting as antigens. Hence the synthesis of inhibitors by the host may be a biological response 
to tissue injury. This in turn, serves to protect the host from the harmful effects of enzymes and/or facilitate 
tissue repair (Silva et al., 1995). Various cystatins have also been shown to inhibit the cysteine proteinase 
(trypanopain) from Trypanosoma brucei in vitro (Lonsdale-Eccles & Grab, 1986). 
1.6.2 Cystatins and Control of Viruses 
The use of proteinase inhibitors as protective mechanisms may also extend to plants in protecting them against 
various viruses and plant pathogens. For example, cysteine proteinase inhibitors have been identified in 
resistant plant species which are able to affect the protein processing of the cowpea mosaic virus (Ponz et al. , 
1987). In fact a number of plant viruses, such as the comoviruses and the potyviruses, as well as a number of 
other types of viruses, require cysteine proteinases for the processing of their precursor polyproteins. These 
protein cleavages are often central to the replication cycle of the viral parasites and if these are prevented, the 
infection process is aborted (Korant et al. , 1986). In the case of the potyviruses, the cysteine proteinase 
responsible for this processing is located at the carboxyl-terminal third of the polyprotein. The role of this 
enzyme is to process itself out of the polyprotein and to then cleave the coat proteins from their precursor. 
This precedes their assembly into viral particles (Carrington et al., 1990). 
In view of the importance of these cysteine proteinases in the virus life cycle they have been considered as 
putative targets for anti-viral therapy using proteinase inhibitors. Molecular modelling approaches and genetic 
engineering techniques could also be used to increase the inhibitory capabilities of the inhibitor against specific 
viral proteinases. 
Turk et al. (1983) investigated the effect of cystatins on the cysteine proteinases of the neurovirulent 
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alteration in protein processing and a decrease in the total quantity of viral protein that was dependent on the 
concentration of chicken cystatin and on whether or not the cells were exposed to the cystatin prior to 
infection. · At high concentrations of chicken cystatin there was no viral protein synthesis and the pattern of 
cellular protein synthesis was preserved. This showed that the ability of the poliovirus to abolish cellular 
protein synthesis was blocked by chicken cystatin. Cystatins thus appear to alter the pattern of viral 
polypeptide processing (Turk et al., 1983). 
Similar antiviral effects have been observed with HSV (Herpes simplex virus type I) by oryzacystatin (Aoki et 
al. , 1995) and cystatin C (Bjorck et al. , 1990; Kondo et al., 1992). In fact, the molar concentrations of cystatin 
C that gave total inhibition of HSV replication were found to be lower than that of acyclovir, a drug most 
frequently used against HSV infections. These results suggest that cysteine proteinase inhibitors might play a 
role as inhibitors of viral replication and that peptide derivatives that mimic their proteinase-binding centres, 
might be useful as antiviral agents. Cystatin C does not inhibit polio virus while chicken cystatin and 
oryzacystatin I do (Bjorck et al., 1990; Aoki et al., 1995). The reason for these differences is still unclear. 
1. 7 Potential of Cystatins as Biocontrol Agents 
This last section, aims to assess the advantages and disadvantages in the use of cysteine proteinase inhibitors 
against insect pests and whether transformation of proteinase inhibitor genes into plants will serve to enhance 
their resistance. 
The potential use of proteinase inhibitors to protect crop plants from insect damage is well recognised. Early 
demonstrations showed that proteinase inhibitors are capable of repressing the activity of proteinases from the 
insect digestive tract (Gatehouse & Boulter, 1983; Wolfson & Murdock, 1987). This is an important 
consideration for biocontrol since economic losses per annum from insect infestation runs into billions of 
dollars worldwide. 
A number of hypotheses have been suggested regarding the efficiency of proteinase inhibitors in this particular 
context. One of the ways they are thought to act is through tight binding to the target digestive proteinases, 
which leads to a general decrease in the proteolytic digestive functions and hence to delays in growth and 
development. A second proposed mode of action is thought to be via feedback mechanisms. Here the 
presence of the inhibitor causes an increase in the production of midgut proteinases. This in turn results in 
amino acid utilisation and wasted energy. 
Much of the work carried out using proteinase inhibitors as biocontrol agents have been done using serine 
proteinase inhibitors. Serine proteinase inhibitors transformed into tobacco plants, for example, have 











Chapter 1 Page 17 
serine proteinase inhibitors, cysteine proteinase inhibitors have proven variable in their potential as biocontrol 
agents in plants. They have, nevertheless, been successful in a number of cases, thus encouraging their use as 
protective agents in plants, especially when used in conjunction with other forms of biocontrol. Furthermore, 
there are many advantages in using cystatins rather than other types of proteinase inhibitors for biocontrol. For 
example, unlike the serine proteinases, cysteine proteinases are not secreted as intestinal digestive enzymes in 
higher animals, but are found in the midguts of several families of Hemiptera and Coleoptera. Thus the 
presence of high concentrations of inhibitors in plants should have no detrimental effects on humans and 
animals. Furthermore, trial studies have shown that cystatins do inhibit midgut cysteine proteinase in vivo. 
For example, oryzacystatin has been shown to retard the growth of the red flour beetle (Chen et al., 1992; 
Liang et al. , 1991), as has E-64 against the bean weevil (Hines et al., 1990) and the Colorado potato beetle 
(Wolfson & Murdock, 1987). These functions have led to the proposal, that inhibitors such as oryzacystatin be 
expressed in transgenic cereals to protect seeds against infestation by stored grain Coleoptera (Liang et al., 
1991 ). 
1. 7.1 The Possibility of Transforming Cysteine Proteinase Inhibitors into Plants 
As has been described in section 1.3 .1, cysteine proteinases appear to play certain physiological roles in plants. 
Since OC I is known to inhibit proteinases of plant origin such as papain and endogenous rice proteinases, the 
concept of introducing these inhibitors into transgenic plants has been controversial. Masoud et al. (1993) 
placed the OC I gene under the control of the CaMV 35S promoter in tobacco. High levels of the inhibitor in 
this case, did not interfere with the plants ' normal developmental processes. The tobacco plants containing the 
OC I gene were found to be normal in appearance, self-fertile, and produced viable seeds. 
Similarly, the OC I gene has been introduced and expressed in poplar trees where it accumulated to high 
levels, especially in older leaves and successfully conferred resistance against the poplar leaf beetle, 
Chrysomela tremulae, with no detrimental effects on the poplar trees (Leple et al., 1995). 
There thus appears to be potential for cystatins such as oryzacystatin to be used in transgenic plants despite the 
possible physiological roles that these proteinases play in the plant itself. Because of the limited expression in 
some plant organs it may be necessary to express the inhibitors in those specific organs which form part of the 
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1. 7 .2 Problems Associated with Cystatins as Biocontrol Agents. 
1. The Wide Diversity of Insect Digestive Enzymes 
All four classes of proteinases are represented within the insect order and different types of insects utilise 
different proteinases for their digestion. Members of the Hemiptera and Coleoptera, for example, use cysteine 
and/or aspartic proteinases (Houseman & Downe, 1980) while pepsin-like enzymes are found in some Diptera 
(Pendola & Greenberg, 1975). Trypsin-like enzymes, on the other hand, are common in Lepidoptera 
(Applebaum, 1985). There are no definite rules to this classification, however, since the pH profiles in the 
midguts of some insects have been shown to exhibit multiple peaks, suggesting that these insects utilise more 
than one type of proteinase (Wolfson & Murdock 1989). 
The reason for such variation in insect digestive enzymes is not particularly clear. Houseman et al. (1985) 
postulated that insect adaptation from using serine proteinases to that of aspartic and cysteine proteinases may 
have occurred as two evolutionary events. The first was the loss of serine proteinases following a change to 
sap feeding by Homopteran-like insects (thought to be the ancestors of the entire Hemiptera order; Terra & 
Ferreira, 1994; Houseman & Downe, 1983). The second event was the advent of predatory habits. With 
higher protein sources or even seed feeding, catheptic lysosomal proteinases became the dominant enzymes for 
digestion (Houseman et al., 1985). Alternatively, it has been suggested (Ryan et al. , 1990) that in both the 
Hemiptera and Coleoptera the presence of catheptic proteinases in the midguts may have been an adaptation to 
feeding on food sources rich in trypsin inhibitors. In this case, the use of alternative proteinases could have 
been developed to overcome the potential toxic effects of these ingested inhibitors. 
The problems associated with this large diversity in insect digestive proteinases is illustrated by the work of 
McManus et al. (1994) who introduced a chymotrypsin inhibitor gene into tobacco and so conferred resistance 
against the green looper (Chrysodeixis erisoma,· Lepidoptera: Noctuidae). It did not, however, inhibit other 
closely related noctuids. This suggests that a single proteinase inhibitor gene may not be universally effective 
against a wide range of insect pests. 
Further evidence for such variability in digestive proteinases within an insect order has come from studies on 
the Coleoptera. Although these insects are thought to use cysteine proteinases for digestion (Wolfson & 
Murdock, 1989; Michaud et al. , 1995a), not all species of beetle use them. Proteolytic activity in the midgut 
homogenates of the milkweed beetle, for example, was not inhibited by cysteine proteinase inhibitors while the 
midgut of the mealworm, Tenebrio molitor, has been shown to utilise a trypsin-like serine proteinase for 
digestion (Applebaum, 1985). The carpet beetle Attagenus megatoma also relies, at least in part, on serine 
proteinases for protein digestion (Baker, 1976) as does Costelytra zealandica (the grass grub; Christeller & 
Shaw, 1989). It is thus clear that proteolytic activity varies within a species as well as from species to species. 
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present in the midgut. Table 1.5 shows a number of insects and the types of midgut digestive proteinases 
identified. From the table, it is clear that some insects utilise more than one type of proteinase for digestion. 
Table 1.5: Proteinases identified in insect midguts. 
Insect 
,. ;; ' '•; ' Proteinases in Inhibitori.'.:. ... Reference "'''P , ;:'· 
mid gut 
?: ; 
- ... "' 
Mexican bean beetle Cysteine E-64 Murdock et al. , 1987 
(Epilachna varivestis) 
Cowpea weevil Cysteine E-64 Murdock et al., 1988 
(Callosobruchus maculatus) 
Red flour beetle Cysteine E-64 Murdock et al., 1987; Chen et al., 
(Tribolium castaneum) OCI 1992; Liang et al., 1991 
Callosobruchus chinensis Cysteine OC I; OC II Kuroda et al., 1996 
Riptortus clavatus Cysteine OC I; OC II Kuroda et al., 1996 
Bean weevil, (Zabrotes subfascaitus) Cysteine E-64 Silva & Xavier-Filho, 1991 
Mealworm (Tenebrio molitor) Cysteine, Serine Bowman-Birk; E-64 Murdock et al., 1987 
Poplar leaf beetle ( Chrysomela Cysteine OCI Leple et al., 1995 
tremulae) 
Carpet beetle (Attagenus megaloma) Cysteine, Serine Bowman-Birk; E-64 Baker, 1976 
Colorado potato beetle Cysteine, OC I; OC II; Wolfson & Murdock, 1987 
(Leptinotarso decemlineata) Aspartic E-64; pepstatin Michaud et al. , 1993 
Milkweed beetle Cysteine, Serine Bowman-Birk; E-64 Applebaum, 1985 
Rice weevil, (Sitophilus oryzae) Cysteine, Aspartic OC I; Antipain; E-64 Liang et al., 1991 
Southern com rootworm Cysteine PMC Orr et al., 1994 
(Diobrotica undecimpunctata) 
Grass grub Serine Bowman-Birk Christeller & Shaw, 1989 
(Costelytra zealandica) 
In conclusion therefore, it appears that there may be disadvantages in transforming single proteinase inhibitor 
genes into plants because of the large diversity in digestive proteinase activity amongst insects. Furthermore, 
insects with multiple proteinases in their guts may be able to resist the effects of single proteinase inhibitors by 
increasing the secretion of proteinases insensitive to these inhibitors. A possible solution to this problem 
would be to clone more than one type of inhibitor gene into plants. In this way, plants would have resistance 
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2. Inhibitory Capabilities of Cystatins 
Kinetic studies carried out with cystatins have shown that the inhibitory constants for different cysteine 
proteinases vary. This presents a further problem for biocontrol since different members of the Coleoptera and 
Hemiptera use different cathepsins for their midgut protein digestion. OC II, for example, is a better inhibitor 
of the midgut proteinases of the Colorado potato beetle, than is OC I (Michaud et al., 1993). A possible reason 
for this is that the major gut proteinases found in this insect are cathepsins Band H (Michaud et al., 1993) and 
although both OC I and OC II are fairly poor inhibitors of cathepsin B, OC II is a better inhibitor of cathepsin 
H than is OC I (Kondo et al., 1990). 
It is therefore important to know the specific proteolytic systems used by the insects to be controlled and either 
use the appropriate inhibitor or, by protein engineering and molecular modelling, develop inhibitors with both 
improved inhibitory capabilities and a wider inhibitory range. 
3. High Concentrations of Cystatins are Required for Effective Inhibition 
Results obtained from the incorporation of cystatins into the diets of insects have depended very much on the 
trial conditions, particularly on the concentrations of inhibitors used. E-64, for example, prolonged the 
developmental time and increased larval mortality of the cowpea weevil, Callosobruchus maculatus, in direct 
proportion to its concentration in artificial seeds (Murdock et al., 1988). Similarly, OC I and OC II, when 
added to the diets of two bean insects, Callosobruchus chinensis (Coleoptera) and Riptortus clavatus 
(Hemiptera) at concentrations of 0.3 - 0.5% (w/w), retarded the growth of these insects (Kuroda et al., 1996). 
At concentrations of 1 % inhibitor in the diets, the insects died. In contrast, studies carried out with Tribolium 
castaneum (Chen et al., 1992) required the addition of 10% (w/w) OC I to the diet in order to achieve 
inhibition of gut proteinases. Thus the outcome, especially with assays in which the insect guts are extracted 
and analysed (i.e. in vitro assays), depends very much on the conditions used, including the type of diet and the 
concentrations of inhibitor. These will also differ with different insects depending on the types of proteinases 
present in the midguts and whether or not there is more than one class of proteinase involved. 
For Coleoptera it is often necessary to have inhibitors in excess in order to avoid recovery of digestive 
proteolytic functions and/or to ensure the inhibition of newly synthesised proteinases. In general, proteinase 
inhibitors need to be present in plants in relatively high concentrations (greater than 5% of the soluble protein) 
in order to be toxic to insects. This presents potential problems since normally plant cystatins, such as 
oryzacystatin, occur in rice seeds at low levels (approximately 0.001 - 0.002%; Kondo et al., 1989), which may 
be insufficient for effective protection against insect pests. In fact, the effects of proteinase inhibitors at low 
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difficulties m delivering sufficient cysteine proteinase inhibitors to interfere with insect growth and 
development in a useful way. 
A further problem is that the oryzacystatin gene is not expressed in the leaves, stems or roots of the rice plant. 
This cystatin would thus be ineffective against rice insect pests, such as Lagynotomous elongatus and 
Saccarosydne procerus that eat the leaves of growing plants. Sitophilus zeamais, on the other hand, invades 
the interior of the rice seeds where the inhibitors are expressed (Irie et al., 1996). It may thus be necessary to 
produce transgenic plants that express higher concentrations of inhibitors and target these inhibitors to specific 
plant organs. 
4. Insect Resistance/ Adaptation to the Presence of Inhibitors in their Diets 
In many of the studies carried out in which insects were fed proteinase inhibitors either mixed with artificial 
diets or, present in the plant material itself, the insect mortality has generally been so low that protection is 
incomplete despite the high levels of inhibitors. It has been suggested that this may be due to the ability of 
insects to overcome the detrimental effects of proteinase inhibitors by over-producing proteinases insensitive 
to the inhibitor (Broadway & Duffy, 1986). Evidence for this apparent 'resistance' of insects over time was 
observed in studies with the Colorado potato beetle (Orr et l. , 1994). Here the addition of phenyl-methyl-
sulphonyl-fluoride (PMSF) to the insect diets caused an increase in the production of cysteine proteinases and 
the insects were able to recover from exposure to some extent. Larvae of the Southern com rootworm were 
also seen to recover, with time, from acute exposure to potato multicystatin (PMC). Orr et al. (1994) proposed 
that these larvae must have avoided a drastic reduction in their digestive capacity through a 2-3-fold increase in 
the secretion of proteinases 'insensitive ' to the PMC and that such larvae possess feedback mechanisms for 
monitoring and maintaining an adequate level of proteinase activity. In the field this may show itself as a 
delay in the developmental time which might not translate to any significant reduction in crop damage. Some 
researchers, however, consider that this over-production itself may be detrimental to insects in terms of energy 
wastage and amino acid utilisation (Broadway & Duffy, 1986; Bolter & Jongsma, 1995). 
In general the ability to counteract the effects of proteinase inhibitors appears to be limited. Often 70% of 
insect digestive enzymes are affected by the proteinase inhibitors, and the production of inhibitor insensitive 
proteinases is often insufficient to restore normal levels of activity. The simultaneous delivery of a few 
proteinase inhibitors with different specificities may help by minimising the effects of insect adaptation seen 
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5. Variation in the Results obtained with in vitro versus in vivo studies 
A further problem observed with proteinase inhibitor tests stems from the fact that the encouraging results seen 
with in vitro tests, are often not observed in in vivo assays. That is, proteinase inhibitors appear to drastically 
reduce the activity of cysteine proteinases from gut extracts, but this is not translated into increased mortality 
rates in the in vitro assays. Chen et al. (1992), for example, found that oryzacystatin was very effective in 
inhibiting the gut proteinases of T. castaneum in vitro, but that high levels (10 % w/w), were required to inhibit 
growth in vivo. 
Furthermore, some in vivo studies have shown proteinase inhibitors to be susceptible to proteolysis by insect 
midgut proteinases "insensitive" to the inhibitor. For example, studies carried out with the black vine weevil 
(Otiorynchus sulcatis) using OC I and OC II showed that OC II was susceptible to proteolysis (Michaud et al., 
1995b). When the inhibitor was incubated with the black vine weevil mid~t proteinases and then sequenced, 
it was found that the C-terminus of OC II had been truncated. This initial cleavage led to a conformational 
destabilisation of the inhibitor. This susceptibility of certain inhibitors, such as OC II, could have major 
implications when planning the use of plant cystatins for insect pest control. Here multicystatins such as PMC 
may be more useful as its individual cystatin domains are less susc ptible to proteolysis. 
One may conclude that cystatins do show potential as possible biocontrol agents in plants, although a number 
of problems are associated with their use in this regard. These and possible solutions are summarised in Table 
1.6. 
Table 1.6: Problems and solutions in the use of cystatins as potential biocontrol agents. 
Wide diversity in insect digestive enzymes 
Specificity of inhibitors for certain cysteine 
proteinases 
Insect resistance to the presence of inhibitors in 
their diets 
Transgenic plants containing multiple inhibitors 
Protein engineering to improve the capabilities of 
the inhibitor against more than one target enzyme 
Transgenic plants containing multiple inhibitors 
1.7.3 Further Approaches to Improve Cystatins for Biocontrol 
In addition to the solutions summarised in Table 1.6, a number of other approaches can be used to overcome 
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1. Use of multicystatin inhibitors in transgenic plants rather than single cystatins e.g. potato multicystatin 
(PMC). 
2. Use of inhibitors in conjunction with other forms of biocontrol e.g. the Bacillus thuringiensis (Bt) toxin. 
These are discussed below: 
1. Advantages of using 'Multicystatins' rather than Individual Cystatins 
The use of multicystatins, such as PMC, has been shown to give better inhibitory activity than the single 
cystatins such as oryzacystatin and chicken egg white cystatin. Orr et al. (1994) investigated the use of PMC 
against the cysteine proteinase activity of the southern com rootworm larvae in vivo and in vitro and its growth 
inhibitory effect was far more potent than either oryzacystatin I or chicken cystatin. Furthermore, its activity 
was comparable to that of the potent, irreversible cysteine proteinase inhibitor E-64 against bean weevil and 
cowpea weevil (Orr et al. , 1994). 
2. Use of inhibitors with other forms of Biocontrol Agents 
A possible means of obtaining efficient protection in plants would be to use different pest resistant factors that 
act through different mechanisms. Such dual approaches have been used successfully in transgenic plants. 
Boulter et al. (1990) expressed both the cowpea trypsin inhibitor gene and/or the lectin gene in tobacco. 
Progeny that inherited and expressed both genes showed an enhanced resistance to H virescens when 
compared to plants that expressed only one of the two genes. 
A further example, is provided by the use of proteinase inhibitors in conjunction with Bt-toxin. Using this 
approach, Bilder et al. (1987) used serine proteinase inhibitors in conjunction with the Bt toxin and found that 
the mortality of tobacco budworms was 2- to 20-fold higher than that obtained with the Bt toxin alone. This 
approach may help to prevent the development of insects that are resistant to this toxin but not to the proteinase 
inhibitor. 
1.8 Aims of this Thesis 
It appears that there are many advantages to improving the potential of proteinase inhibitors as biocontrol 
agents. One approach (as mentioned briefly in section 1.7.2) would be to optimise the interactions between 
proteinase inhibitors and their target proteinases. This could be carried out by screening many naturally 
occurring inhibitors with in vitro enzyme assays using gut extracts from insect pests. The gene encoding the 
inhibitor with the strongest interaction could then be expressed in transgenic plants. This strategy does 
however, have its limitations, since, as mentioned previously, positive in vitro results do not always predict 
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however, have its limitations, since, as mentioned previously, positive in vitro results do not always predict 
effective in vivo inhibition. 
A second option could be to develop molecular modelling approaches. Many of the interactions of proteinase 
inhibitors with their cognate enzymes have been studied in detail at the structural level and functional residues 
on the inhibitors have been well characterised. One could thus use protein engineering methods to try and 
increase the strength of these interactions. It is this latter point which was applied in this thesis. 
The success of manipulating cystatins via protein engineering approaches to improve biocontrol has been 
demonstrated by Urwin et al. (1995a) who developed a variant of natural OC I that carried a mutation in the 
form of a deleted Asp86 residue. This inhibitor was found to retard the growth of the plant nematode 
Globodera pallida, and had a greater inhibitory effect than that of the natural OC I. In fact, it reduced the size 
of G. pallida females to the extent that fecundity was greatly affected (Urwin et al. , 1995a). Thus, 
modification of inhibitors has shown potential as a means of increasing their biocontrol capabilities. 
Although successes such as this are encouraging, the rational engineering of protein inhibitors is still an 
uncertain and somewhat unpredictable science. The knowledge of structure-function relationships is as yet 
incomplete and the current lack of structural data on insect and nematode proteases means that the modelling 
approach relies more heavily on speculation rather than on the sound definitive basis that would support 
effective prediction. 
The aim of this thesis was to investigate further the possible interactions of cystatins by means of structural 
modifications. Oryzacystatin I was used as the model inhibitor because plant cysteine proteinases have shown 
potential as biocontrol agents against certain insect pests (Liang et al. , 1991; Leple et al., 1995; Michaud et al., 
1995a; Irie et al., 1996). Oryzacystatin I was used rather than oryzacystatin II as it has proven to be a better 
inhibitor in the majority of insect trials (Michaud et al. , 1995b ). It has also been shown to be less susceptible 
to proteolysis in in vivo assays. 
The inhibitory constants of a number of cystatill inhibitors were obtained from the literature and compared to 
oryzacystatin. It was found that OC I, which has a Ki of about 1 o-8 M for papain, binds about 4 orders of 
magnitude less efficiently than does, for example, chicken egg white cystatin (10-12 M). The fact that these two 
cystatins display such a marked difference in their affinity for the same proteinase suggested that the plant 
cystatin could be modified to improve its efficiency against both papain and possibly insect proteinases. 
Molecular modelling studies were thus carried out to determine where in OC I changes could be made without 
disrupting the entire structure. Following a study of the cystatin structures, it was decided to substitute the N-
terminus of oryzacystatin with the chicken cystatin N-terminus, for the reasons discussed in Chapter 2. The 
inhibitory capabilities of this ' hybrid ' cystatin were then compared with those of the natural inhibitors. The 
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binding of OC I to papain. Such manipulations of the inhibitor structure may also give some insight into the 
interactions of cystatins in the amino-terminus. Furthermore, should the inhibitory activity of this 'hybrid 
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CHAPTER 2 
Design and Molecular Modelling of the Hybrid Oryzacystatin 
Gene 
PART 1: Literature Review 
2. 1 Introduction 
Several approaches have been used to study cysteine proteinase inhibitors. These include crystallographic 
structure determination of both free and proteinase-bound inhibitors (Bode et al., 1988; Stubbs et al., 1990), 
molecular modelling studies of enzyme-inhibitor interactions (Bode et al. , 1990), the use of recombinant 
cystatins modified by site-directed mutagenesis (Shibuya et al., 1995; Machleidt et al. , 1995; Bjork et al., 
1995) and kinetic analyses of enzyme:inhibitor interactions (Bjork et al., 1989). 
Many of the models proposed for the interactions of cystatins with their cysteine proteinases suggest that this 
mechanism differs from that of serine proteinase inhibitors. Instead of forming covalent bonds with the active 
site residues, as is seen with serine proteinase inhibitor complexes (Laskowski & Kato, 1980; Bode & Huber, 
1992b), cystatins interact with minimal conformational changes (Lindahl et al., 1992; Pol et al. , 1995). Steric 
hindrance of substrate binding is achieved by close interactions of the binding regions of the cystatins with the 
active site cleft of the proteinase (Bode & Huber, 1992b; Auerswald et al., 1992). 
Models have been proposed to describe the interactions between cystatins and their cysteine proteinases 
(Machleidt et al., 1995) and the importance of the various binding areas of cystatins have long been debated. 
In designing the hybrid oryzacystatin gene that is the focus of this thesis, these and the structure-function 
relationships as outlined in the following sections were taken into account. 
2.2 Cysteine Proteinase Structure and Enzymatic Mechanisms 
Of the cysteine proteinases, only papain (from papaya fruit, Carica papaya; Drenth et al., 1971 ), calotropin DI 
(from the Indian Madar plant, Calotropis giganta; Heinemann et al., 1982), actinidin (from kiwifruit, Actinidia 
chinensis; Carne & Moore, 1978), human cathepsin B (Musil et al. , 1991) and carican (papaya proteinase n; 
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Papain is one of the most studied enzymes of the cysteine proteinase group. Many of these studies have 
concentrated on the chemical, physical or the kinetic properties of papain. This enzyme consists of a single 
polypeptide chain which is folded to form a cleft between two regions, known as the L and R domains. Each 
domain has a central core of hydrophobic residues, with the interface between the two being predominantly 
polar in nature. The L-domain is mostly a-helical with three a helices, designated A (residues 24 - 42, a long 
a helix through the centre of the molecule at the interface between the two domains), B (residues 50 - 57) and 
C (residues 67 - 78) (Figure. 2.1). The R-domain, on the other hand, is a twisted anti-parallel f3-sheet which is 
folded over in the form of a barrel. Its interior is filled with hydrophobic side-chains. Two a-helices; D 
(residues 117 - 127) and E (residues 138 - 143) on the molecular surface, seal opposite ends of this barrel. 
Figure 2.1: Diagram of a model showing the chain folding patterns of papain. The stars represent the 
positions of the catalytic cysteine and histidine residues. The cylinders represent the a helices and the 
arrows the f3-sheets . 
The cleft between the L and R domains contains the catalytic site residues. Cys25 forms part of the L-domain 
while the catalytic site histidine residue forms part of the R-domain (Drenth et al., 1971 ; Baker & Drenth, 
1986). Figure 2.2 shows the positions of the active site residues of papain and the coincident stefin B binding 
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Figure 2.2: Ribbon model of stefin B (pink) docked onto papain (white) . The positions of the active site 
'd C 75 dH' 159 . d' d resz ues ys- an zs are zn zcate . 
Cathepsin B is the only member of the cathepsins whose X-ray crystallographic structure has been elucidated 
(Musil et al., 1991 ). Unlike the other cysteine proteinases, cathepsin B can act as both an endopeptidase and a 
peptidyldipeptidase (Musil et al., 1991 ). This latter capacity to remove C-terminal di peptides has been 
attributed to the presence of a 20-residue insertion termed the occluding loop, which is formed by residues 108 
- 119. This loop blocks the right-hand side of the substrate binding cleft through steric hindrance. The 
residues His 11 to Asn11 3 of the occluding loop have been shown to collide with the second hairpin loop of 
cystatins (Musil et al., 1991 ), thus making the fit with cathepsin B less efficient than with pa pain. This may 
explain the reduction in affinity for the interaction of cathepsin B with chicken cystatin and stefin B (Thiele et 
al., 1990) and with cystatin C (Illy et al., 1997). The loss of affinity is less with stefin A as it has a shorter 
second hairpin loop (Popovic et al., 1988). 
Many studies have also been carried out with cathepsin H which has aminopeptidase activity. These have 
highlighted the role of an additional disulphide linked peptide in cathepsin H which originates from a part of 
this enzyme known as the mini-chain. This peptide is probably located in the S2 region of the active site cleft 
and blocks the left-hand side of the substrate binding site, thus mediating the aminopeptidase activity (Rothe et 
al., 1994). These structural differences between the various cysteine proteinases are thought to account for 
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2.2.1 Catalytic Mechanism 
Crystallographic studies (Drenth et al., 1971) have implicated the thiol residue Cys25 (papain numbering) and 
also the imidazole group of His 159 (papain numbering) as the catalytic site residues of cysteine proteinases. 
The basic steps involved in the hydrolysis of polypeptide substrates are shown schematically in Figure 2.3. 
F9 
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Figure 2.3: A generalised scheme for proteolytic cleavage. Xis the essential nucleophile, while DH is 
a proton donor that is able to protonate the leaving group (from Baker & Drenth, 1986). 
Formation of an enzyme-substrate complex occurs (the Michaelis complex; step 1). The nucleophilic group of 
the enzyme then attacks the carbon atom of the peptide bond to be cleaved, resulting in the formation of a 
tetrahedral intermediate that may be stabilised by interaction of the oxyanion (-C-0-) with an appropriate group 
on the enzyme. Bond cleavage is then completed by proton donation (by the donor group D) to the leaving 
group. This leaving group can then diffuse away (step 2), leaving the acylated enzyme which in this case is a 
thioester. This can then be hydrolysed by nucleophilic attack of Off (from a water molecule; step 3). Release 
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2.3 Structure of Cystatins 
The structures of a number of cystatins have been elucidated by X-ray crystallography. The first of these was 
that of chicken cystatin (Bode et al. , 1988). The crystal structure of stefin Bin complex with papain (Stubbs et 
al., 1990) and the NMR structure of free stefin A in solution (Martin et al., 1995; Tate et al. , 1995) were 
subsequently identified. The solution structures of natural phosphorylated (Dieckmann et al. , 1993) and a 
recombinant variant Arg-Glu-Phe[Met]lle29,leu 89 of chicken cystatin have also been solved by NMR 
analysis (Auerswald et al., 1994). More recently, a preliminary X-ray crystallographic analysis of human 
salivary cystatin has been carried out (Ramasubbu et al. , 1996). 
These and kinetic studies have shown that cystatins and stefins are tight binding, reversible inhibitors. Their 
basic structure consists of a long central a -helix, wrapped in a five-stranded anti-parallel 13-pleated sheet, with 
a subsidiary helix in the case of cystatins (family II cystatins) and a strand in the case of the stefins (family I 
cystatins). There is a highly conserved "QXVXG" region (first hairpin loop) in all cystatins which is flanked 
by the projecting amino terminus and a second hairpin loop also containing conserved residues. A schematic 
representation of the chicken cystatin structure bound to papain is shown in Figure 2.4. 
The wedge-shaped hydrophobic edge of the inhibitor is complementary in shape to the active-site cleft of 
papain. Docking experiments with papain (Bode et al., 1988) have shown that both the cystatin loops interact 
with areas that lie adjacent to papain' s catalytic residues. The amino terminus loops over the catalytic Cys25 
residue of pa pain and interacts with the S 1 and S2 subsites of papain. The first hairpin loop is believed to 
confer most of the stability to the complex, whereas interactions of the N-terminus with papain appear to 
strengthen complexes with the enzyme (Bode et al. , 1990; Turk & Bode, 1991 ; Bode & Huber, 1992). 
However, as will be reviewed later, the importance of the interactions of the various cystatin binding regions 
may be dependent on the particular cysteine proteinase to which the inhibitor is bound. 
2.4 Primary Structure Sequence Similarities between the Cystatins 
The cystatin superfamily shows strong homology amongst its members. Sequence alignments carried out, 
(Figure 2.5) show that one of the most highly conserved residues of fragments is the QVV AG region or 
variants thereof (QLVSG in chicken cystatin, Figures 2.4 and 2.5). The strong homology amongst the 
members in this region suggests that it plays an important part in the functioning of the inhibitors. Other 
common features include a conserved Gly9 residue (chicken cystatin numbering) and a conserved Pro103 -
Trp 104 region (chicken cystatin numbering). These Pro and Trp resides are also conserved in the third domain 
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Figure 2.4: A diagrammatic model showing the interaction of chicken cystatin with papain (adapted 
from Bode et al. , 1988). The residues of chicken cystatin which are important for interaction with 
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The experimentally determined structures of the cystatins (Bode et al., 1988; Stubbs et al., 1990) suggest that 
the conserved Gly
9 
residue may confer some flexibility to the amino terminus. Despite the conserved regions 
in the cystatins, there are also regions of high variability. These are often the site of modifications, for 
example, phosphorylation found on Ser80 in chicken cystatin (Dieckmann et al., 1993) and glycosylation found 
in the kininogen domains (Kellermann et al., 1986). 
As mentioned previously (section 2.3), cystatins (family II) have a second helix (amino acid residues 69 - 91 in 
chicken cystatin), while stefins have a strand. Other differences between these two families are as follows: 
• the stefins do not contain the two disulphide bonds found in the family II cystatins. 
• the carboxy-termini of the stefins (family I cystatins) often extend beyond those of the cystatins in family 
II by 9 residues. 
• compared to the family I cystatins, the family II cystatins have much longer N-terminal regions. The 
conserved glycine in these cystatins is often preceded by some 10 amino acid residues. 
2.5 The Functions of the Cystatin Binding Loops 
A number of substitution and deletion experiments have been carried out in order to establish 
structure/function relationships between the different regions of the cystatins and their inhibitory activity. 
These have identified the amino-terminus, the first hairpin loop and the second hairpin loop as the most 
important regions. 
2.5.1 Importance of the Amino-Terminus 
Although it has been estimated that 36 - 40% of the binding energy in the formation of the complex between 
chicken cystatin and papain is contributed by the N-terminal residues (Martin et al., 1994; Lindahl et al., 
1992), the importance of the N-terminus in the binding of members of the cystatin superfamily to their cognate 
enzymes remains a controversial issue that has yet to be resolved. 
A survey of the literature has shown that the family I and II cystatins interact differently with their cognate 
enzymes so that the relative importance of the different binding region varies. For this reason, the different 
families are affected to different degrees by modifications of their amino terminus and a separate discussion of 
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1. Importance of the N-terminus in Family I Cystatins 
The best characterised representatives of this family are stefins A and B (Barrett et al., 1986; Turk & Bode, 
1991). Despite the fact that NMR analyses of the structure of stefin A (Martin et al., 1995; Tate et al., 1995) 
have shown a number of similarities in the overall pattern, amino acid substitution and deletion experiments in 
the N-terminus of stefins A and B have very different effects on the inhibitory activity of these proteins. 
In experiments with stefin A, deletion of the first eight residues (Shibuya et al., 1995) or the first six residues 
(Pol et al., 1995) from the N-terminus led to complete inactivation of the inhibitor when tested with papain or 
cathepsin B. Truncation of the first two residues caused no change in activity against papain, whilst deletion 
of Pro3 led to inactivation of the inhibitor (Shibuya et al., 1995). Substitution experiments, on the other hand, 
in which Pro3 was replaced with small amino acids such as leucine, had no effect on inhibitor activity. This 
suggests that, while an amino acid residue in this position is important for the functioning of the N-terminus, 
the proline residue is not required for tum formation or main chain rotation but is important for the contacts it 
provides with the proteinase (Shibuya et al., 1995). Studies carried out on a truncated N-terminus of cystatin-
a from rat epidermis showed similar results to those found with human stefin A (Takeda et al., 1985). This is 
not surprising, since these two cystatins are highly related (Barrett et al., 1986). 
Shibuya et al. (1995) have used 2D 15N-1H HSQC NMR spectra to study further the effects of amino-terminal 
truncation on stefin A. Four-residue truncation of the amino-terminus was found to cause changes in the 
conformation of the V47 and V48 residues that make up part of the conserved QVV AG region of the first 
hairpin loop. The authors concluded therefore, that N-terminal truncation may cause a conformational change 
in the first loop which in tum, may also cause a conformational change in the second binding loop. The 
resulting lack of sufficient contact between the hairpin loops and the proteinase would severely affect 
inhibitory activity. The N-terminus of stefin A must therefore contribute to both the contact with the 
proteinase and maintain the conformational integrity of the tripartite wedge of the inhibitor. 
Elongation of the N-terminal region of stefin A had only a minor effect on the affinity of the inhibitor for 
papain and cathepsin H (Pol et al., 1995). These findings are contrary to results obtained with stefin B where 
elongation of the N-terminus resulted in weaker binding to cathepsin H (Jerala et al., 1994). Pol et al. (1995) 
suggested that this was due to the fact that the N-terminal regions of the two stefins interact with cathepsin H 
in different ways. 
Oryzacystatin differed from stefin A in that the amino-terminal truncation of the first 21 residues had little or 
no effect on the inhibition of papain (Abe et al., 1988). Similarly, the removal of the N-terminal residues from 
stefin B resulted in little change in inhibitory activity (Jerala et al. 1990). However, Stubbs et al. (1990) have 
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the crystal structure protein because of possible reactivity of the Cys3 side chains), are responsible for most of 
the contacts with the proteinase in the N-terminal region. 
Thiele et al. (1990) made several truncated forms of stefin B. Removal of the first two amino acids and the 
substitution of Cys3 with a hydrophobic phenylalanine did not significantly change the inhibition constants. 
The introduction of a negatively charged glutamic acid in place of the Cys3, on the other hand, increased the K; 
for both papain and cathepsin B (Thiele et al., 1990). The glutamic acid obviously interfered electrostatically 
with both the active-site cleft of the proteinase. These authors suggested, therefore, that it is electrostatic 
interactions which are important in the contacts of stefin B at the amino-terminus. It thus appears that only 
certain residues can be accommodated at the contact area with the proteinase. 
Since the effect of N-terminal truncation of the different stefins are inconsistent, many believe that the main 
contact area of stefins with their cognate enzymes comes from the first (QVV AG) binding loop with the N-
terminal 'trunk' helping to pilot the inhibitor into the active site cleft following binding to the enzyme (Stubbs 
et al., 1990; Thiele et al., 1990). This would imply that the N-terminus is flexible and Martin et al. (1995) 
have indeed shown, by NMR, that the N-terminus of free stefin A aoes not populate any single conformation 
to a significant degree but changes its conformation on binding. Jerala (1992) also suggests that the 
conformation of the N-terminal residues of free and bound stefins differ. It seems, therefore, that the N-
terminal 'trunk' of stefin A bends and aligns itself to the groove of the enzyme upon binding to the proteinase 
so helping to 'anchor' the inhibitor. The contribution of the amino-terminus of stefin B to binding in this 
region is, however, negligible (Jerala, 1992). This may explain why truncation of the N-terminal part of stefin 
B does not weaken binding to the enzyme. 
Tate et al. (1995) have used the differences between the inhibitors to propose a basis for the classification of 
the cystatins. They argue that cystatins can essentially be divided into two groups. Those in group I include 
cystatins such as oryzacystatin and stefin B that do not require the N- and/or C-terminal segments to maintain 
the active conformation of the first hairpin loop. Those in group II, on the other hand, such as stefin A, do 
require both the N- and C-termini. In the case of stefin A, for example, truncation of a few residues after Pro3 
from the N-terminus would cause the N-terminal peptide segment to pull apart from the C-terminal region thus 
causing a change in the conformation of the first hairpin loop (Tate et al., 1995). In the case of stefin B (Jerala 
et al., 1991) and oryzacystatin 1 (Abe et al., 1988) where the N- and C-terminal interactions are not required to 
maintain their active conformation, these deletions are without effect. Further experiments are needed to 
determine the validity of this theory, especially since there is now conflicting evidence on the effect of N-
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2. Importance of the N-terminus in Family II Cystatins 
The function of the N-tenninus of family II cystatins has, as in the case of the family I cystatins, been 
elucidated by inhibition experiments with N-terminally truncated forms of the inhibitor. Detailed analyses of 
the N-terminal segments of chicken cystatin and human cystatin C indicate that, when family II cystatins 
inhibit their target proteinases, residues near the N-terminus bind in a substrate-like manner to one or more of 
the unprimed substrate-binding subsites in.the enzyme. The experimental results indicate that the specificity of 
different cystatins for the different cysteine proteinases is partially determined by the residues present in this 
area of the enzyme (Bjork et al., 1994). 
Chicken cystatin has been shown to form complexes with cysteine proteinases even after their catalytic sites 
have been inactivated by bulky active-site-directed reagents (Anastasi et al., 1983). Keilova & Tomasek 
(1974) showed that a complex could be formed between chicken cystatin and cathepsin B even if the free SH-
group of the catalytic site was blocked with mercury. These findings raise the pos~ibility that, in the complex, 
the surface of the proteinase and inhibitor are not closely associated in the region of Cys25 (papain numbering). 
Truncation of chicken cystatin from its full length (N-terminal serine) to the truncated form beginning with 
Leu7, causes no change in the inhibitory activity (Machleidt et al., 1989). Truncation beyond Leu8, leads to an 
approximately 5000-fold lower affinity for papain (Machleidt et al., 1989). Truncation of chicken cystatin 
beyond Giy9, on the other hand, caused no further loss of inhibitory activity. Thus, Gly9 and residues 1 to 6 
account for a substantially smaller portion of the binding energy than do the two leucine residues (Auerswald 
et al., 1995). 
Bode et al. ( 1988) claimed that the functional importance of Leu8 stemmed from its interaction with the S2 
subsite of papain. Lindahl et al. (1992) showed that this residue only contributes approximately one-third of 
the unitary free energy of bind:i:ig of the N-terminal region of cystatin to papain. Leu7, on the other hand, 
contributes a larger portion of the binding energy (Lindahl et al., 1992). The general consensus (Machleidt et 
al., 1989; Abrahamson et al., 1991; Lindahl et al., 1992; Bjork et al., 1994) is therefore, that Leu7 and Leu8 are 
important for interactions of the N-terminus, while residues N-terminal to Leu7 stabilise the interactions 
between the enzyme and the inhibitor. These results are in accord with the X-ray studies on chicken cystatin 
which show that the N-terminus is flexible. Removal of this region shows no alteration in the 3-D 
conformation of the rest of the protein (Bode et al., 1990) and the loss of affinity following truncation is due. to 
the loss of contacts in the N-terminal region. The N-terminus thus contributes to stability by keeping the 
inhibitor anchored to the proteinase and thereby reducing the rate of dissociation (Bjork et al., 1994). 
The function of the N-terminal segment of chicken cystatin is not entirely straightforward in the sense that the 
effect of its removal depends upon the structure of the active-site region of the proteinase with which it is 
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decreased association rate constant or an increased dissociation rate constant, or both, depending on the target 
enzyme (Bjork et al., 1994). For example, the decreased affinity ofN-terminally truncated chicken cystatin, is 
due to an increased dissociation rate constant in the case of papain, to both a decreased association constant 
and increased dissociation rate constant for actinidin, and finally, to a decreased association constant for 
cathepsin B. The differences between papain and actinidin may be due to the fact that these enzymes differ in 
their S2 subsites (Drenth et al., 1971) and may thus bind the N-terminal regions of cystatins differently. In the 
case of cathepsin B, the presence of the occluding loop causes collision around Trp 104 in chicken cystatin 
which prevents close contact ofthis residue with the active site of cathepsin B (Bjork et al., 1994). 
Truncations and substitutions in the N-terminus of cystatin C have also been extensively studied (Abrahamson 
et al., 1991; Hall et al., 1993; Lindahl et al., 1994; Hall et al., 1995). As with chicken cystatin, it appears that 
the N-terminus of this inhibitor makes an important contribution towards its inhibitory activity. For example, 
truncated forms of human cystatin C starting with Leu9 and Val10 before the conserved Gly11 (Gly9 in chicken 
cystatin) has the same affinity for papain as the full length sequence. However, a truncated form starting with 
Gly12 is a 1000-fold weaker inhibitor (Brzin, 1984). 
The glycine residue (Gly11 in cystatin C and Gly9 in chicken cystatin) is highly conserved in the family II 
cystatins and in the other cystatin families. Experiments that have replaced the evolutionary conserved Gly11 
residue with different amino acids (Hall et al., 1993), even those with small side-chains such as a serine or 
alanine have shown decreased affinities for papain, cathepsin B and ficin (Lindahl et al., 1994). Substitutions 
with bulky side-chains had the same effect. This further confirms the hypothesis that the conserved glycine 
residue, by conferring flexibility on the N-terminal region of the inhibitor, allows maximum interaction 
between this segment and the substrate binding pockets of the target enzyme. The glycine residue that is 
similarly conserved in family I is also responsible for flexibility of these cystatins. 
Despite the findings that truncation of the N-terminus affects the binding of chicken cystatin to the 
endopeptidases, Nicklin & Barrett (1984) showed that the N-terminus of chicken cystatin makes no 
appreciable contribution to the inhibition of the exopeptidase, dipeptidyl aminopeptidase I ( cathepsin C). 
Thus, the N-terminal contact region of cystatins seems to be indispensable for effective inhibition of cysteine 
endoproteinases, but not for the inhibition of the exopeptidase cathepsin C. 
In conclusion, it appears that in the family II cystatins, the conserved glycine residue, as well as one or two 
residues preceding this glycine, are responsible for the tighter binding of cystatins to papain. The amino 
terminus may be important in family II cystatins to compensate for less favourable contacts made in the hairpin 
loops such as the QLVSG sequence in chicken cystatin, for example. Family I cystatins (with the exception of 
stefin A) can be truncated to only one residue before the glycine residue without loss of activity (Machleidt et 
al., 1989). Furthermore, in the case of both the cystatins and the stefins, the amino terminal residues have 
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Cathepsin L is perhaps the most sensitive proteinase to changes in the N-terminal region of cystatins 
(Auerswald et al., 1995). It can thus be concluded that the importance of the N-terminus may depend on the 
cysteine proteinase and thus the amino acid residues involved in the contacts with the inhibitor. 
Table 2.1 gives a summary of some of the mutation experiments reported in the literature, and the Ki obtained 
with different cysteine proteinases as a result of these mutations. 
2.5.2 Variants of the First Hairpin Loop 
X-ray analysis of chicken cystatin has revealed three contact regions between the inhibitor and papain. The 
most important of these is the first hairpin loop containing the QXVXG region that has been shown, by 
sequence alignments, to be highly conserved and therefore involved in the inhibitory activity of the protein 
(Barrett et al., 1986; Abrahamson et al., 1987; Turk & Bode, 1991). Experimental results using site-directed 
mutagenesis have for the most part, established the validity of this conclusion. 
Studies on papain have shown that this enzyme does not have a binding pocket that is selective and specific for 
the QXVXG sequence of the inhibitor as there is no specific interface for this arrangement of amino acids 
(Yamamoto et al., 1992). It is rather the hairpin loop structure that this sequence contributes to the tertiary 
structure of the inhibitor that is important. Most of the binding energy comes from the tight interaction of the 
first hairpin (QVV AG) loop with the S1-pocket of the enzyme (Thiele et al., 1990 ). 
Of the amino acids in the first hairpin loop, the most highly conserved are Gln53 (which forms a H-bond with 
Gly9 of the N-terminus), Val55 and Gly57 (chicken cystatin numbering, see Figure 2.5). Mutations in any of 
these positions results in a reduced affinity for the cysteine proteinases by up to three orders of magnitude 
(Turk & Bode, 1991). The extent to which substitutions in any of these regions affects inhibition is very much 
dependent on the various cysteine proteinases. 
Nikawa et al. (1989) probed exchanges in this conserved region by replacing the QVV AG of cystatin A with 
KVVAG or QVTAG. They found that these replacements did not significantly affect the inhibitory activity of 
cystatin A towards papain or the cathepsins B, H and L. In the case of Oryzacystatin I, on the other hand, 
substitutions of Pro and Leu for Q53 and G57 respectively or Asp for the second Valine (V55) resulted in an 
increase in the Ki (Abe et al., 1991). It has been suggested (Bjork et al., 1995) that the increased Ki from 
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Table 2.1: Summary of mutation experiments reported in the literature and the effect on the Ki 
Sequence * K; (nM) 
Pa pain Cathepsin Cathepsin Cathepsin B Reference 
H L 
Family l Cystatins . .· 
Human Stefin A 
MIPGGLSEAKP ... 1.2 ND ND 17.7 Shibuya et al., 1995 
IPGGLSEAKP ... 2.45 ND ND 20.5 Shibuya et al., 1995 
GLSEAKP ... 414 ND ND ND Shibuya et al., 1995 
LGGLSEAKP ... 6.35 ND ND 293 Shibuya et al., 1995 
Human Stefin B 
l\1MCGAPSATQ ... 0.12 ND ND 73 Barrett et al., 1986 
LLCGAPSATQ ... 0.004 ND ND 113 Thiele et al., 1990 
LLFGAPSATQ ... 0.005 ND ND 273 Thiele et al., 1990 
LLEGAPSATQ ... 0.120 ND ND 881 Thiele et al., 1990 
SATQ ... 0.008 ND ND ND Thiele et al., 1990 
CGAPSATQ ... 0.010 ND ND ND Thiele et al., 1990 
Family II Cystatins t"-
., 
·J ·.:. :\. . ;; 2. 
Chicken Cvstatin 
SEDRSRLLGAPVPVDEND ... 0.006 ND ND 4 Bjork et al., 1994 
AEFMVPVDEND ... 166 ND 1.6 ~ 20 000 Auerswald et al., 1994 
GAPVPDEND ... 12 ND ND 1800 Bjork et al., 1994 
LLGAPVPDEND ... 0.05 ND ND ND Lindahl et al., 1992 
LGAPVPDEND ... 0.12 ND ND ND Lindahl et al., 1992 
GAPVPDEND ... 33.9 ND ND ND Machleidt et al., 1989 
APVPVDEND ... 31.6 ND ND ND Machleidt et al., 1989 
Cystatin C 
SSPGKPPRL VGGPMDASVEE. 0.0011 ND ND 0.3 Bjork et al., 1994 
SSPGKPPRL VGGPMDASVEE. 0.0011 ND ND 0.28 Lindahl et al., 1994 
SSPGKPPRLRGGPMDASVEE. 0.13 ND ND 4.2 Lindahl et al., 1994 
SSPGKPPRL V AGPMDASVEE. ND ND ND 8.1 Bjork et al., 1995 
SSPGKPPRL VEGPMDASVEE. 1.7 ND ND 18000 Bjork et al., 1995 
SSPGKPPRL VWGPMDASVEE. 0.8 ND ND 9600 Bjork et al., 1995 
GGPMDASVEE. ND ND ND 1.3 Bjork et al., 1995 
GGPMDASVEE. ND 2.15 2.11 101 Abrahamson et al., 1991 
SSPGKPPGL VGGPMDASVEE. ND 0.27 <0.01 1.9 Hall et al., 1995 
SSPGKPPRGVGGPMDASVEE. ND O.Ql <0.01 46 Hall et al., 1995 
SSPGKPPRLGGGPMDASVEE. ND 10 <0.01 500 Hall et al., 1995 
SSPGKPPRL V ~GPMDASVEE. 0.024 ND ND 4.4 Hall et al., 1993 
SSPGKPPRL V~GPMDASVEE. 0.077 ND ND 14 Hall et al., 1993 
SSPGKPPRL VWGPMDASVEE. 2.4 ND ND >50 Hall et al., 1993 
SSPGKPPRL VEGPMDASVEE. 3.5 ND ND >50 Hall et al., 1993 
SSPGKPPRL VRGPMDASVEE. 3.8 ND ND >50 Hall et al., 1993 
GGPMDASVEE. 29 ND ND 13 Hall et al., 1993 
* The above K; determinations were carried out using Z-Phe-Arg-AMC as the substrate in the case of papain and the 
cathepsins B and L. The substrate Arg-AMC was used for cathepsin H 
Amino acids shown in bold and underlined represent changes made by mutation experiments. 
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Peptide inhibitors that mimic the QVV AG loop of cystatih surfaces have been synthesised (Lalmanach et al., 
1993; Serveau et al., 1994). These were shown to retain significant inhibitory activity towards papain. 
However, the inhibition by this QVV AG peptide was time dependent. Peptide backbone cleavage was found 
to occur at the A-G bond following long incubation with papain whereas the QVV AG sequence is not cleaved 
in the natural inhibitors. This may be due to the particular spatial conformation of this sequence within the 
natural cystatin structure (Lalmanach et al., 1993; Serveau et al., 1994). 
It is clear that the first hairpin loop is extremely important in the binding of cystatins to their cysteine 
proteinases. This loop may contribute most of the free energy of binding. 
2.5.3 The Second Binding Loop 
In comparison with the N-terminus or the first binding loop, relatively little is known of the importance of the 
second hairpin loop for the stability of the molecule or its contribution to inhibitory activity. It is however, 
generally believed that all three regions must contribute to the "overall fit" of the inhibitor into the active site 
cleft of the enzyme. 
The second binding loop, like the first is quite hydrophobic in nature. Pro103 and Trp104 (chicken cystatin 
numbering) are well conserved in the family II cystatins and in the third domain of the kininogens (Kellermann 
et al., 1986) suggesting that they are functionally important. No counterpart to this conserved region has been 
· found in stefin A. In fact, stefin A and rat cystatin a are devoid of any aromatic amino acids in their second 
binding loop, whereas most of the other cystatins have a his/trp residue on this loop (Bode et al., 1988). 
Support for the contribution of the second hairpin loop to the function of chicken cystatin was obtained by 
Nycander & Bjork, (1990) who modified Trp104 with a 2-hydroxy-5-nitrobenzyl group and showed that the 
product had a 100,000-fold lower affinity for papain than the intact inhibitor. 
Similar results were obtained for oryzacystatin I, where substitution of amino acids in the second binding 
region resulted in a significantly higher Ki value, indicating the importance of this region for the inhibition of 
proteinases (Urwin et al., 1995). Complete loss of the second hairpin loop of oryzacystatin i.e. a large deletion 
at the carboxyl-terminus, also resulted in weaker inhibitory activity (Abe et al., 1988). 
Despite the importance of the second loop, mutations in this region have been shown to have a significantly 
lower effect on the stability of the molecule and on the affinity for proteinases than mutations in the N-
terminus or the first hairpin loop (Auerswald et al., 1992;. Auerswald et al., 1995; Stubbs et al., 1990). On the 
other hand, Trp104 of chicken cystatin and the N-terminus have been shown to be equally important for the 
inhibition of cathepsin S, whereas Trp106 is more important than the N-terminus in the case of cathepsin Hand 
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These results further support the observation that modifications of the inhibitors have effects that differ 
depending on the enzyme that is used to test them. Binding to cathepsin B has been shown to be even more 
affected by insertion of a 'wrong' second hairpin loop than variations in the first loop (Auerswald et al., 1995). 
This is due to steric collision with the occluding loop of cathepsin B. 
2.5.4 Studies Involving 'Whole Cystatin Region' Substitutions 
Relative to the substitution and deletion experiments, very little has been done with whole sequence 
replacement of cystatin binding areas. Those experiments which have been carried out have yielded 
interesting results. When, for example, stefin B was used as the master protein onto which different blocks 
similar either to cystatin C or kininogen were ligated (Jerala et al., 1994), both amino termini were longer than 
that of the original stefui B and both substitutions introduced an ionic residue. The affinity and kinetic 
properties of these hybrid stefins was nevertheless found to be largely unaffected for papain and cathepsin L. 
These modifications did not improve inhibition of cathepsin B, which is only moderately inhibited by stefin B, 
and inhibition of cathepsin H was found to be weaker than that of the original stefin (Ki 0.14 nM and 0.9 nM 
compared to 0.02 mM for wild-type stefin B) and approached that of human cystatin C (0.28 nM) and the 
second domain of human kininogen (1.2 nM). Most differences that were observed could be ascribed to a 
decrease in association constants of both mutants, indicating that the rate of complex formation is altered by 
adding a charged group to the amino terminus (Jerala et al., 1994). 
Auerswald et al. (1996) substituted the N-terminus as well as the first and second hairpin loops of chicken 
cystatin for the corresponding regions of human kininogen domain 2 in a single and combined manner. The 
characteristic feature of this second kininogen domain is that it can inhibit calpain (Miiller-Esterl et al., 1986; 
Bradford et al., 1993). Temporary inhibition of calpain was achieved with hybrids carrying the N-terminus of 
kininogen alone and with those carrying both the N-terminus and the first hairpin loop. Hybrids of the second 
loop were weaker inhibitors of calpain. This suggested, therefore, that the N-terminus and first hairpin loop 
play the niost important role in the calpain inhibition by human kininogen domain 2. 
In this project, the N-terminus of oryzacystatin was substituted for amino acid residues from the N-terminus of 
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2.5.5 General Conclusions 
It can perhaps be concluded that both hairpin loops, as well as the N-terminal trunk of the inhibitor complex, 
contribute to complex formation. The first hairpin loop possibly maintains its conformation so as to fit 
properly into the active site cleft of the enzyme. The N-terminus and the second hairpin loop, which often 
have weaker contacts with the proteinase, adopt a conformation which stabilises the interactions between the 
first binding loop and the enzyme (Tate et al., 1995). In fact, the importance of 'correct conformation' of the 
hairpin loops for binding has been shown (Machleidt et al., 1995). In these experiments, papain activity was 
only transiently inhibited and reappeared with time. This was found to be due to a selective cleavage of the 
Gly9- Ala10 bond in the N-terminal region of chicken cystatin (Machleidt et al., 1995) and the Gly11- Gly12 
bond in cystatin C variants (Grubb et al., 1990). This resulted in truncated inhibitors with lower affinities. 
These results suggest therefore, that distorted contacts of one of the hairpin loops affects the binding of the N-
terminal contact area. Covalent interaction of the Gly-Ala or Gly-Gly bond with the active site cysteine 
residue of papain can thus occur, and the bond is cleaved in a substrate-like manner (Machleidt et al., 1995). 

















Figure 2.6: The 'elephant-trunk' model showing cystatin binding to papain. Cleavage of the Gl/-Ala10 
bond is thought to occur via one of two possible mechanisms. (1) competition of inhibitor-like and 
substrate-like complexes for free papain; or (2) rearrangement of the inhibitor-like conformation by 
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PART 2: Molecular Modelling 
. 
2.6 Aims of the Molecular Modelling 
From the literature, it is clear that the regions interacting in the complex of cystatins with their cysteine 
proteinases have been identified, and site-directed mutagenesis can be employed to probe the importance of 
each residue or region for inhibition. The aim of the molecular modelling was two-fold: 
• To determine a possible structure for oryzacystatin. 
• By studying the structures of chicken cystatin and the generated OC I model, determine which sections 
of the amino terminus of OC I could be replaced by those in chicken cystatin. 
• Having decided on the areas to substitute, determine how this new 'hybrid' inhibitor might interact with 
pa pain. 
Any improvement in the inhibitory capabilities of this hybrid inhibitor would be beneficial, since a long term 
goal of this project is to utilise protein engineering methodology for the development of a proteinase inhibitor 
which has strong inhibitory activity against physiologically relevant cysteine proteinases such as those found 
in the insect order Coleoptera. 
2. 7. Reasons for using Papain in the Modelling Studies 
Papain was used as the model proteinase in the modelling studies for the following reasons: 
• It is well-characterised (Polgar, 1973; Angelides & Fink, 1979; Berti et al., 1990; Matsumoto et al., 1994) 
and is often used in the study of protein-inhibitor interactions with cystatins. 
• It is available in pure form and in large quantities. This would be useful for the kinetic studies performed 
in this project. 
• Its X-ray structure has been elucidated and its co-ordinates are readily available for use in computer 
modelling and docking studies with cystatins. 
Since the long-term goal of this project is to look at insect biocontrol, it is perhaps more appropriate to use 
insect cysteine proteinases in the modelling studies, specifically those from the Coleoptera. However, very 
little work has been done on insect proteinases, and most have not been characterised. Thus, since the 
foremost aim of this project was to investigate the effects of substitutions in the amino terminus, papain would 
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2.8 Oryzacystatin Secondary Structure Predictions 
Although coordinates for the X-ray crystallographic structure of oryzacystatin are not available, the tertiary 
structures of a number of cystatins are known and from these and sequence alignments it appears that all 
cystatins have a similar basic structure. Given the high degree of homology seen in the primary sequence 
alignments (Figure 2.5), one may assume that oryzacystatin I (OC I) should form a very similar structure to 
that of the other cystatins and hence base prediction on this assumption. 
1 2 3 4 5 6 
Al2345678901 A23456789012345678901234567890123456789012345678901AB2345 
OCI: MSSDGGPVLGGV---EPVGNENDLHLVDLARFAVTEHNKKANSLL--EFEKLYSVKQQVVAGTLYYFTIEVK 
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Figure 2. 7: Primary sequence alignments of oryzacystatin I (OC I) with chicken cystatin (CC) and 
ste.fin B (SB) (numbering is as for chicken cystatin, extra amino acids in the other cystatin structures are 
represented using letters from the alphabet; adapted from Turk & Bode, 1991). The predicted 
secondary structures for chicken cystatin (Bode et al., 1988) and ste.fin B (Stubbs et al., 1990) are 
shown above and below the sequences respectively. 
Key: 
a= a-helix 
f3 = f3-sheet 
t = f3-turn 
c = random coil 
The Chou and Fasman algorithm (Chou & Fasman, 1978) was used to predict local structural elements, such as 
a-helices, f3-sheets and f3-turns and this revealed a possible secondary structure similar to that of other 
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amino-termini. An almost equal number of a-helix former and helix breakers were shown to occur in the first 
18 amino acids. This would make up the N-terminal region of OC I and suggests that this region has no 
definite a-helix or 13-sheet structure. Residues Asp 18 to Lys34 (numbering as in Figure 2.7, above) showed 
strong a-helix formation, which is similar to results shown for stefin B and chicken cystatin. The last 60 
residues showed a high probability for 13-sheet formation, with some a-helix. 
An alternative method for modelling OC I was to consider the known structures of chicken cystatin and stefin 
B (Figure 2.7) and together with their primary sequence alignments (as reported by Turk & Bode, 1991) with 
each other and OC I, predict a secondary structure for OC I. 
Thus, from the above sequence alignments, patterns of homologous residues are evident amongst the 
sequences which can be used to infer similar secondary structure. Figure 2.8 shows a predicted secondary 
structure for OC I as deduced from primary sequence alignments and Chou-Fasman secondary structure 
predictions. 








Figure 2.8: Secondary structure prediction for OC I (numbering as for chicken cystatin, extra amino 
acids in the OC I structure are represented using letters.from the alphabet). 
Key: 
a= a-helix t = 13-turn 
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A number of observations can be made from these primary and secondary structure predictions. For example: 
• The QVV AG region is common to both stefin B and oryzacystatin, while chicken cystatin has a similar 
sequence in the form of the QLVSG region. These sequences have been shown by X-ray crystallographic 
data to be involved in the formation of a hairpin loop (Bode et al., 1988; Stubbs et al., 1990) and so this 
corresponding region in OC I would be expected to take on a similar conformation. Furthermore, the 
importance of this region in the inhibitory activity of OC 1 has been demonstrated (Abe et al., 1991 ). Thus, 
from the secondary structure predictions, it seems likely that oryZacystatin forms a similar wedge in the 
binding region as chicken cystatin and stefin B. 
• From the alignment, it can be seen that the PWMD sequence of oryzacystatin is equivalent to the PHEN 
sequence in stefin B and the PWL sequence in chicken cystatin. The tryptophan residue is thus conserved 
and this loop in oryzacystatin was presumed to form a similar conformation to that of the other two 
cystatins. 
• There are regions of homology in the amino-terminus with respect to the conserved glycine residue. 
2.9 A Tertiary Structure Model of Oryzacystatin I 
To construct a model of the natural OC I inhibitor, it was decided to use one of the known cystatin structures 
(available in the Brookhaven data bank) to serve as a 'backbone model'. The question of which cystatin 
should be used for this purpose then arose and the f llowing points were considered in making this choice:· 
• Firstly, although OC I is a member of family V in the cystatin superfamily, it has a high degree of 
sequence homology with the family I cystatins and indeed, Turk & Bode (1991) have suggested that it 
could be considered a member of this family. The only member of family I whose structure was available 
at the time of modelling was stefin B (Stubbs et al., 1990). This structure (available in the Brookhaven 
data bank) was therefore used rather than chicken cystatin (Bode et al., 1988) which belongs to the family 
II cystatins. 
• Secondly, the coordinates for stefin B represent the inhibitor in the bound form (i.e. complexed to papain). 
I thought this was more informative in terms of the contacts the amino terminus makes with papain. It has 
been suggested (Martin et al., 1995), that owing to the flexibility of the amino terminus, changes in the 
position of this region occur on binding. 
In constructing a model of OC I, greater emphasis was placed on the three binding regions of this cystatin, 
since these are the main areas which interact with the proteinase. Therefore, I assumed that any insertions or 
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region joining helix I to strand B (Stubbs et al., 1990), or in the open 13-hairpin loop region from va166 -Asp93 
( ste:fin B numbering; Stubbs et al., 1990). This is however, discussed more fully in section 2.11. 
Alignment of the sequences of oryzacystatin I and stefin B (Figure 2.9) showed two obvious differences 
between the two structures: 
• the OC I amino terminus extends beyond the stefin B amino terminus by 6 residues. 
• the stefin B carboxy terminus extends beyond the OC I C-terminus by 5 residues. 
In the case of OC I, the shorter C-terminus is compensated for by a longer N-terminus - a feature that should 
allow the two termini to come into contact with each other when the inhibitor is in the unbound form as was 
shown with stefin A (Tate et al., 1995). In this conformation the N- and C-termini interact very closely with 
one another to form a more compact structure, making the N-terminus less susceptible to proteolytic attack. 
The authors do, however, caution that the relative orientation of the N~terminal segment in their structure was 
in sharp contrast to the random conformation of the N-terminal segments in the solution structure of cystatin A 
as deduced by Martin et al. (1995) at pH 5.5. With respect to OC I the question therefore arose as to how the 
extended N-terminus would lie when free in solution or when bound to the proteinase. 








Figure 2.9: Sequence alignment of oryzacystatin I (OC I) and stefin B (SB) (numbering as for chicken 
cystatin, extra amino acids in the OC I structure are represented using letters from the alphabet; 
adapted.from Turk & Bode, 1991). The similarities between the sequences are highlighted in bold. 
As no model of a cystatin with as long an amino terminus was available to determine the interactions in this 
area, a possible model was inferred from a consideration of the interactions of the amino acid residues of the 
inhibitor and those of papain in this region. Biograf software (Biodesign, Pasedena, U. S. A) on an Evans and 
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Primary sequence alignments were used as a point of departure to model the N-terminus of OC I onto that of 
stefin B. In the OC I model, the Gly9-Gly10-Val11 residues of OC I (nwnbering as in Figure 2.9) replaced the 
Gly4-Ala5 -Pro6 sequence of stefin B (stefin B nwnbering; Stubbs et al., 1990). The additional Glu11A residue in 
the OC I sequence (Figure 2.9), was inserted after the Val12 (ex-Pro6) residue in the stefin B structure, as there 
was no corresponding residue in stefin B. 
The extra amino acids required for the construction of the OC I N-terminus were MA to L 8 (numbering as in 
Figure 2. 9). These were then built onto the end of the N-terminus beyond Gly9 (ex stefin B Gly4). This 
produced a long extended strand which projected off the papain surface while the other amino acids in this 
region remained fixed. A series of steps consisting of alternating energy minimisations and simple dynamics 
were then set up to minimise this structure. Both papain and the N-terminal 17 residues of OC I were included 
in this energy expression. This was done to minimise bad through-space contacts and to regularise the steric 
hindrances between the N-terminus and papain in this region. 
Most of the movement during these energy minimisation steps was found to occur in the N-terminal 5 residues 
(A - 4). Residues Gly5 - Leu8 (numbering as in Figure 2.9) showed little movement, possibly due to steric 
hindrance from papain. This model suggests therefore, that on binding, the amino acids from Gly5 to Leu8 
could lie along the surface of papain. Gly? of OC I in this model kept its open type II tum following the 
energy minimisations and simple dynamics. This residue may, therefore, provide the anchorage for the 
contacts in the amino terminus as is seen with Gly9 of chicken cystatin (Bode et al., 1988) and the Gly4 
residues of stefin B (Stubbs et al., 1990) and stefin A (Martin et al., 1995). 
To determine if it were plausible for the N-terminus of OC I to 'wrap' around papain rather than projecting out 
into solution, the carbonyl bond of the Gly4 residue was rotated. This moved the first four residues of OC I 
down close to pa pain (Figures 2.10 and 2.11 ). This new structure was then energy minimised with pa pain also 
being included in the ener:gy expression. 
The result of this rotation brought the first methionine residue, for example, into the vicinity of the Trp67, Val57 
and Phe207 residues of the enzyme. Whether or not these first few residues of OC I do make contact with 
papain could only be deduced from X-ray crystallography studies. It is clear, however, that any contacts made 
by these four amino acids with papain would not strengthen the binding in this area. This was in accord with 
Urwin et al. ( 1995b ). These authors found that removal of the first 21 amino acids from the N-terminus of OC 
I did not affect its inhibitory activity towards papain. This is in contrast to chicken cystatin whose N-terminal 
Leu7 and Leu8 residues make contacts with similar papain residues in this region. However, if these last four 
residues projected out into solution, they could be susceptible to proteolytic attack. Unlike chicken cystatin, no 
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Figure 2.10: The half-bonded backbone structure of the OC I amino-terminus along the groove of 
papain (blue) . The final four amino terminal residues (indicated by the red arrow) are bending down. 
Figure 2.11 shows a ribbon model for a proposed structure of OC I with the N-terminus 'wrapping' around 
pap am. 
Figure 2.11: A ribbon model of a proposed structure of OC I on binding to papain. The arrow 
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2.9.1 Observations from the Model 
The literature offers conflicting views of the functions of the N-terminus. Urwin et al. (1995b) found that the 
K; value of an amino-terminally truncated oryzacystatin mutant lacking Gl/ (numbering as in Figure 2.9) was 
comparable to that of the full-length oryzacystatin, while the removal of Gly9, on the other hand, drastically 
reduced the inhibitory capabilities of this inhibitor (Urwin et al., 1995b ). In contrast, Abe et al. (1988) showed 
that oryzacystatin hybrid mutants lacking the amino-terminal 21 residues but having an additional 15 amino 
acids from the cloning vector, efficiently inhibited papain activity. 
From the sequence alignments of OC I with stefin B (Figure 2.9) it appeared that Gly9 of oryzacystatin could 
correspond to Gly9 in chicken cystatin. This is different to the alignment proposed by Abe et al. ( 1988), who 
suggested that the GI/ residue of oryzacystatin is analogous to the Gly9 residue in chicken cystatin. 
According to the docking models of chicken cystatin (Bode et al., 1988), however, the Gly9 residue of this 
cystatin appears to be involved in a tight turn formation which brings Leu8 in contact with the S2-subsite 
binding region of papain. From the alignment, oryzacystatin has a leucine residue (Leu8) in the equivalent 
position to that in chicken cystatin. Since conserved residues often occur in equivalent positions in the 
cystatins, one would expect the Gly9 residue to contribute to the turn formation as is seen in the case of chicken 
cystatin. Furthermore, if Gly9 of chicken cystatin were aligned with GI/ of OC I, this would put the Pro 12 
residue (numbering as in Figure 2.9) in the a-helix region and proline is generally regarded as a helix breaker 
(Chou & Fasman, 1978). Although the presence of a praline residue in the a-helix of stefin A is described 
(Martin et al., 1995; Tate et al., 1995), it nevertheless seemed probable that chicken cystatin and oryzacystatin 
would interact in a similar manner and that the alignment of Gly9 of OC I with Gly9 of chicken cystatin and 
Gly4 of stefin B (stefin B numbering- Stubbs et al., 1990) seems more feasible. 
OC I has the same QVV AG sequence as stefin B and would hence form a similar structure. A study of the 
model of OC I with papain shows that this QVV AG loop exerts its inhibitory effect by forming a rigid loop 
structure over the catalytic site residues as is suggested by Yamamoto et al. ( 1992 ). This conformation of the 
first binding loop is very important for the cystatin inhibitory activity since it is primarily responsible for the 
tight binding to proteinases (Thiele et al., 1990) and has been demonstrated experimentally (Abe et al., 1991) 
to be important for the inhibitory activity of OC I. 
With regard to the second binding loop of cystatin, substitutions of amino acids in this region (i.e. a tryptophan 
residue replacing His104 of stefin B (numbered as in Figure 2.9), methionine replacing Glu105 and aspartic acid 
replacing Asn105A), resulted in changes which could be well accommodated in the structure of the second 
binding loop, following energy minimisations and simple dynamics. This occurred as the amino acid side 
chains found different locations in space with respect to papain. It is clear from the model that the second 
hairpin loop (which contains the conserved tryptophan residue) does not make as strong a contact with papain 
as the first hairpin loop, but rather makes contact with the enzyme through its side-chains. As in the case of 
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demonstrated (Abe et al., 1988; Urwin et al., 1995a). Removal of this loop resulted in weaker inhibitory 
activity. A comparison of the OC I and stefin B models is shown in Figure 2.12. This shows the small 
changes that have occurred in the second loop by insertion of the OC I sequence. It also shows the extended 
amino-terminus. The other changes seen (i.e. in the first loop after the a-helix), occurred through substitutions 
of the OC I sequence onto the stefin B structure. This section of the OC I model is similar to model 3 and so 
the changes made in this area will be discussed in terms of the models in section 2.11 . 
Carboxy-terminal contacts of oryzacystatin with papain appeared from the modelling studies to be similar to 
those of chicken cystatin i.e. there is no contact with papain. Stefin B, on the other hand, was shown by X-ray 
crystallographic studies to contact papain through the side-chains of residues Tyr124 and Phe125 (Stubbs et al., 
1990). The importance of these C-terminal contacts of stefin B is controversial. Despite the X-ray 
crystallographic findings , deletion of the C-terminus resulted in little change in the inhibitory activity of stefin 
B (Jerala et al. , 1991). In the case of oryzacystatin, removal of the C-terminal 11 residues also showed no 
change in the activity of the inhibitor (Abe et al., 1988). This is in agreement with the modelled structure of 
OC I which suggests that there are no contacts with papain in the C-terminal regions. 
Figure 2.12: Ribbon models of OC I and stefin B showing the differences between them. The arrows 
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2.10 Construction of the Hybrid Oryzacystatin 
The OC I model together with the protein sequence alignments, secondary structure predictions and published 
Ki values for cystatins, were used to consider possible sites for introducing mutations that might improve the 
inhibitory capacity of OC I and, at the same time, shed light on the possible functions of the amino terminus. 
In this regard, the approach that appealed to me as the most interesting and potentially the most informative 
was that in which the N-terminus of oryzacystatin would be removed and the N-terminus of chicken cystatin 
inserted in its place. The reason for this choice was as follows: 
• It is clear that, along with human cystatin C, chicken cystatin is one of the most potent inhibitors of papain, 
with a Ki in the region of 0.006 nM (Machleidt et al., 1989). 
• It has been proposed (Auerswald et al., 1992) that chicken cystatin has strong interactions in its amino-
terminus in order to compensate for less desirable contacts in the QL VSG binding loop. In fact, Machleidt 
et al. (1991) estimated that 36% of the binding energy is involved in the formation of a complex between 
the N-terminal residues of chicken cystatin and papain. The N-terminal residues of stefin B on the other 
hand contribute less to the binding energy in complex with papain (Thiele et al., 1990). A similar effect is . 
thought to occur with OC I (Abe et al., 1988). Hence, the amino terminal contacts in the family II 
cystatins may be more important than in the family I cystatins (Tate et al., 1995). Thus, by substituting the 
N-terminus of chicken cystatin for the oryzacystatin IN-terminus it was hoped that this would create a 
hybrid oryzacystatin with stronger interactions in its N-terminal region and thus a more potent inhibitor. 
In deciding how much of the N-terminus of oryzacystatin to substitute or replace, the following points were 
considered: 
• Firstly, according to Abe et al. (1988), the amino acids in the N-terminus of OC I do not make any 
contribution to the inhibitory capability of the inhibitor. Thus, alteration of any of these residues 
would not be expected to change the inhibitory activity of the inhibitor. This is, of course, debatable in 
view of the recent findings of Urwin et al. (1995b) who found that removal of Gly10 of OC I greatly 
decreased its inhibitory activity. 
• Secondly, according to the sequence alignment of OC I with chicken cystatin (Figure 2.13), it is 
evident that there are regions of homology between the two sequences in the N-terminal region. For 
example, the sequence 'END' is common to both sequences. In chicken cystatin this is the start of the 
a-helix (Bode et al., 1988). A similar prediction was made in this area for OC I using Chou-Fasman 
predictions of protein secondary structure. Thus, since the 'END' sequence could form the start of the 
a-helix in both sequences, the addition of the chicken cystatin sequence onto the N-terminus before 
these three residues should not affect the structure of the rest of the protein, particularly considering 
















7 8 9 10 11 
67890123456789012345678901234567A89012A345A6789012345ABCDEFGHIJK 
oc I: EGD- - - - - - - - - - - - - - - - - - - - - - -AKKLYEAKVWEK-PWMDFKELQEFKPVDASANA 
CC: IGRTTCPKSSGDLQSCEFNDEPEMAKYTTCTF-VVYSI-PWL-NQIKLLESKC-Q 
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Figure 2.13: Sequence alignment of oryzacystatin I (OC I) and chicken cystatin (CC) (numbering as 
for chicken cystatin, extra amino acids in the OC I structure are represented using letters from the 
alphabet; adapted.from Turk & Bode, 1991). The similarities between the sequences are highlighted in 
bold 
• A final consideration was the extent to which the N-terminus of chicken cystatin was to be substituted. 
It is known that the full length and the truncated forms of chicken cystatin (starting at Leu7) are equally 
active (Machleidt et al., 1989). Since this hybrid inhibitor was to be synthesised, the shorter N-
terminal sequence is preferable in terms of both cost and ease of synthesis. Thus, the first 18 residues 
of oryzacystatin were replaced with the truncated chicken cystatin sequence to generate the following 
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2.10.1 The Hybrid Oryzacystatin Models 
Having decided upon the sequence substitutions and hence the sequence alignment, the structure was then 
modelled to determine whether the N-terminal substitutions were likely to have any structural effects in this 
region. Since stefin B was used as the basic structure for modelling OC I it was used again for the HO which 
should have essentially the same structure as OC I but with changes in the position of the amino-terminus. 
Before modelling the HO structure, a series of alignments were carried out using the GCG computer 
programme (Devereux et al., 1984). With computer alignments it is possible to vary the gap weight and so 
obtain a number of different alignments. Thus, when aligning, it is important to bear in mind the structural 
characteristics of the protein so that the sequence is aligned structurally as well as sequentially. 
From a comparison of the hybrid and stefin B sequences, it was clear that, in order to model the HO onto the 
stefin B backbone, a number of substitutions and deletions of amino acids needed to be accommodated. 
Furthermore, since different alignments were possible, the positions of these deletions and insertions, with 
respect to the stefin B sequence, would vary. Three models were generated. Their features were as follows: 
The HO - Model 1 
The first alignment carried out on the GCG program used a gap weight of 1 and a length weight of 0.1. From 
this alignment (Figure 2.14), a table was drawn up to highlight the areas common to stefin B (shaded), as well 
as the areas where deletions (DEL) and insertions into the stefin B structure should occur in order to 
accommodate the oryzacystatin sequence (Table 2.2). This table was then used as the basis to produce the first 
model. 
Model 1 represents the construction made according to the alignment shown in Figure 2.14. The stefin B 
molecule was used as the backbone structure. Using the table created (Table 2.2), amino acids in the stefin B 
structure that differed from the HO sequence were replaced with the corresponding hybrid amino acid residues. 
The insertions and deletions were then studied. The first modification in this alignment was to delete the Sers 
and Ala13 - G1n15 (stefin B sequence, see Table 2.2.). The first deletion was catered for by deleting the Sers 
residue and forming a bond between Leu7 and Gly9 (HO sequence). The second deletion, following the 
'GAPV' sequence (residues 9 - 12, stefin B numbering, Table 2.2), was catered for by moving the 'GAPV' up 
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Gap Weight: 1.000 Average Match: 0.540 
Length Weight: 0.100 Average Mismatch: -0.396 
Quality: 5 5. 7 Length: 109 
Ratio: 0.605 Gaps: 8 
Percent Similarity: 58.824 Percent Identity: 35.294 
Hybrid Sequence (HO) x Stefin B Sequence (SB) 
HO 1 11.gapv ... pvdendlhlvdlarfavteh.nkkansllefeklvsvkqq 45 
· · 111 I · · · = · I : · I · I · : · I 111 I I II . I I 
SB 1 MMSGAPSATQPATAETQHIADQVRSQLEEKYNKK ... FPVF.KAVSFKSQ 46 
HO 46 vvagtlyyftievkegdakklyeakvwek.pwmdfk .. elqefkpvd ... 86 
11111 I · · . · · I : : I : : I : : I : I : I .... · .. 
SB 47 VVAGTNYFIKVHVGDED ... FVHLRVFQSLPHEN.KPLTLSNYQTNK ... 93 
HO 87 asana ... 92 
I ... 
SB 94 AKHDELTYF 102 
Figure 2.14: Sequence alignment of oryzacystatin I (OC I) and stefin B (SB) generated using the GCG 
computer programmes (Devereux et al., 1984). Alignment was carried out using a gap weight of 1.0 
and a length weight of0.1. 
This sequence was then processed by repeated steps of energy minimisation and simple dynamics to 
give a theoretical structure with the amino terminus moved away from the surface of papain. Rotating the 
carbonyl bond of the HO Gly9 (stefin B numbering) did not bring the amino terminal leucine residues into 
sufficient contact with the papain surface, so that one would not expect an improvement in the inhibitory 
activity from such a structure. 
Insertions of amino acids were also required to convert the stefin B structure into that of the HO. From the 
alignment in Figure 2.14, the 'ANS' insertion (residues 39A - 39C; see Table 2.2) occur outside the binding 
loop regions of the inhibitor. There is also a deletion of the Tyr36 residue of stefin B in this area. Thus, the 
tyrosine residue was deleted, a bond formed between His35 and Asn37, and the inserts at residues 39A - 39C 
and at 45A (Table 2.2) were accommodated by bulging the loop, following the a-helix, outwards. This region 
from Thr30 to Val48 was then energy minimised. 
A similar procedure was carried out for the other insertion, AKK (residues 93A - 93C; Table 2.2), since these 
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Table 2.2: Positions of substitutions, insertions and deletions for Model 1. 
StefinB Stefin B Hybrid Stefin B Stefin B Hybrid 
Residue Number Residue Residue Number Residue 
Met 6 Leu Gly 57 Glv 
Met 7 Leu Thr 58 Thr 
Ser 8 DEL Asn 59 Leu 
Gly 9 Gly Tyr 60 Tvr 
Ala 10 Ala Phe 61 Tyr 
Pro 11 Pro Ile 62 Phe 
Ser 12 Val Lvs 63 Tur 
Ala 13 DEL Val 64 Ile 
Tur 14 DEL His 65 Glu 
Gin 15 DEL Val 66 Val 
Pro 16 Pro Gly 67 Lys 
Ala 17 Val Asp 68 Glu 
Tur 18 Asp Glu 92 Gly 
Ala 19 Glu Asp 93 Asp 
Glu 20 Asn 93A Ala 
Tur 21 Asp 93B Lvs 
Gln 22 Leu 93C Lys 
His 23 His Phe 94 Leu 
Ile 24 Leu Val 95 Tyr 
Ala 25 Val His 96 Glu 
Asp 26 Asp Leu 97 Ala 
Gln 27 Leu Arg 98 Lys 
Val 28 Ala Val 99 Val 
Arg 29 Arg Phe 100 Trp 
Ser 30 Phe Gin 101 Glu 
Gin 31 Ala Ser 102 Lys 
Leu 32 Val Leu 102A DEL 
Glu 33 Tur Pro 103 Pro 
Glu 34 Glu His 104 Trp 
Lys 35 His Glu 105 Met 
Tvr 36 DEL Asn 105A Asp 
Asn 37 Asn 105B Phe 
Lys 38 Lys Lys 106 Lys 
Lys 39 Lys Pro 107 DEL 
39A Ala Leu 108 DEL 
39B Asn Thr 109 Glu 
39C Ser Leu 110 Leu 
Phe 40 Leu Ser 111 Gln 
Pro 43 Leu Asn 112 Glu 
Val 44 Glu Tyr 113 Phe 
Phe 45 Phe Gln 114 Lys 
45A Glu Tur 115 Pro 
Lys - 46 Lys Asn 115A Val 
Ala 47 Leu Lys 116 Asp 
Val 48 Val Ala 117 Ala 
Ser 49 Ser Lys 118 Ser 
Phe 50 Val His 119 Ala 
Lys 51 Lys Asp 120 Asn 
Ser 52 Gln Glu 121 Ala 
Gln 53 Gln Leu 122 DEL 
Val 54 Val Tur 123 DEL 
Val 55 Val Tyr 124 DEL 











Chapter 2 Page 57 
Figure 2.15: Ribbon structures of stefin B (white) and model 1 (pink). The different positions of the 
amino-termini (arrow 1) and the loops generated by insertions (arrow 2) are shown. The papain 
surface is shown in yellow. 
The Hybrid Oryzacystatin - Model 2 
A second alignment was generated as shown in Figure 2.16. In this alignment the early deletions in the amino 
terminus seen in model 1 have been moved to the end of the a-helix. Structurally, this results in removal of 
the last few turns of the a-helix. Thus, to determine the structural effects of this new alignment, a second 
model, was created. 
Thus, to generate this model, the stefin B amino acids which differed from the HO sequence, were replaced 
with the HO residues as in model 1 (see Table 2.3). In this alignment (Figure 2.16), the first methionine 
residue of stefin Bis removed, and two leucine residues replace the Met7 and Ser8 residues. 
The second deletion occurs at residues Glu33 -Tyr36 in the stefin B sequence. These residues were thus deleted 
and a peptide bond was then formed between His32 and Asn37 (stefin B numbering) of the OC I sequence. The 
insertions, Ala39A-Ser39c required to form the HO model, were built in following Lys39 (Table 2.3). Energy 
minimisations and simple dynamics steps were then carried out over this region. However, despite these steps, 
there was still a large net energy in this region. An analysis of the surface of this modified area (see Figure 
2.17), showed the formation of a 'hole'. It was therefore concluded that this model was not a compact 
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Gap Weight: 0.500 Average Match: 0.540 
Length Weight: 0.500 Average Mismatch: -0.396 
Quality: 54.6 Length: 107 
Ratio : 0.593 Gaps: 10 
Percent Similarity: 57.471 Percent Identity: 34.483 
Hybrid Sequence (HO) x Stein B Sequence (SB) 
HO 1 .llgapvpv dendlhlvdlarfav teh .... nkkansllefeklvsv kqq 45 
: 11 1 · · · · · · · · · · ·. . . 11 1 I I 11. I I 
SB 1 MMSGAPSATQPATAETQHIADQVRSQLEEKYNKK ... FPVF.KAVSFKSQ 46 
HO 46 vvagtlyyftievkegdakklyeakvwe . kpwmdfkelqefkpvdas. 91 
1111 1 I::.:. I ==I.. : : I . I = =.I I =:. . . I. 
SB 47 VVAGTNYFI KVHVGDED . . . FVHLRVFQSLPHEN.KPLSNYQTNKAK. 95 
HO 92 ana .... 92 
SB 96 HDELTYF 102 
Figure 2.16: Amino acid sequence alignment of stefin B (SB) and the hybrid oryzacystatin (HO) 
generated through GCG (Devereux et al., 1984). A gap weight of 0.5 was used and a length weight of 
0.5. 
Figure 2.17: Ca-trace of model 2. The amino acid side-chains (cyan) and the surface of the outer 
loops (yellow) are shown. The arrow indicates the problem areas, generated by the sequence 
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Table 2.3: Positions of substitutions, insertions and deletions for Model 2. 
Stefin B Stefin B Hybrid StefinB Stefin B Hybrid 
Residue Number Residue Residue Number Residue 
Met 6 DEL Gly 57 Gly-
Met 7 Leu Tur 58 Tur ' ' 
Ser 8 Leu Asn 59 Leu 
Glv 9 ' Gly •Tyr 60 Tyr ''"' 
Ala ', 10 ' ' Ala Phe 61 Tyr 
Pro 11 Pro ,'.·• 
,,, 
Ile 62 Phe 
Ser 12 Val Lys 63 Tur 
Ala 13 Pro Val 64 Ile 
Tur 14 Val His 65 Glu 
Gln 15 Asp Val 66 · Val ... ·• -
Pro 16 Glu Gly 67 Lys 
Ala 17 Asn Asp 68 Glu 
Tur 18 Asp Glu 92 Gly 
Ala 19 Leu Asp .,. 93 Asp 
Glu 20 His 93A Ala 
Tur 21 Leu 93B Lys 
Gin 22 Val 93C Lys 
His 23 Asp Phe 94 Leu 
Ile 24 Leu Val 95 Tyr 
Ala 25 Ala His 96 G!u 
Aso 26 Arg Leu 97 Ala 
Gin 27 Phe Arg 98 Lys 
Val 28 Ala ·Val ,,. ,, ' 99 ... , Val ;. 
' ' 
Arg 29 Val Phe 100 Trp 
Ser 30 Tur Gin 101 Glu 
Gln 31 Glu Ser 102 Lys 
Leu 32 His Leu 102A DEL 
Glu 33 DEL ' Pro '""' "' , '" •· 103 
••'' ;:;:, Pro: "" >~ 
Glu 34 DEL His 104 Trp 
Lys 35 DEL Glu 105 Met 
Tyr 36 DEL Asn 105A Asp 
Asn 37 '·'' Asn. 
; 105B Phe 
Lvs 38 Lys ,, '·' Lys 106 Lys 
Lys 39 Lys Pro 107 DEL 
39A Ala Leu 108 DEL 
39B Asn Tur 109 G!u 
39C Ser Leu 
,, 
110 Leu '' 
Phe 40 Leu Ser 111 Glil 
Pro 43 Leu Asn 112 Glu 
Val 44 Glu Tyr 113 Phe 
Phe 45 Phe Glil 114 Lys 
45A Glu Tur 115 Pro 
Lys - 46 ' Lys '§ Asn 115A Val 
Ala 47 Leu Lys 116 Asp 
Val .48 Val '"" ' Ala 
··.;- 117 7 Ala ·:;.,,. 
Ser 49 Ser Lys 118 Ser 
Phe 50 Val His 119 Ala 
Lys 51 Lys Asp 120 Asn 
Ser 52 Gin Glu 121 Ala 
Gin 53 Glil Leu 122 DEL 
Val 54 Val Tur 123 DEL 
Val 55 Val ' ,. Tyr 124 DEL 
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To try to solve this problem, amino acid side-chains of hydrophobic residues (such as Leu43, stefin B 
numbering), which had their side chains pointing outwards, were rotated inwards into the more hydrophobic 
environment. A number of constraints on torsion angles were also set. However, despite these changes, there 
was still no improvement in the structure of this model. It was thus concluded, that this alignment was not 
structurally feasible . 
The Hybrid Oryzacystatin - Model 3 
The alignment used to generate model 3 is shov.'11 in Figure 2.18. In this alignment, as with model 2, only a 
single deletion (the first methionine residue) occurs in the N-terminus . 
In model 3 (Figure 2.19) insertions occurred in the top loop area outside of the a-helix (see Table 2.4). These 
areas are not important for binding of the inhibitor to the proteinase active site and changes in this region 
should have no effect on the inhibitory capabilities of this inhibitor. As mentioned previously, Auerswald et 
al. (1994) showed that deletion of the outer a-helical loop of chicken cystatin had no significant effect on the 
inhibitory activity towards papain, actinidin as well as the cathepsins B and L. 
Gap Weight: 1.000 Average Match: 0.540 
Length Weight: 1.000 Average Mismatch: -0 .396 
Quality: 46.5 Length: 102 
Ratio: 0.505 Gaps: 2 
Percent Similarity: 45.652 Percent Identity: 23.913 
Hybrid Sequence (HO) x Stefin B Sequence (SB) 
HO 1 .l lgapvpvdendlhlvdlarfavtehnkkansllefeklvsvkqqvvag 49 
= 111 .. .... .: I .. =·I I· ... I 11 ·I 111 11 
SB 1 MMSGAPSATQPATAETQHIADQVRSQLEEKYNKKFPVFKAVSFKSQVVAG 50 
HO 5 0 tlyyftievkegdakklyeakvwek.pwmdfk .. elqefkpvdasana .. 92 
I I · ·· .. I ==I . ... I· I.· : I· ·I ····I 
SB 51 TNYFIKVHVGDED ... FVHLRVFQSLPHEN.KPLTLSNYQTNKAKHDELT 100 
Figure 2.18: Sequence alignment of stefin B (SB) and the hybrid oryzacystatin (HO) . The alignment 
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Table 2.4: Positions of substitutions, insertions and deletions for Model 3. 
Stefin B StefinB Hybrid Stefin B StefinB Hybrid 
Residue Number Residue Residue Number Residue 
Met 6 DEL Tyr 60 ,,,, ,, Tyr 
Met 7 Leu Phe 61 Tyr 
Ser 8 Leu Ile 62 Phe 
Gly 9 Gly Lys 63 Thr 
Ala IO Ala Val 64 Ile 
Pro 11 I,>ro His 65 Glu 
Ser 12 Val Val 66 Val 
Ala 13 Pro Gly 67 Lys 
Thr 14 Val Asp 68 Glu 
Gin 15 Asp Glu 92 Gly 
Pro 16 Glu Asp 93 Asp 
Ala 17 Asn 93A Ala 
Thr 18 Asp 93B Lys 
Ala 19 Leu 93C Lys 
Glu 20 His Phe 94 Leu 
Tur 21 Leu Val 95 Tyr 
Gln 22 Val His 96 Glu 
His 23 Asp Leu 97 Ala 
Ile 24 Leu Arg 98 Lys 
Ala 25 Ala Val 99 Val 
Asp 26 Arg Phe 100 Tro 
Gln 27 Phe Gfu 101 Glu 
Val 28 Ala Ser 102 Lys 
Arg 29 Val Leu 102A DEL 
Ser 30 Thr Pro 103 Pro ; 
Gin 31 Glu His 104 Trp 
Leu 32 His Glu 105 Met 
Glu 33 Asn Asn 105A Asp 
Glu 34 Lys 105B Phe 
Lys ' 35 Lys ' ' - Lys ' ••'' 106 "' 1' Lys 
; 
Tyr 36 Ala Pro 107 DEL 
Asn 37 Asn Leu 108 DEL 
Lys 38 Ser Tur 109 Glu 
Lys 39 Leu Leu , 110 ':,• ' Leu ,+ 
Phe 40 Leu Ser 111 Gfu 
Pro 43 Glu Asn 112 Glu 
Val 44 Phe Tyr 113 Phe 
Phe 45 Glu Gin 114 Lys 
Lys 46 Lys Thr 115 Pro 
Ala 47 Leu Asn 115A Val 
Val 48 Val Lys 116 Asp 
Ser 49 Ser Ala 117 Ala 
Phe - 50 Val Lys 118 Ser 
Lys 51 Lys His 119 Ala 
Ser 52 Gin Asp 120 Asn 
Gfu 
' 
53 ., ;;Gm Glu 121 Ala 
Val 54 Val 
,,, .. ~. 
i Leu 122 DEL 
Val 55 .val Tur 123 DEL 
Ala 56 Ala Tyr 124 DEL 
Gly 57 ,, Gly ; Phe 125 DEL 
GLy . ; •:'' 57 ' ,, ',Gly Tyr 124 DEL 
Thr 58 Tur Phe 125 DEL 
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Figure 2.19: Ribbon structure of model 3 (green) and stefin B (white) . The papain surface is shown in 
blue and the different N- (bottom arrow) and C-termini(top arrow) are indicated. 
The Amino-terminal Interactions 
The main area of interest in these models is the amino-terminus since the strength of the interactions in this 
area may have an impact on the inhibitory constants. In chicken cystatin the residues located N-terminal to 
Ala10, that is, Leu7, Leu8 and Gly9 are of major importance for the binding to papain subpockets S2, S3 and S4 
(Machleidt et al. , 1989). Thus it was predicted that Leu7 and Leu8 of HO should make similar contacts. The 
alignment of stefin B with the HO (Figure 2.18) shows the glycine of HO in equivalent positions to that of 
stefin B. It would hence be presumed to form a similar open type II turn conformation. This glycine residue in 
stefin B provides a flexible region allowing the N-terminal segment to adopt a conformation suitable for 
interaction with the substrate-biding pockets of the enzyme (Stubbs et al., 1990). 
Figure 2.20 shows the N-terminal 5 residues of model 3 and in Figure 2.21 , the hydrophobic areas of papain 
are also shown. The leucine residues have their side-chains directed towards the hydrophobic residues of 
papain. These hydrophobic residues of the enzyme in this area include Tyr61, Tyr67, Pro68, Trp69, Val 133, Val157, 
Ala160, Phe207• Leu7 of the HO (stefin B numbering) has its side-chains directed over a hydrophobic pocket 
(filled with water molecules) as is indicated by the white arrow (Figure 2.20). A serine residue is on the other 
side of this pocket where it is shielded from contacts with the leucine residues by the water molecules. Thus 
there appears to be strong hydrophobic interactions of the residues in this region. In the interactions of 
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dominates the interactions (Stubbs et al., 1990). Whether or not these contacts would improve the hybrid 
could only be deduced from kinetic studies (see Chapter 6). 
A further observation made from this model is that the glycine residue lies close to the active site residues of 
papain, as does the first hair-pin loop which lies close to the depression of the cleft between Cys25 and His159 of 
papain. Energy minimisations on the N-terminus brought the N-terminal four residues close to the active-site 
residues, although not too close to be cleaved at this site. 
The single amino acid deletion at the amino terminus seen from the alignments of models 2 and 3 provides a 
better scenario than that shown in model 1. In models 2 and 3, the N-terminus lies in close contact with the 
enzyme, forming similar contacts to those seen with chicken cystatin (Stubbs et al., 1990). Model 1, however, 
has no contact with the enzyme in this region. Of all the alignments, that of model 3 was considered to be 
structurally the most feasible. 
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Figure 2.21: Half-bonded structure of the N-terminalfour residues. The hydrophobic amino acid side-
chains of papain amino acids are shown in orange. Water molecules are denoted by the tetrahedra. 
2. 12 Conclusions 
It is clear from a review of the literature that the importance of the cystatin binding loops is still a matter of 
debate. The study that I have made of this has led me to suggest the following: 
• The N-terminal contacts do play an important role since contacts in this area help anchor the inhibitor and 
so enable the other loops (particularly the first) to fit correctly into binding site cleft of the proteinase. The 
-
contacts may, however, be more important in some cystatin families (e.g. family II) than others (e.g. 
family I). Thus the loss of activity seen with truncation, particularly in the family II cystatins, could as 
suggested by the trunk model (Machleidt et al., 1995), be due to loss of conformation in the rest of the 
loops. This suggests that the cystatin binding loops do not act independently of each other but rather in a 
concerted fashion so that each contributes to the stability of the interactions of the others. 
• The importance of the various binding regions may be dependent on the stereochemistry of the proteinase, 
i.e. the fit of the inhibitor into the proteinase active site. Papain and actinidin, for example, are two similar 
enzymes with widely different susceptibilities to different cysteine proteinase inhibitors. These differences 
have been attributed to the differences in the catalytic-site reactivity, to small changes in the Srsubsites 











Chapter 2 Page 65 
al., 1988). My inclination, however, is to agree with Bjork et al. (1994) who suggest that the extent of 
inhibition is determined by steric interactions between the inhibitor and the enzyme. This would explain 
the many different results seen in the literature for substitution/truncation and deletion experiments. 
The three different alignments of HO and stefin B have given 3 alternative configurations for the HO structure. 
Of these, model 3 appears to be the most compatible with the structural characteristics of the cystatins, with the 
obvious reservation that the actual structure of OC I or the HO can only be deduced definitively by Nl\.1R or X-
ray crystallography. 
Despite possible variations in the structure of the hybrid protein, it should shed some light on the function of 
the amino-terminus. If the amino-terminus does interact, one would expect that the substitution of the chicken 
cystatin amino terminus would improve the inhibitory activity since chicken cystatin is such a potent inhibitor. 
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CHAPTER 3 
Automated DNA Synthesis of the Hybrid Oryzacystatin Gene 
and Cloning into Escherichia coli 
3.1 Introduction 
The supply of proteins of clinical, industrial or research interest is often limited by their low natural 
availability and gene cloning and expression can provide a more abundant source. In this case, large quantities 
of the HO inhibitor were required for study and hence the aim was to clone the gene into a suitable expression 
system thereby producing the inhibitor in large quantities for inhibition assays. 
This chapter will thus describe the synthesis and cloning of the hybrid oryzacystatin inhibitor gene into a 
suitable bacterial system. Cloning of the amplified gene into an expression vector for production of the 
protein is discussed in Chapter 4. 
3.1 .1 Considerations Prior to Gene Design 
Two general considerations led to the selection of an E. coli-based expression system to produce the HO gene, 
for example: 
1. The technology for DNA manipulation and cell culture compared with that of other expression systems is 
well established. 
2. It is the most frequently used expression system, a large amount of information is available and genetic 
techniques have been well described. This information can be used to address any difficulties encountered 
in the expression of a particular gene. 
Two optiqns for producing the hybrid gene were considered. The first was to obtain the two inhibitor genes, 
oryzacystatin I and chicken cystatin. These two sequences could then be cut and joined together at the junction 
as determined by the hybrid model. The second option would be to synthesise the modified gene on an 
automatic DNA synthesiser. 
After careful consideration, the second option was chosen for the following reasons: 
1. Synthesis of the gene enables the selection of gene codons optimal for the expression system being used 
which can improve expression levels. De Boer et al. (1983) showed that the use of genes with low codon 
usage for the organism in which it is expressed could result in poor expression levels. For this gene, the 
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2. Synthesis also makes it possible to introduce restriction sites and other features necessary for cloning into 
the required vector systems. 
PART 1: Cloning of the Gene in Two Parts 
3.2 Considerations in the Design of the Gene for Cloning and Expression 
Prior to synthesis it is necessary to consider the methodology to be used for cloning since this may have a 
bearing on the gene design. The modified HO has 94 amino acids. This results in a gene sequence of 282 
bases, which is too long to be synthesised in a single step on an automatic DNA synthesiser without loss of 
purity and fidelity (D.P. Botes, personal communication). Thus, to try and reduce the incidence of any errors, 
it was decided to divide the gene into smaller fragments which would then be cloned, in a step-wise manner, 
into p UC 18 for gene amplification. 
A number of methods have been used for cloning multiple sections of a gene, including the oligonucleotide-
directed double-strand break repair method ofMandecki (1986) and PCR methods such as that of Michaels et 
al. (1992). It was decided to use this latter method as it has a number of advantages, for example: 
• Low amounts of template DNA are required, reducing the cost of synthesis. 
• It enables the inclusion of unique restriction sites which, by designing them on the end of a primer, can be 
incorporated into the template. These restriction sites can then aid in cloning of the gene into the required 
vector. 
A further consideration in the design of synthetic genes is that of the stop and start codons, especially (as in 
this case) if these are not supplied by the expression vector. The TAA termination sequence was thus used as 
the stop codon at the end of the gene sequence (Figure 3.1). The start codon was not included in the gene 
design since it was to be supplied by the pMAL system of vectors (New England Biolabs) that were to be used 
to express the inhibitor following gene amplification. In the pMAL system (discussed in Chapter 4), foreign 
genes are expressed as a fusion linked to the maltose binding protein whose coding sequence is provided by 
the transcription start codon. 
3.2.1 Dividing the Gene into Two Templates 
To decide where division of the gene should occur, the sequence was scanned for restriction sites using the 
Genetics Computer Group (GCG) database of 181 restriction enzymes (version 7.1; Devereux et al. , 1984). As 
no restriction sites were found that were unique to the HO compared with the pUC18 vector, and which cut the 
sequence into two manageable pieces, the sequence was then scanned for partial restriction sites. The GCG 
program is able to determine where in a sequence changes in the wobble base of degenerate codons will 
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was generated by changing the codon of alanine from its preferred codon GCG to GCC. This approach 
allowed for the introduction of new restriction sites and produced two shorter sequences of 147 (template A) 
and 143 bases (template B) for synthesis (Figure 3.1). 
As cloning was to be carried out in a step-wise manner, template A followed by template B, it was necessary to 
include the Ala-Gly amino acids at the end and at the beginning of templates A and B respectively. Template 
A could then be cut with Nael, thus opening up the vector for insertion of template B (also cut with Nael; 







L G A P V P V D E N D L H L V D L 
CAGCTGCTTGGTGCTCCAGTTCCAGTTGACGAAAACGACCTTCACCTTGTTGACCTT 
GTCGACGAACCACGAGGTCAAGGTCAACTGCTTTTGCTGGAAGTGGAACAACTGGAA 
A R F A V T E H N K K A N S L L E F E 
GCTCGTTTCGCTGTTACCGAACACAACAAAAAAGCGAACAGCCTGCTGGAGTTCGAA 
CGAGCAAAGCGACAATGGCTTGTGTTGTTTTTTCGCTTGTCGGACGACCTCAAGCTT 
K L V S V K Q Q V V A G 





A G T L Y Y F T I E V K E G D A K K L 
NaeI - - - - - - - - - - - - - - - - - - - - - - -
57 
114 




Y E A K V W E K P W M D F K E L Q E 
TATGAAGCTAAAGTTTGGGAAAAAAACCTGGATGACTTCAAAGAAGACCAGGAA 
ATACTTCGATTTCAAACCCTTTTTTTGGACCTACTGAAGTTTCTTCTGGTCCTT 
F K P V D A S A N A STOP 





Figure 3.1: The DNA and amino acid sequence of the synthetic HO gene showing the division of the 
gene into two fragments. Restriction enzymes were incorporated into the sequence by modification of 
the codon usage. The first 3 bases of the Pvull site are contributed by the forward primer to template A. 
Similarly, the last 4 residues making up the Hindlll site are contributed by the reverse primer to 
template B. The repeated amino acid residues are shown in bold as is the 'TAA 'stop codon. 
Primer sequences were designed to incorporate restriction sites for easy insertion and excision of the cloned 
gene from the vector. Since the pUC18 vector was only to be used as a vehicle for gene amplification with 
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was included at the start of the gene sequence (Figure 3.1). This was possible because the codon for the amino 
acid at the start of the gene sequence, leucine, is CTG and the cutting site for Pvull is CAG i CTG. This 
blunt-ended restriction site was useful in that on cloning into the expression vector, no undesirable pUC 18-
derived amino acids residues would be added to the amino-terminus. The first three bases of the Pvull 
recognition sequence were included in the forward primer sequence for template A (Table 3.1). A BamHI site 
was also engineered onto both the forward and the reverse primers to enable cloning into the BamHI site of the 
pUC18 vector (Figure 3.2). 
The reverse primer for template A contained the Nael restriction site. This restriction site requires ' buffering 
sequences' 3' to the Nael site, as this enzyme does not cut well at the end of a gene sequence (Promega 
manual, 1992). These were provided by the BamHI sequence. A sixteen base-pair overlap with the template 
was also included for both primers (Table 3 .1 ). 
For template B, a HindIII restriction site was incorporated, following the stop codon, into the reverse primer 
sequence. This was done to enable removal of the gene from pUC18 (using Pvull and HindIII) and to allow 
' blunt/sticky' directional cloning into the pMAL vectors (which contain Stu! and HindIII restriction sites in the 
multiple cloning site; Appendix D). 
A Nael site was included in the forward and reverse primer sequences for template B (see Table 3.1), since the 
vector containing template A (named pUC18a), was to be cut with Nael for cloning in of template B (Table 
3.2). 
Before synthesis, the primer sequences were optimised using the computer program 'Primer' (Version 5.0; 
Whitehead Institute for Biomedical Research, Cambridge, MA). Primers with restriction sites are shown in 
Table 3.1. 
Table 3.1: Primer sequences and their restriction enzyme sites required for cloning 
Forward, Template A BamHI, Pvull 
Reverse, Template A 5' CAGGTGCGCTTGCCGGCAACAACC 3' BamHI, Nael 
Forward, Template B 5' GCGGGCGGCGCCGGC4CCCTTTATTA 3' Nael 
Reverse, Template B 5' CATGCCGGCGTACAAGCTTAGCATTAGCAG 3' Nael, HindIII 
The underlined sequence show the restriction sites in the order as indicated in the last column. 
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Page 70 
Figure 3.2: Schematic diagram showing the planned cloning procedure for templates A and B. 
Template A was amplified by PCR, cut with BamHI and cloned into the BamHI-linearised pUC18 to 
generate pUC l 8a. Template B was to be inserted by cutting the PCR product with Nae! and inserted 
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3.3 Materials and Methods 
3.3.1 Bacterial Strains, Plasmids and Growth Conditions 
E.coli strain JM109 (recAJ , end.Al, gyrA96, thi, hsdR17, supE44, re!Al, '),;, D..(lac-proAB), [F', traD36,proAB, 
laclq D..ZM15]) was used for these experiments. The cultures were grown in Luria broth (LB) at 37°C with 
vigorous shaking. Transformed strains carrying pUC18a and b were grown as above but with 100 µg/ml 
ampicillin (Sigma). 
3.3.2 Gene Synthesis 
Oligonucleotides were synthesised with nucleoside-0-(2-cyanoethyl)-N,N-diisopropyl phosphoramidites. 
These and other reagents for synthesis were obtained from Bioresearch. Synthesis was performed on a model 
6500 Autogen ™DNA synthesiser (Milligen Bioresearch, Burlington, U.S.A). Primers were synthesised as for 
the template oligonucleotides. This was carried out in a glass column containing 1 µmole (for the templates) 
and 0.2 µmole (for the primers) of an appropriate 5' -0-dimethoxytrityl deoxynucleoside-3 '-0-succinyl-
derivatised 1000 A control pore glass support at a loading of 18 µmol/g. 
For the template A reverse primer containing biotin (for purification of the PCR product; section 3.4.2), a 
biotin phosphoramidite (Glen Research) was added during synthesis as described (Nelson et al., 1992). The 
reaction kinetics of this phosphoramidite is virtually identical to a nucleoside phosphoramidite and has a 12 -
15 minute coupling optimum. 
3.3.3 Purification of Oligonucleotides by Reverse-phase HPLC. 
Following synthesis the last unblocking step was omitted in order to retain the terminal dimethoxytrityl (DMT) 
group. This 'DMT-containing' synthesis product was dissolved in Buffer A (50 mM LiCl, 10 mM NaOH, pH 
12.0) and loaded onto a Pharmacia Mono Q HR 515 ion exchange column. Elution was via a linear gradient 
with Buffer B (3 M LiCl, 10 mM NaOH, pH 12.0). The tritylated oligonucleotides were recovered by 
precipitation with ethanol/acetone (1:3), and centrifugation at 15 000 rpm for 1 hour. The oligonucleotide 
pellet was then resuspended in concentrated ammonia and dried. The final DMT group was removed by 
adding 100 µl 80% acetic acid for 1 hour at room temperature. Recovery was by butanol precipitation and 
pellets were resuspended in 50 µl TE buffer (10 mM Tris; 1 mM EDTA, pH 7.6). The purity of the template 
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3.3.4 Gene Amplification by PCR 
PCR amplification of oligonucleotide templates was carried out in a 50 µl reaction volume. PCR cycles were 
optimised for template, primer and magnesium concentrations and annealing temperature. An average cycle 
consisted of a denaturation step at 93°C for 20 seconds, an annealing step of 55°C for 30 seconds and an 
extension step of 72°C for 1 minute. DNA amplification cycles were controlled by a custom-made 
thermocycler (JDI Model 8012). Pro.mega buffers and Taq DNA polymerase were used for PCR. Following 
amplification, 10 µl aliquots were removed and electrophoresed on 10% non-denaturing polyacrylamide gels 
to check the PCR product was the predicted size. 
3.3.5 Removal of DNA Bands from Polyacrylamide Gels 
A modification of the method of Maniatis et al. (1982) was used to purify DNA from polyacrylamide gels. 
Full-length PCR products or templates were removed from 10% non-denaturing polyacrylamide gels as 
follows: 
The required DNA bands were removed using a razor blade, chopped into small pieces, and placed into 1.5 
ml Eppendorf tubes. The gel pieces were covered with elution buffer (0.5 M Ammonium Acetate; 10 mM 
Magnesium Acetate; 0.1% SDS; 1 mM EDTA, pH 8.0) and incubated overnight at 37°C in a shaking air 
incubator. The DNA fragments were recovered from the supernatant solution by precipitating in 2 volumes 
of ethanol and centrifuging at 14 000 rpm for 20 minutes. Pellets were washed in 70% ethanol, dried and 
resuspended in TE buffer. 
3.3.6 Streptavidin Purification of Biotin Labelled PCR Products 
PCR products in which biotin labelled primers had been used during PCR were purified using magnetic 
Dynabeads (Dynal, Norway) which had streptavidin attached. Forty microlitres of the beads was placed in a 
1.5 ml Eppendorf tube and washed twice with 1 x PBS (phosphate-buffered saline; Sambrook et al., 1989), to 
remove the sodium azide used to store the beads. The beads were then equilibrated with PCR buffer 
(Pro.mega) without MgCl. This buffer was then removed by placing the Eppendorf in the magnetic holder 
supplied by the manufacturer (Dynal, Norway). Following equilibration of the beads, 50 µl of the PCR 
product was added to the beads and these were placed on a roller (to keep the beads from settling) for 15 
minutes at room temperature. The non-bound DNA (supernatant), was then removed from the beads by again 
placing the Eppendorf in the magnetic holder. The beads were then resuspended in restriction enzyme buffer 
H (Boehringer Mannheim) and the bound DNA was then removed from the beads by digestion with uracil 
dehydrogenase (Gibco). Purified DNA products were visualised on 10% non-denaturing polyacrylamide gels 
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3.3.7 Standard molecular methods 
All standard molecular genetic techniques were carried out using the methods described in Sambrook et al. 
(1989). Restriction enzymes were obtained from Boehringer Mannheim. For the cloning of template A, 
pUC18 was 'maxi-prepped,' cut with BamHI, and purified from a 1% agarose gel in TAE buffer using the 
GENECLEANR II kit (Bio 101, Inc.) according to the manufacturer 's instructions. The purified vector was 
digested and the 5'-phosphates removed using calf intestinal phosphatase (Boehringer Mannheim). The vector 
was ligated to the BamHI-cut template using T4 DNA ligase (Promega). The dimethyl sulphoxide (DMSO) 
transformation method of Chung and Miller ( 1988) was used to prepare competent E. coli cells. 
3.3.8 Screening for Positive Clones using PCR 
For PCR screening, a few colonies were selected from plates and grown in 3 ml of LB containing 100 µg/ml 
ampicillin. 10 µl aliquots were then used in the PCR reaction. 10 pmoles of the pUC18 forward and reverse 
primers were used for the PCR. An average cycle consisted of a denaturation step at 93°C for 20 seconds, an 
annealing step of 50°C for 30 seconds and an extension step of 72°C for 1 minute. After 30 cycles, a final 
extension step of 5 minutes at 72°C was used. After PCR the aqueous phase was removed and electrophoresed 
on a 1 % agarose gel. Positive clones were identified by an increase in size of the PCR band from the control 
(vector only, or vector plus insert). The insert sequences were confirmed using the dideoxy chain termination 
sequencing method (Sanger et al., 1977) with the Sequenase kit (version 2.0; United States Chemical Corp). 
3.4 Results and Discussion 
3.4.1 Synthesis and PCR Amplification 
Template_A and the forward and reverse primers were synthesised as described (section 3.3.2) and the quality 
of these oligonucleotides is shown in Figure 3.3 (lanes 2 - 4). From the template only band in lane 4, it is clear 
that template A did not consist of a single 147-bp species but was contaminated with a number of shorter 
'failure' sequences. These arise in even the most efficient synthesis strategies as a result of incomplete 
coupling of nucleoside 3' -phosphoramidites with the controlled pore glass (CPG) supported 5'-hydroxyl DNA 
(Hom & Urdea, 1988). In addition, shorter fragments also arise when the oligonucleotide is removed from the 
CPG by treatment with concentrated ammonia. This cleaves the DNA at any apurinic sites (Hom & Urdea, 
1988). The primers to template A, forward (lane 3) and reverse (lane 2) were purer, possibly because the 
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PCR of the 'mixed' template A species was highly inefficient and in order to obtain full length PCR product 
conditions had to be optimised for template, primer and magnesium concentrations, as well as for optimal 
annealing temperatures (results not shown). Figure 3.3 (lane 5) shows the most optimal amplification product 
obtained. 
1 2 3 4 5 
Figure 3.3: 10% Non-denaturing polyacrylamide gel showing the synthesised oligonucleotides and the results 
of PCR amplification for template A. Lanes I , molecular weight markers pBR322 digested with Hpall; 2, 
reverse PCR primer; 3, forward PCR primer; 4, template A only; 5, PCR product for template A. 
The presumed full length PCR products (top band in lane 5) was then excised from the polyacrylamide gel and 
eluted, cut with BamHI and ligated to the BamHl-linearised pUC18. After transformation, positive clones 
were detected by PCR screening and the sequence checked by DNA sequencing. This showed that the PCR 
products were not full length, despite the removal of the upper-most PCR band from the polyacrylamide gel 
prior to cloning. Twelve residue deletions were observed from the 3' end indicating that the smaller PCR 
products had been cloned. Purification of the top template band from the polyacrylamide gel before PCR did 
not solve this problem. These base deletions were clearly too small to be detected by PCR screening because 
the differences between those with deletions and the full length PCR products were not detectable on a 1 % 
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resulted from errors made during synthesis. Furthermore, the efficiency of the synthesis process may have 
been too small to accommodate the long length of this template (D. P. Botes, personal communication). 
3.4.2 Use of Biotinylated Primers for Purification of the Full Length PCR Product 
To overcome the problems encountered in 3.4.1, two steps were taken: 
• Firstly, it was decided to resynthesise the template using a larger CPG glass column. The 147-base 
template A had previously been synthesised on a 1000 A column. In this case we decided to use a 
2000 A CPG column as this larger size would accommodate the larger DNA length and might result in 
a purer template with fewer truncated sequences. 
• A second step was to use biotinylated oligonucleotides for affinity purification as has been 
documented (Arnold & Hodgson, 1991 ; Hultman et al., 1989). Si ce biotin can be randomly 
incorporated into the oligonucleotide during synthesis (Hultman et al., 1989), incorporation of biotin 
onto the reverse primer, followed by affinity purification using streptavidin Dynabeads, would ensure 
the recovery of only the full-length PCR product. 
Dynabeads containing streptavidin covalently attached to the bead surface were obtained from Dyna! 
(Norway). Streptavidin is a protein CMr of approximately 66,000) which is made up of four identical subunits, 
each containing a high affinity binding site for biotin (KD = 10-15 M; Argarana et al., 1986). During affinity 
purification the biotin binds to the streptavidin (in this case, only the full-length product will be biotinylated 
since only the reverse primer contains biotin; Figure 3.4) and the shorter PCR products are removed by 
washing steps. Cleavage of the desired product from the streptavidin is facilitated by the presence of a uracil 
residue which is added onto the 3' end of the reverse primer during synthesis. The enzyme uracil DNA 
glycosylase is then used to cleave the DNA at the uracil residue, thus releasing the full length PCR product. 
The newly synthesised oligonucleotide (template A), made on the 2000 A CPG column was found to be only 
slightly purer than that synthesised previously. It was therefore necessary to use the biotin purification 
described above to further purify the template. 
The new template A was amplified by PCR using the reverse primer which had biotin attached. The full 
length PCR product was then purified using the streptavidin Dynabeads. The results of this purification 
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The full-length PCR product 
containing biotin attaches to 
the Streptavidin Dynabeads 
Purified full-length 
PCR product 
Shorter PCR products 
without biotin attached 
are purified away 
Figure 3.4: A schematic diagram showing the purification of the full length biotinylated PCR product 
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Uracil DNA glycosylase was used for the removal of the full length PCR product from the Dynabeads (lane 4 ). 
However, cleavage using this enzyme was found to be extremely slow and inefficient leading to poor yields of 
cleaved product. To overcome this problem, the PCR product was cleaved off the Dynabeads using the 
BamHI restriction site present at the end of the reverse primer for template A (lane 5), a process found to be 
far more efficient. The incubation time was also considerably less (1 hour as opposed to 4 hours with uracil 
DNA glycosylase ). 
160bp ~ 
147bp ~ 
1 2 3 4 5 
Figure 3.5: 10% non-denaturing polyacrylamide gel showing the results of affinity purification using 
streptavidin Dynabeads. Lanes 1, molecular weight markers, pBR322 digested with Hpall; 2, template A; 3, 
template A PCR product; 4, uracil DNA glycosylase cleaved PCR product; 5, BamHl cleaved PCR product. 
This BamHI-cut template A was then ligated to the dephosphorylated BamHI-cut pUC18 vector and 
transformed into E. coli. Of the 37 colonies that appeared on the ampicillin-LA plates, 20 were selected for 
PCR screening. Of these, 12 colonies showed an increase in size by PCR screening (results not shown). Four 
of these were then selected and the plasmid purified by CsCl ultracentrifugation and sequenced. 
DNA sequencing results showed that although the template used was now full length, it still contained errors. 
These were found to occur towards the 5' end of the DNA in the form of a deletion and two incorrect base 
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concluded that these errors were more likely to have occurred during synthesis than during the PCR 
amplification since it is possible to amplify 3 - 6 kb of DNA with minimal errors (Ponce & Micol, 1991 ). 
Thus, although the higher pore glass size had increased the purity of the synthesised oligonucleotides, the 
templates were still too long for synthesis and as a result there was a loss of fidelity. This is especially true 
since the error occurred at the 5' end of the DNA which is where the final bases are added. 
PART 2: Design of the Gene in Four Parts 
3.5 Considerations in the Design of the Gene 
Despite the small errors in the sequence being minor, they would nevertheless have major impacts. For 
example, there was a single G missing near the beginning of the sequence, which would have caused a frame 
shift and resulted in meaningless amino acid sequences. There are methods available to correct these errors 
such as site directed mutagenesis. However, since the resources were available for whole gene synthesis, it 
was decided to determine ways to improve this process. The following modifications to the cloning approach 
were made: 
1. The gene was divided into even smaller sections which shortened the oligonucleotides to be synthesised. 
It has been shown that synthesis and cloning of a 516-bp synthetic Erythrina trypsin inhibitor was more 
successful if the DNA used was of shorter, more manageable lengths (Teixeira, 1992). 
2. The synthesis process was improved by coupling the oligonucleotides to the larger pore size columns as 
before (i.e. 2000 A). 
3. A combination of anion exchange HPLC in denaturing conditions combined with non-specific 
hydrophobic dimethyl trityl (DMT) selection was used to purify the oligonucleotides. This step would 
ensure that the full-length template was separated from the failure sequences. 
For HPL<::: purification, the DMT group (which is attached to the last base during the synthesis process) is not 
removed after synthesis but is kept attached. Hence only the full length sequences will be tritylated (Volker, 
1993). During HPLC purification, this DMT group binds specifically (hydrophobic interaction) to the column 
matrix. The full-length sequences are thus retarded and elute last, well separated from any of the shorter 
' trityl-free ' failure sequences. With only the full length oligonucleotides present in the PCR reaction, more 
efficient PCR amplification could occur since it is the smaller failure sequences which are more likely to be 
amplified at the expense of the full length product as they occur in higher molar abundance. 
To find restriction sites which would enable the gene to be divided into four parts, the gene was again scanned 











Chapter 3 Page 79 
(Xhol, Nae! and Sty!) which divided the gene into four parts of 105, 48, 72 and 81 bases. These were named 






L G A P v P V D E N D L H L V D L 
CAGCTGCTTGGTGCTCCAGTTCCAGTTGACGAAAACGACCTTCACCTTGTTGACCTT 
GTCGACGAACCACGAGGTCAAGGTCAACTGCTTTTGCTGGAAGTGGAACAACTGGAA 






L E F 
Xhol - -
E K L V S V K Q Q V V A G 











Y E A K V 







A K V W E K P W M D F K E L Q E 
Sty/ - - - - - - - - - - - - - - -
GCCMGGTTTGGGAAAAACCATGGATGGACTTCAAAGAACTGCAGGAA 
CGGTTCCAAACCCTTTTTGGTACCTACCTGAAGTTTCTTGACGTCCTT 
F P V D A S A N A STOP 







Figure 3.6: DNA and amino acid sequences of the HO templates showing the division of the gene into 
four fragments . Restriction enzymes were incorporated into the sequence by modification of the codon 
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obtained from the primers 
Page 80 
Figure 3. 7: Schematic diagram of the cloning procedure used to clone the gene in 4 parts into p UC 18. 
Template A was amplified by PCR, cut with BamHI and cloned into the BamHI-linearised pUCJ8 to 
generate pUCI 8a. The template B PCR product was cut with Xhol and inserted into the Xhol linearised 
pUCl8a to generate pUCl8b. The template C PCR product was cut with Naef and inserted into the 
Naef linearised pUC I 8b to generate pUC I 8c. Finally the template D PCR product was cut with Sty! 
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Primers, which contained these restriction sites, were then designed as was done previously (section 3.2.1). 
For example, in the new template A, BamHl was included in the forward and reverse primer sequences so that 
this template could be cloned into the BamHI site of the linearised plasmid. An Xhol restriction site was 
engineered into the reverse primer sequence, just before the BamHl site enabling pUC18 carrying template A 
(pUC18a), to be linearised usingXhol for cloning in of template B. Template B hadXhoI on each primer set 
so that it could be cloned in at this point. A Nael restriction site was engineered into the reverse primer 
sequence of template B, just before the Xhol sequence. This enabled the new vector named pUC18b, to be 
linearised with Nael for cloning in of template C, and so on (Figure 3.6). Primers were checked for any 
adverse secondary structure using the program 'Primer' (Version 0.5; Whitehead Institute for Biomedical 
Research, Cambridge, MA). Primer sequences are shown in Table 3.2. 




Forward, Template A 5'CGCGTGCGCAGCAGCTGCTTGGTGCTCCAGTTC 3' BamHl, Pvull 
Reverse, Template A 5' TCTGTGCGCAGGACTCGA GCA GGCTGTTC 3' BamHl, Xhol 
Forward, Template B 5' CTAGGCGCTCTCGAGTTCGAAAAAC3' Xhol 
Reverse, Template B 5' CACATACTCGAGAGCCGGCAACAACC3' Xhol, Nael 
Forward, Template C 5' CGTATGCCGGCACCCTTTATTA 3' Nael 
Reverse, Template C 5' CTATGCCGGCAACCTTGGCTTC3 ' Nael, Styl 
Forward, Template D 5' CTAGCCAAGGTTTGGAAAA 3' Styl 
Reverse, Template D 5'ATACCAAGGTGGCAAGCTTAGCATTAGCAGA 3' Styl, Hindlll 
The underlined sequence shows the restriction sites in the order as indicated in the last column. 
The overlap region with the template is shown in bold and italics. 
3. 6 Results and Discussion 
Template A was synthesised using a 2000 A CPG column and was purified by HPLC (Figure 3.8). It is clear 
that despite the use of a larger pore size column, there was still a large proportion of failure sequences (lanes 3-
10). The previous 147-bp template A is shown in lane 2. Lane 11 , shows the purified 'DMf-containing' peak 
which eluted last off the ion exchange HPLC column. This DMf group was finally removed by the addition 
of 80% acetic acid. 
The HPLC procedure was carried out for all four templates. Since they now consisted of only a single species, 
PCR was much more efficient. Figure 3.9 shows the full length PCR products for template B (lane 1), C (lane 
3) and D (lane 5) in relation to the purified templates. Template A also showed a single full-length band, 
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Figure 3.8: Purification of oligonucleotides by HPLC using a Pharmacia Mono Q HR 515 ion 
exchange column. 
(A) HPLC profile of the purification. Elution was via a linear gradient of 3M LiCl, JO mM NaOH, pH 
J 2. 0. The peak numbers correspond to the lane numbers in (B) . 
(B) J 0% non-denaturing polyacrylamide gel. Carrying 20 µI of samples eluted from the column, 
processed as described in Materials and Methods (section 3.3.3). Lanes J, molecular weight markers, 
pBR322 digested with Hpall; 2; previous template A synthesised (section 3.4.J); Lanes 3 - JO, are the 
different peaks which eluted off the HPLC column. Lane J J, final 'DMT-containing ' peak which is the 
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1 2 3 4 5 6 7 
Figure 3.9: 10% non-denaturing polyacrylamide gel showing the fall length PCR products in relation to the 
purified templates. Lanes I, template B PCR product; 2, template B; 3, template C PCR product; 4, template 
C; 5, template D PCR product; 6, template D; 7, molecular weight markers, pBR322 digested with Hpall. 
After each successive HO portion was cloned in, the resultant plasmid was termed pUC18a to d, depending on 
the oligonucleotide most recently inserted (Figure 3.7). Because the templates contained the same restriction 
sites on each end, the orientation of the insert also had to be confirmed at each stage. This was done by 
restriction enzyme mapping of 'miniprepped' DNA or of the products of PCR screening. The insert DNA at 
each stage was then sequenced to confirm orientation and that the sequence was correct before continuing 
further. 
Sequencing results showed that each cloned template was not only full length but was correct. Once all the 
templates had been cloned the gene was again sequenced from beginning to end using the forward and reverse 
pUC18 primers. This was to make a final check to ensure that there was no frame shift or error in the gene 
sequence. 
In conclusion therefore, all 282 bases of the HO gene have been successfully cloned into the pUC18 vector. 
With regard to the synthesis of long lengths of DNA, the following conclusions can be drawn: 
1. Sufficiently sized CPG column should be used to accommodate the required length of DNA to be 
synthesised. 
2. The length of DNA used for synthesis should not be too long such that the fidelity of the sequence is 
compromised. 
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CHAPTER4 
Expression of the Hybrid Oryzacystatin Gene in Escherichia coli 
PART 1: Cloning, Expression and Purification of the Hybrid 
Oryzacystatin in the pMAL System. 
4.1 Introduction 
High-level expression of eukaryotic genes in microorganisms has often proved difficult to achieve despite the 
use of strong promoters (Nagai & Th.0gersen, 1984). The most common problems encountered with 
recombinant proteins include insolubility, aggregation or incorrect folding (Marston, 1986). To overcome 
these problems, many eukaryotic proteins have been efficiently produced as hybrids in which expressed genes 
are fused to the coding sequences of E. coli genes such as 13-galactosidase. 
A similar approach has been developed by New England Biolabs in the form of the pMAL vectors. In this 
system, target proteins are fused to a maltose binding protein (MBP; Maina et al., 1988). This protein has a 
high affinity for amylose such that a cross-linked amylose resin can be used as an affinity matrix to purify high 
yields of the fusion protein in a single step. It is this pMAL system that was used for the expression and 
purification of the hybrid inhibitor. The characteristics of the pMAL vector system and the purification 
method are discussed more fully in the following section. 
4.1 .1 The pMAL Series of Vectors for High-level Expression of Foreign Genes in E. 
coli 
In the pMAL vector system, the cloned gene is inserted downstream from the malE gene, which encodes the 
MBP (New England Biolabs manual). This, as mentioned previously, results in the expression of a MBP 
fusion. 
The tac promoter controls transcription of this fusion complex. Strong rrnB ribosomal RNA transcription 
terminators have been cloned downstream of the lacZa gene to prevent transcription from ptac from 
interfering with plasmid functions (Maina et al., 1988; Figure 4.1). The promoter is kept in a switched off or 
repressed state by the lac repressor (the product of the lacl gene), which is also carried by the pMAL vectors. 
In order to separate the target protein from the MBP, a sequence coding for the cleavage site of blood 
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Figure 4.1 ). This provides a mechanism for cleavage of the fusion protein, to release the target protein from 















malE ........ ..... TCC ATC GAG CCT AGG CCT 
Ile Glu Gly Arg 











GAA TIC AGT AAA ACC CTC GAT GGA TCC TCT AGA GTC GAC CTG CAG GCA AGC TTG ... lacZ 
Figure 4.1: The pMAL vectors, pMAL-p and pMAL-c. These vectors contain the inducible P1ac promoter 
positioned to transcribe a malE-lacZa gene fusion. The factor Xa cleavage site which is located near 
the Stu! restriction site (of the multiple cloning site), is shown in bold. pMAL-p contains the signal 
sequence of the MalE gene for periplasmic expression. 
There are two types of vectors in this system, pMAL-p and pMAL-c (see Figure 4.1). For the purpose of this 
study, the pMAL-p vector was used. This vector contains the signal sequence of the malE gene which dire~ts 
the MBP fusion proteins to the periplasm. The pMAL-c vector lacks this signal sequence and the product thus 
remains localised in the cytoplasm. Such localisation may be undesirable if a protein contains disulphide 
bonds as the reducing environment of the cell prevents their formation. In this case, the HO has no disulphide 
bonds. However, since cystatins have been shown to be extremely susceptible to proteolytic degradation, 
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The strategy for expression and purification of proteins using the pMAL system is shown schematically in 
Figure 4.2 . The cleared lysate of induced cells is run through a cross-linked amylase column. After washing, 
the fusion protein is eluted with a dilute maltose solution. The purified fusion protein is then cleaved wi th the 
protease factor Xa and the target protein is purified away from the MBP domain by repassage through the 
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Figure 4.2: Schematic diagram shoiving (A) a portion of a pAfAL vector with the Ma!E gene, the 
coding region for factor Xa and a hypothetical gene cloned into the poly/inker and the protein that 
results from expression of this gene. (BJ the purification of the fusion protein from the cross-linked 











Chapter 4 Page 87 
4.2 Materials and Methods 
4.2.1 Escherichia coil Strains and Culture Conditions 
All plasmids constructed for protein expression were cloned into E. coli strain TBI. E. coli cells were grown at 
37°C in Luria broth (LB) containing 0.2% glucose with shaking at 300 rpm. Strains carrying the plasmid were 
grown as above, with the addition of 100 µg/ml ampicillin (Sigma) to the medium. 
4.2.2 Construction and Analysis of Recombinant Plasmids 
Unless otherwise stated all molecular biology techniques were carried out according to Sambrook et al. (1989). 
The HO insert was removed from pUC18 by cutting with the restriction enzymes PvuIT and Hindill 
(Boehringer Mannheim). This 282-bp DNA fragment was gel purified from a 10% non-denaturing 
polyacrylamide gel as described in section 3.3.5. 
For preparation of the pMAL vector, 10 µg of pMAL-p was cut with Stul and Hindill and purified from a 1 % 
agarose gel in TAB buffer (0.4 M Tris; 0.4 M Acetic Acid; 0.002M EDTA) using the GENECLEANR II kit 
(Bio 101 Inc.) according to the manufacturer's instructions. The 5'-phosphates were removed using calf 
intestinal phosphatase (Boehringer Mannheim) and ligated to the HO insert using T4 DNA ligase (Promega). 
Colonies carrying the correctly inserted plasmid, designated pMAL-HO, were detected by colony blots using a 
digoxygenin (DIG) labelled probe of the HO gene (see section 4.2.3). These were then confirmed by 
'miniprepping' the DNA and digesting with various restriction enzymes. DNA sequencing was carried out 
using primers designed to anneal to the multiple cloning site of the pMAL vector. The designed sequences 
were as follows: 
Forward primer: 5' GCAGCGACATTTTGCTGCCGTTCGGGCCCGCATTAGTAT 3' 
Reverse primer: 5' TCGAGCTCGGTACCCGGCCG 3' 
4.2.3 Colony Blot Hybridisation and DIG Detection 
Colonies were replica plated onto two LB plates containing 100 µg/ml ampicillin. Following growth overnight 
at 37°C, Hybond N membranes (Amersham International) were blotted over the colonies onto the surface of 
the agar plates. The membranes were then placed onto filter-paper soaked in denaturing buffer (0.5 M NaOH; 
1.5 M NaCl) for 3 minutes and onto filter-paper soaked in neutralising buffer (0.5 M NaCl; 1 mM EDTA; 0.5 
M Tris-Cl, pH 7.0) for 7 minutes. The membranes were then washed in 5 x SSC (0.6 M NaCl, 0.06 M Sodium 
Citrate) for 5 minutes, allowed to dry and UV cross-linked at .595 nm for 5 minutes. A probe labelled with 
DIG (Boehringer Mannheim) was made by PCR amplifying the insert. The PCR method used is as described 
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manufacturer (Boehringer Mannheim). The primers used for PCR were the forward primer to template A (the 
first template in the '4-part'. cloning strategy) and the reverse primer to template D (the last template in the '4-
part' cloning strategy). Detection of the DIG-labelled probe was as described by the manufacturer (Boehringer 
Mannheim). 
4.2.4 Expression of the Hybrid Oryzacystatin Fusion Protein in E. coli 
Overnight cultures of E. coli TBI transformed with parental (pMAL-p) or recombinant (pMAL-HO) plasmids 
were grown in one litre LB containing 2 g/l glucose. Cultures were grown at 37°C until the A600 reached 0.4 
(approximately 2 hours). Isopropylthio-J3-o-galactopyranoside (IPTG; Sigma) was then added to 0.3 mM. 
Preliminary studies of the time required for induction (see section 4.3.2) had shown maximum expression after 
24 hours, so cultures were grown for a further 24 hours before isolation of the periplasmic :fraction. 
4.2.5 Periplasmic Fraction Isolation 
Cells were grown at 37°C for 24 hours, pelleted by centrifugation at 5000 rpm for 20 minutes at 4°C and 
resuspended in 20% sucrose; 30 mM Tris-Cl, pH 8.0. This sus ension was incubated for 20 minutes at room 
temperature with stirring. The cells were then pelleted, as before, resuspended in 5 mM MgS04 and incubated 
at 4°C for 20 minutes. The suspension was centrifuged and the supernatant kept as the 'cold osmotic shock' 
fluid. 
4.2.6 Optimisation of Induction Time 
The induction time with IPTG that gave optimum concentrations of fusion protein was determined as follows. 
Five millilitre samples were withdrawn from a one litre culture at various times after the addition of IPTG and 
these were used to prepare the cold osmotic shock fluid (periplasmic fraction) as described above. Twenty 
microlitre samples of this was used for SDS-PAGE gels. The concentration of fusion protein in the cold 
osmotic shock fluid was determined by incubation of 0.5 ml of the fluid with 0.5 ml of packed amylase resin in 
column buffer (0.2 M NaCl; 1 mM EDTA; 20 mM Tris-Cl, pH 7.4). This was then spun down at 14,000 rpm 
in a bench top centrifuge. Following washing with column buffer, the fusion was again spun down, and eluted 
from the amylase resin with 10 mM maltose. The protein concentrations in the eluate were determined using 
the Bio-Rad protein assay (Bradford, 1976) as described in Appendix C. 
4.2.7 Column Purification of the Fusion Protein 
The periplasmic extract was diluted 1:5 with column buffer (0.2 M NaCl; 1 mM EDTA; 20 mM Tris-Cl, pH 
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column was then washed with 8 column volumes of column buffer to remove the last of any unbound proteins. 
The fusion protein was finally eluted with column buffer containing 10 mM maltose. Five millilitre fractions 
were collected using a fraction collector and the A280 of each 5 ml fraction was read on a Beckman DU-64 
spectrophotometer. The inhibitory activity of the various fractions was determined as described in Appendix 
c. 
4.2.8 Polyacrylamide Gel Electrophoresis (PAGE) and Western Blotting 
Fusion proteins were separated on 13% SDS-PAGE gels with 6.4% stacking gels as described by Laemmli 
(1970; Appendix C). Electrophoresis was performed at 4°C at constant current (15 to 40 mA) until the 
bromophenol blue tracking dye reached the bottom of the gel. The proteins were identified by staining with 
Coomassie brilliant blue R-250 (Chen et al., 1993). 
The 10-kDa hybrid inhibitor was electrophoresed in triton gels using the loading buffer and procedure as 
described (Schligger & von Jagow, 1987). Electrophoresis was performed at 4°C at constant current (15 to 40 
mA) until the tracking dye reached the bottom of the gel. Separated proteins were visualised using the silver 
staining method of Merril et al. (1983). 
For Western blotting, proteins were electroblotted onto nitrocellulose and processed according to Towbin et al. 
( 1979) with modifications (Appendix C). The antibodies used were: 
• anti-OC I (a gift from Professor Soichi Arai, Department of Agricultural Chemistry, Faculty of 
Agriculture, University of Tokyo, Japan) used at a 1/1000 dilution. 
• anti-MBP antibodies (New England Biolabs) used at a 1/10 000 dilution. 
4.2.9 Digestion of the Fusion with Factor Xa 
The fusion product, eluted from the amylose column, was diluted to 400 ml with 100 mM NaCl; 10 mM Tris-
Cl, pH 8.0. This was then dialysed against 5 litres of 0.1 M NaCl; 10 mM Tris-Cl, pH 8.0, with a number of 
changes over 48 hours at 4 °C. The dialysed protein was concentrated by ultrafiltration under pressure using a 
PIO membrane (Amicon Inc., U.S.A) and the concentration of the fusion protein was determined using the 
BioRad protein assay (Bradford, 1976; Appendix C). Factor Xa was then added at a ratio of 1:200 (factor 
Xa:fusion), and incubated for 12 hours at 25°C. 
4.2.10 Purification by Ion Exchange Chromatography 
Following digestion with factor Xa, the proteins were dialysed against 5 litres of column buffer (25 mM NaCl; 
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and equilibrated in column buffer before placing the dialysed proteins over the column. The column was 
washed with 5 column volumes of column buffer and proteins were eluted using a salt gradient from 25 mM 
NaCl, 20 mM Tris-Cl, pH 8.0 to 500 mM NaCl, 20 mM Tris-Cl, pH 8.0. Fractions (2.5 ml) were collected and 
the A280 was read on a Beckman DU-64 spectrophotometer. 
4.3 Results and Discussion 
4.3.1 Construction of the Hybrid Oryzacystatin Fusion Protein 
The synthesised gene was subcloned into the pMAL vector after removal from pUC18 by digesting with Pvull 
and Hindfll. This resulted in the removal of a 282-bp :fragment (Figure 4.3) which was gel purified to separate 
the insert from the rest of the plasmid. This was particularly necessary since Pvull cuts in the pUC18 plasmid 
(Appendix D) so the correct size band had to be isolated. 
The recognition site for the factor Xa protease consists of four amino acids, Ile-Glu-Gly-Arg (Nagai & 
Th0gersen, 1988). The ideal cloning procedure would be to insert the gene of interest directly 3' to the coding 
sequence for factor Xa. To do this, the gene of interest must be cloned into the Stu! site in the vector multiple 
cloning site (New England Biolabs manual). By cutting the insert at the specifically engineered Pvull site a 
blunt-ended :fragment resulted, with the first amino acid (leucine) at the start of the gene. Cutting the vector 
and the insert with Hindfll allowed directional ligation of the Pvuil-HindII.1-cut insert into the desired position 
and in frame with the ma/E and factor Xa sequences. 
The insert and vector were ligated and transformed into E. coli strain TB! by the method of Chung & Miller 
(1988). When the putative recombinants were transferred onto fresh LB plates containing 100 µg/ml 
ampicillin, 80 µg/ml 5-bromo-4-chloro-3-indoyl-[3-o-galactopyranoside (X-gal) anq 0.1 mM IPTG, the 
majority of white colonies did not grow well. This could be attributed to the over expression of the foreign 
fusion protein on the plates. Some fusion proteins have been shown to be toxic to E. coli when IPTG and X-
gal are included in LB plates, even at induction levels of 10 µM IPTG (New England Biolabs Manual). The 
identity of positive clones was thus further verified by colony hybridisation using a DIG-labelled probe of the 
HO gene. The DNA of a few of these positive clones was extracted using the 'miniprep' method (Sambrook et 
al., 1989) and digested with restriction enzymes present in the insert (Figure 4.4). The Stu! and Xbal 
restriction sites (lanes 2 and 3) are lost from the multiple cloning site once the insert is cloned (see Figure 4.1) 
and thus would not be expected to cut. They do cut the pMAL-p plasmid, as is shown in lanes 6 and 7. The 
restriction enzyme, Sty!, was used to clone in template D of the insert in the 4-part cloning strategy (Chapter 
3). It is not present in the pMAL-p vector (Appendix D) as can be seen from the uncut band (lane 5). The 
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Figure 4.3: Schematic diagram showing the cloning procedure. The insert was removed from pUCJ8-
HO by cutting with Pvull and Hind!!! and ligated into the pMal-p plasmid (linearised with Stu! and 
















Figure 4.4: 1 % agarose gel showing plasmid DNA, pMAL-p & pMAL-HO, digested with various 
restriction enzymes. Lanes 1-4 are the recombinant plasmid pMAL-HO and lanes 5-8 are the pMAL-p 
plasmid only. Lanes 1 & 5, Sty! cut plasmid; lanes 2 & 6, Stu! cut plasmid; lanes 3 & 7, Xbal cut 
plasmid; lanes 4 & 8, uncut plasmid; 9, molecular weight markers A. digested with Eco RI and Hindi!!. 
The DNA was sequenced using the dideoxy chain termination method of Sanger et al. (1977) to ensure that the 
gene was correct and in frame with the factor Xa cutting sequence. 
4.3.2 Analysis of Expression of the Fusion Protein 
Expression was induced (section 4.2.4) by addition of IPTG to a mid-log phase culture and then incubated for 
a further 24 hours to allow for the accumulation of the fusion protein. Samples of the cold osmotic shock 
solution were taken before and after induction and analysed on a 13% SDS-PAGE gel to detect the presence of 
the fusion (Figure 4.5). No fusion product was observed for the controls, i.e. the uninduced and induced 
bacterial periplasmic fractions without plasmids (lanes 2 and 3) and fractions containing the pMAL-p (lanes 4 
and 5). Bacterial periplasmic fractions (lanes 2 and 3) did show expression of E. coli periplasmic proteins as is 
seen in lanes 4 - 6, however, these were faint and did not photograph well. 
On induction with IPTG, pMAL-p (lane 5) showed accumulation of a 42-kDa protein. This is close to the 
predited size of 42,700 Da (lane 8; Duplay et al., 1984). In lane 7, there is an accumulation of a predominant 
product of approximately 52 kDa following induction of pMAL-HO with IPTG. This is in agreement with the 
expected size of 52 kDa for the fusion protein since the :tvIBP is a 42-kDa protein and the HO protein is 
approximately 10 kDa. A :tvIBP-HO fusion would not be expected to include the a-fragment of the lacZ gene 
as the stop codon at the end of the HO gene would prevent its inclusion during translation. Some induction can 
be seen in the uninduced lanes, the fusion protein (lane 6) and the :tvIBP (lane 4 ), because the strong tac 
promoter often causes readthrough even in uninduced cultures. A similar result was observed when expressing 



























Figure 4.5: 13 % SDS-PAGE gel showing results of protein expression before and after induction with 
IPTG. Lane I , molecular weight markers; lanes 2 & 3, the TB! periplasmic fractions ; lanes 4 & 5, 
pMAL-p plasmid only; lanes 6 & 7, pMAL-HO periplasmic fractions; lane 8, MBP control. The 
addition of IPTG is indicated by a (+). 
4.3.3 Optimisation of Induction Time 
The experiment described in section 4.2.6 was conducted to determine the best time to harvest the cells 
following induction with IPTG. As can be seen from both the SDS-PAGE gel (Figure 4.6 (B); lanes 7 - 13) 
and the results of the Bio-Rad protein assays (Figure 4.6. (A)), the fusion protein showed optimal expression 
after 24 hours induction, well after stationary phase had been reached. A similar result was seen with the MBP 
(lanes 3 - 6). This pattern has also been shown with the expression of the Bt-toxin under the control of the tac 
promoter {Ge et al. , 1990). These authors suggested that the reason the longer incubation times further 
increased the amount of expressed protein, was that E. coli cells do not lyse in the stationary phase and 
therefore have more time to synthesise the expressed protein. 
4.3.4 Western Blot Analysis of the Expressed Fusion Protein 
SDS-PAGE gels were analysed by western blotting using antibodies to both the maltose binding protein (New 
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Figure 4.6: (A) Levels of expressed fusion protein over time. (B) 13% SDS gel showing fusion protein 
produced over time. 20 µ!.of the cold osmotic shock fluid was loaded onto the gel. Lanes 1, molecular 
weight markers; 2, MBP control; 3 - 6, pMAL-p expressed for 0, 1, 3 and 24 hours after induction; 
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As expected, the antibody to the MBP bowid to the MBP only (Figure 4.7; lane 1) and the pMAL-p expressing 
the MBP (lane 5). Since the fusion also contains the MBP, the antibody bowid to the 52-kDa fusion protein in 
lanes 6 and 7. The uninduced lanes (lane 4, MBP and lane 6, fusion protein) show some expression, since as 
mentioned above, the~e is often read-through from the tac promoter. In lane 7, other bands lower than the 52-
kDa fusion protein were visible, which were possibly degradation products. The middle of the three major 
bands were similar in size to the MBP and is either endogenous MBP or a cleavage product of the fusion 
protein. No MBP production was detected in the uninduced and induced bacterial periplasmic fractions 
containing no plasmid (lanes 2 and 3). 
In the western blot carried out using antibodies to OC I (Figure 4.8), the OC I antibody bowid to the fusion 
protein (lanes 6 and 7). More than one band is seen in lane 7, presumably due to premature termination of the 
fusion protein or its digestion with E. coli proteases (Maina et al., 1988). As in the case with the MBP 
antibody, the uninduced periplasmic fraction showed a band (lane 6). This is as a result of read-through from 
the tac promoter. As expected, no bands were seen for the uninduced and induced bacterial fractions 
containing no plasmid (lanes 2 and 3), in the MBP only (lane 1), or the pMAL-p uninduced (lane 4) and 
induced (lane 5). 
4.3.5 Purification of the Expressed Fusion Protein 
A one litre culture of TB 1 containing the pMAL-HO plasmid was induced, processed by isolating the cold 
osmotic shock fluid and purified on a column of cross-linked amylose. The elution profile is shown in Figure 
4.9 (A). A large fraction of the p otein eluted with the column buffer while the fusion protein remained 
attached to the column. On addition of 10 mM maltose, the fusion protein was eluted. The presence of the 
fusion protein in this final fraction was confirmed by inhibitory assays with papain (see Appendix C) and by 
SDS-PAGE gel analysis (Figure 4.9 (B)). Lane 2 shows the total protein before purification over the amylase 
column while lane 3 shows the purified protein fusion which eluted with the 10 mM maltose. This appears as 
a single band with a molecular weight of 52 kDa. 
Crude extracts from one litre of cell suspension contained approximately 42 mg of periplasmic protein (Table 





















Figure 4. 7: Western blot of a 13% SDS-PAGE gel. Proteins were detected using antibodies to the 
MBP. Lane 1, MBP control (New England Biolabs); TB! uninduced (lane 2) and induced (lane 3); 
pMAL-p uninduced (lane 4) and induced (lane 5); pMAL-HO uninduced (lane 6) and induced (lane 7). 









Figure 4.8: Western blot of a 13% SDS-PAGE gel. Proteins were detected using antibodies to the 
natural OC I inhibitor. Lane 1, MBP control (New England Biolabs); TB! uninduced (lane 2) and 
induced (lane 3); pMAL-p uninduced (lane 4) and induced (lane 5); pMAL-HO uninduced (lane 6) and 
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Figure 4.9: (A) Cold osmotic shock proteins were loaded onto a 2.5 x 10 cm column equilibrated in 
0.2 M NaCl; 1 mM EDTA; 20 mM Tris-Cl, pH 7.4. The fusion protein was eluted by the addition of 10 
mM maltose. The % inhibition was determined as described in Appendix C. (B) Silver stained, 13% 
SDS-PAGE gel showing the results before and after purification on the affinity column. Lane 1, 
molecular weight markers; 2, total periplasmic proteins before placing over the column; 3, fusion 
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a Data in the table refers to an initial starting volume of 400 ml of periplasmic extract after all other cellular 
proteins from the origional 1 litre culture have been removed. 
b Measured as total protein by the Bio-Rad protein assay (Bradford, 1976; Appendix C). 
0 One unit is arbitrarily defined as the amount of inhibitor that can reduce the activity of 0.5 µM papain by 50% 
under the assay conditions. 
4.3.6 Digestion of the Fusion Protein with Factor Xa Protease 
The pooled, eluted fractions from the amylase column contained 10 mM maltose. This maltose had to be 
removed by dialysis before cleavage with factor Xa to enable further purification over the affinity column. 
Although experiments with fluorescent microscopy have shown that the rate of dissociation of the complex 
between maltose and the MBP is extremely high (Silhavy et al., 197 5), to enhance diffusion of maltose from 
the dialysis bag, the protein solution was diluted to 200 ml with 100 mM NaCl; 10 mM Tris-Cl, pH 8.0, giving 
a concentration of approximately 1.2 µg/ml . This was then dialysed against the above buffer (used for 
dilution) and concentrated by ultrafiltration under pressure with a 10-kDa molecular weight cut-off membrane 
(Am.icon Inc., U.S .A). 
To separate the HO from the MBP the fusion protein was incubated with factor Xa. In order to determine the 
optimal time for digestion, the fusion protein was added at a ratio of fusion: factor Xa of 200: 1. Samples were 
incubated at various time intervals at 25°C and then analysed on a triton SDS-PAGE gel (Schagger & von 
Jagow, 1987; Figure 4.10). Lanes 4 - 7 show the digestion of the fusion protein with factor Xa. Over the time 
period of the digestion the 52-kDa protein band disappeared, and two new lower bands of 42-kDa and 10-kDa 
(lower arrow) appeared, representing the two domains of the MBP-HO fusion. It appears that the most 
efficient cleavage occurred after 12 hours incubation at 25°C. Trial digests at 37°C and 42°C showed no 
increase in the efficiency in the time required for or in the efficiency of cleavage (results not shown). Similar 
results were obtained even after incubation for 12 hours with a 5-fold higher concentration of enzyme (results 
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that the 4-amino acid recognition site was accessible to the protease. Furthermore, factor Xa did not appear to 
cleave the MBP or the hybrid oryzacystatin as no further cleavage products were obtained. 
From the SDS-PAGE gel, it appears that the amount of cleaved product (the 10-kDa inhibitor) is extremely 
low. Guan and Dixon (1991) showed that cleavage of many proteins in their laboratory with factor Xa was 
slow and often extremely inefficient. Other researchers (Dr. John Hastings, personal communication) have 
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Figure 4.10: Triton-SDS gel showing the results of factor Xa cleavage with time. Lane 1, 55 kDa 
molecular weight marker; 2, small molecular weight markers; 3, MBP; lanes 4 - 7, digests over 0, 2, 6 
and 12 hours respectively. The arrow indicates the position of the HO inhibitor. 
4.3.7 Purification of the HO Inhibitor by Ion Exchange Chromatography 
Rather than placing the factor Xa-cut fusion protein over the amylase column as described by Mania et al., 
1988, it was decided to purify the HO by ion exchange chromatography. The advantage of this method is that 
it allows for separation of not only the MBP, but also the factor Xa protease, from the HO. This is necessary 
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Three protein peaks were obtained and the column fractions for each were pooled and dialysed against 5 mM 
phosphate buffer to remove the NaCl. The different peaks were then analysed by SDS-PAGE (Figure 4.11 ). 
Lane 2 (control) is a partial digest of the MBP-HO fusion showing the three possible band sizes. The 
uppermost band is the uncut fusion protein, the second and third are the two cleaved domains of the fusion 
protein the MBP and the HO inhibitor respectively. Lane 3 shows the purified HO which eluted between 
0. 02 5 M and 0 .1 M Na Cl. Lane 4 is the MBP. This eluted between 0 .1 and 0 .15 M Na Cl while the factor Xa 
protease, the concentration of which was too low for the protein to be visualised on the gel, eluted at 
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Figure 4.11: 13% SDS-PAGE gel showing the results of ion exchange protein purification. Lanes 1, 
molecular weight markers; 2, partial digest of the fusion protein with factor . Xa; 3, purified HO 
inhibitor - eluting between 0.025 Mand 0.1 M NaCl; 4, MBP - eluting between 0.1 Mand 0.15 M 
NaCl. 
N-terminal sequencing of the purified HO inhibitor was then carried out to ensure that the factor Xa protease 
had produced the required N-terminus for the HO inhibitor. For this, the Edman degradation sequencing 
method was used. In this method, the a-amino group of the polypeptide chain is coupled under alkaline 
conditions to phenylisothiocyanate which allows the terminal amino acid to be cleaved from the remainder of 
the peptide under acidic conditions. The resulting amino acid derivative (an anilinothiazolinone) is converted 
into the more stable phenylthiohydantoin (PTH) form which can be analysed by HPLC while the remaining 
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Sequenceing of the ion exchange sample showed high background from glycine and Tris ...,ontaminants and 
thus only the first two leucine residues and a proline residue in the fifth cycle could be determined with any 
accuracy. Purification by HPLC on a C18 reverse phase column would have been a better option as it would 
have removed the contaminants. However, since the sequence (obtained by subtracting the background from 
the previous cycle) appeared to be correct and since factor Xa, had cut at the correct cutting site in the pMAL 
system under the same experimental conditions as described in section 4.2.9 (Pei-yin Ma, personal 
communication; Teixura, 1992), and Ki data obtained with the cut inhibitor was in agreement with the results 
determined by Urwin et al., 1995b using a similar inhibitor, the sequence was assumed to be correct. 
PART 2: Assessment of the Inhibitory Capabilities of the Fusion Protein 
4.4 Introduction 
Although many proteins expressed as fusion hybrids have been shown to be biologically active (Smith & 
Johnson, 1988), it is questionable as to whether the 10-kDa HO protein would still be active and able to bind to 
the cysteine proteinase when attatched to such a large 42-kDa MBP which can offer steric hindrance. 
Contrary to expectations, however, a survey of the literature showed that cystatin fusions are, in fact, 
biologically active. For example, Michaud et al. (1994) expressed oryzacystatins I and II as fusion proteins 
linked to glutathione-S-transferase (GST), a 26-kDa protein. These oryzacystatin fusions were found to be 
biologically active when assayed with papain. Similarly, Thiele et al. (1990) constructed inhibitor fusions of 
stefin B and mutant variants with MS-2 polymerase. These fusions were found to be tight-binding inhibitors 
of papain (Thiele et al., 1990) as were stefin A fusions with adenylate kinase (Kaji et al. , 1990). 
We thus proceeded to test the MBP-HO protein for its ability to inhibit papain in the hope that should the 
fusion protein show activity against cysteine proteinases, it could be used in biological control assays and so 
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4.5 Materials and Methods 
' 
4.5.1 Fluorimetric Assays to Test for Activity 
To test for activity of the fusion protein, 200 nM fusion inhibitor was incubated with 300 nM papain in papain 
assay buffer (Appendix B) in a total volume of 140 µl at 30°C for 30 minutes. 10 µl of this incubation mix 
was then removed and assayed with 5 µM substrate (Z-Phe-Arg-AMC; Sigma). Activity was detected using a 
Perkin-Elmer rvIDF-43A fluorescence spectrophotometer at an excitation wavelength of 380 nm and an 
emission wavelength of 460 nm. 
Distilled water or a solution of a non-cystatin fusion protein (i.e. MBP-phosphinothricin acetyl transferase 
(PAT); a gift from Kenneth Palmer, Microbiology Department, University of Cape Town, Cape Town, South 
Africa), replaced the MBP-HO in negative control assays. The PAT protein is a 22-kDa protein from 
Streptomyces hygroscopicus (Thompson et al., 1987) which was also expressed using the pMAL system and 
recovered as a fusion protein. 
4.5.2 Assays to Determine whether the Inhibitor was Cleaved by Papain 
A modification of the method of Machleidt et al. (1995) was used for these assays. Papain (0.4 µM) was 
incubated with the MBP-HO fusion (4 µM) or the MBP-PAT fusion (4 µM) in papain assay buffer (Appendix 
B) at 30°C. The incubation was carried out for various lengths of time as indicated in Figures 4.13 (A) and 
(B). The reaction was stopped at each stage by the addition of 1 mM iodoacetate. Results were analysed by 
SDS-PAGE gels (Appendix C) and fusion bands were scanned using a Hoefer GS300 scanning densitometer. 
4.5.3 Gelatin Gel Assays to Test the Stability of the Inhibitor/Enzyme Complexes 
Cystatin/papain complexes were subjected to mildly-denaturing gelatin-PAGE gels as described by Michaud et 
al. (1993) and Heussen & Dowdle (1980). For this assay, various cystatin inhibitors (50 µM) were incubated 
with 2 µM papain and 25 µl papain assay buffer (Appendix B) for 15 minutes at 37°C. Following incubation, 
this mix was added to 6 µl of gelatin-PAGE sample buffer (Heussen & Dowdle, 1980). Negative controls for 
inhibitory activity were prepared by incubating the proteinase with both 1 mM PMSF and 50 µM soybean 
trypsin inhibitor (SBTI). Positive controls for proteinase activity consisted of papain incubated with 50 mM 
Tris-Cl, pH 7.0 instead of the inhibitors. 
Proteins were then electrophoresed on polyacrylamide gels containing 0.1 % w/v gelatin. To avoid migration 
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29:1.1. Gels were run overnight at constant current (18 mA) at 4°C and transferred to a 25% v/v aqueous 
solution of Triton-X-100 for 30 minutes at room temperature, to allow for renaturation of proteinases. The 
gels were then immersed in papain assay buffer (Appendix B) for one hour at 37°C. Gels were then stained in 
Coomassie Brilliant blue R250 stain as described by Chen et al. (1993). 
4.5.4 Preparation of the Fusion Protein for Insect Trial Assays 
Cold osmotic shock proteins of parental (pMAL-p) or recombinant pMAL-HO plasmids, were isolated as 
described previously (sections 4.2.4 and 4.2.5). These were then freeze-dried. Samples of the cold osmotic 
shock protein were analysed on 13% SDS-PAGE gels to estimate the expression levels. The amount of fusion 
or MBP present in the total periplasmic fraction was quantitated using a Hoefer GS300 scanning densitometer. 
4.5.5 Insect Assays 
Insect assays were carried out by D. Van der Linde at the South African Bureau of Standards (S.A.B.S.), in 
Pretoria according to the following protocol (D van der Linde, personal communication): 
The test was conducted in plastic containers (top diameter, 120 mm; bottom diameter, 90 mm and depth 65 
mm). Five replicates were used for the controls (MBP only and the no protein control), and the experiment 
(HO-MBP fusion protein). 200 g of a standard breeding medium mix was placed in each test container. This 
consisted of 2250 g white bread flour, 180 g fish meal and 270 g full cream milk powder. 0.1% of the fusion 
protein (equivalent to 400 mg of the MBP-HO fusion periplasmic fraction, and 400 mg of the MBP 
periplasmic fraction) was dissolved in distilled water and sprayed onto the surface of the rearing mixture using 
an Aerograph spray gun. For the untreated controls, distilled water was sprayed onto the surface of the 
breeding medium and mixed in. Protein-containing samples were seen to form a crust on top of the medium 
when dry. This crust was then ground to a fine powder using a coffee blender, and mixed in with the medium. 
Twenty adult test insects of the confused flour beetle (Tribolium confusum) were placed in each container and 
the contaipers were covered with glass panels to prevent the insects escaping. Observations for larval activity 
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4. 6 Results and Discussion 
4.6.1 Fluorimetric Assays 
The MBP-HO was tested for inhibitory activity as described (section 4.5.1) and the results are shown in Figure 
4.12. From the figure , it is clear that the MBP-HO-fusion protein inhibited papain whereas 200 nM of the 
MBP-PA T fusion protein and 200 nM MBP failed to inhibit the enzyme. 
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Figure 4.12: Enzyme activity profiles of papain incubated with and without fusion proteins 
To see if the MBP-HO protein was acting as a substrate for papain, the MBP-HO fusion (4 µM) was incubated 
with papain (0.4 µM) for the different times shown in Figure 4.13 (A) and the reaction was stopped by the 
addition of 1 mM iodoacetate. As can be seen from the 13% SDS-PAGE gel, there appears to be no digestion 
of the MBP-HO, even after 60 minutes, a far longer period than used in the fluorimetric assay. Densitometric 
scanning of the PAGE gel showed no change in the relative concentrations of the bands with time. 
To determine whether the MBP-PAT fusion product showed any difference in results, 4 µM of this fusion 
protein was incubated at the same time intervals as used for the MBP-HO fusion. Results showed complete 
digestion of this fusion protein even after 5 minutes incubation with papain (results not shown). Hence this 
experiment was repeated using a shorter time scale. The results are shown in Figure 4.13 (B). In this case 
digestion occurred even after 10 seconds incubation with papain and the fusion was completly digested after 2 
minutes. On cleavage with papain there is the appearance of an approximately 42-kDa band which is the size 
of the MBP. The cleavage site is possibly at the start of the PAT sequence since no cleavage sites for pa pain 
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Figure 4.13: (A) 13% SDS-PAGE gel showing results of incubation of the fusion protein with papain at 
37 CC. The incubation times are indicated (lanes 2 - 9) and the reaction was stopped by the addition of 1 
mM iodoacetate. Lanes 1, molecular weight markers. (B) 13% SDS-PAGE gel showing results of 
incubation of the MBP-PAT fusion protein with papain as described above. The incubation times are 
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22-k.Da band can be seen which is the size of the PAT protein (Thompson et al., 1987) and is similar to papain 
(M, 23 000 Da; Cunningham, 1965). 
A further point that must be noted, is that no enzyme:inhibitor complexes of the HO-rvIBP fusion with papain 
were seen presumably because the samples were boiled in the presence of SDS and iodoacetate for 10 minutes 
before electrophoresis. Others (Nicklin & Barrett, 1984; Anastasi et al., 1983; Barrett et al. , 1979), using a 
similar experimental approach have also failed to illustrate complex formation. However, should this be a 
theoretical requirement, complex formation could be shown using experiments such as non-denaturing 
electrophoresis at the appropriate pH (without boiling) or gel exclusion chromatography of labelled 
components (Heussen-Schemmer & Dowdle, 1993). Hence this study does not reflect the stability of 
inhibitory papain-fusion complexes during SDS-PAGE, but rather, the aim was to show that unlike the 'non-
cystatin' fusion protein, the HO fusion is not degraded on interaction with papain, but acts as an inhibitor. 
4.6.2 Gelatin Gel Electrophoresis 
To study the behaviour of different papain-inhibitor complexes under mildly denaturing conditions of SDS-
PAGE, mixtures of papain with either E-64 (an irreversible cysteine proteinase inhibitor that originates from 
AspergU!us japonicus; Hanada et al., 1978), the HO, OC I, chicken cystatin, PMSF or SBTI were 
electrophoresed at 4 °C in the presence of 1 % SDS, in a polyacrylamide gel containing gelatin as co-
polymerised substrate (Heussen & Dowdle, 1980; Michaud et al., 1993, Michaud et al., 1996). 
After electrophoresis the SDS was removed by immersing the gel in Triton-X-100 and bands of lytic activity 
were developed by incubating the gel in assay buffer at 37°C. The bands of gelatin hydrolysis were revealed 
as clear areas against a dark background when the gel was stained with Coomassie brilliant blue R250. 
The results (Figure 4.14) showed (predictably) that the serine proteinase inhibitors, PMSF and SBTI, had no 
discemable effect upon the migration or the activity of the enzyme (lanes 3 and 4). The E-64 (lane 2) inhibited 
papain completely, OC I (lane 5) and HO (lane 7) very nearly so and chicken cystatin (lane 6) to an 
appreciable but lesser extent. 
Since residual enzyme activity with the M, of papain represents free enzyme and since HO, chicken cystatin 
and OC I were all used in the same molar enzyme:inhibitor ratio, one may conclude that the chicken 
cystatin:papain complex is less stable in the presence of 1 % SDS than are either HO:papain or OC l:papain 
complexes. This is of interest considering that the K; of chicken cystatin is several orders of magnitude lower 
(in the 10·14 M range; Auerswald et al., 1992) than that for OC I which has a K; in the 10·9 M range (Arai et al. , 
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1 2 3 4 5 6 7 
Figure 4.14: 13% SDS-gelatin-PAGE gel showing the stability of cystatin/papain complexes following 
electrophoresis. Lanes I , papain only; 2, E-64/papain complex; 3, PMSF and papain; 4, SBTI and 
papain; 5, HO-fusion protein/papain complex; 6, Chicken cystatin (CC)/papain complex; 7, OC 
Ilpapain complex. 
4.6.3 Insect Trial Assays 
Since the MBP-HO was an effective inhibitor of papain and is available in relatively large amounts, this 
compound was used for insect trial assays using the confused flour beetle, Tribolium confusum. This insect 
was chosen for two reasons: 
1. It was readily available as a test system at the S.A.B.S. in Pretoria, South Africa. 
2. Initial investigations of casein hydrolysis by the midgut proteinases of T confusum have shown maximal 
activity between pH 6.5 and 6.9 (Birk et al., 1962). This suggests that these insects use catheptic 
proteinases for digestion. 
Crude periplasmic proteins containing 55% HO-MBP (determined by densitometric scarring of SDS-PAGE 
gels) were isolated as described in section 4.2.5. These and control MBP fractions were freeze-dried and sent 
to the S.A.B.S. in Pretoria. 
The results of the insect assays are shown in Table 4.3. Problems were encountered in the administration of 
the fusion protein in the trial assays as the proteins were not easily crushed with the media. Repeated attempts 
to do this resulted in the proteins becoming sticky and difficult to mix in with the dry media. The proteins thus 
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Table 4.3: Insect trial assay results using the confused flour beetle, Tribolium confusum. 
Number of Tribolium Confusum adults that have emerged 
.Replicates · . 
1 . 2 3 4 5 
Proteinase Inhibitor >600 >700 >700 >600 >400 
Control Protein (MBP) >800 >700 >700 >500 >600 
Untreated Control >700 >600 >700 >400 >500 
Results showed very ,little difference between the controls (the maltose binding pr~tein and the untreated 
control) and the fusion. This could be attributed to a number ofreasons: 
l. There may have been other proteinases besides cysteine proteinases in the insect midgut which could have 
overcome any toxic effects of the inhibitor. 
2. The concentrations of inhibitor used in this assay (0.1%) may not have been sufficient to deliver toxic 
effects. Should this be the case, the use of this inhibitor in transgenic plants would be questionable since 
it would be difficult to achieve higher concentrations in plant tissues. 
3. In this study, an artificial diet was used. In many cases, the relative effectiveness of proteinase inhibitors 
has been shown to vary with dietary proteins of differing digestibility and/or quality (Kuroda et al., 1996). 
4. The procedure used in this experiment, for adding inhibitor to the dry medium may not have been effective 
for obtaining adequate mixing with the medium or dosage. 
4. 7 Conclusions 
The HO fusion protein has been successfully cloned and expressed in the pMAL system. 42.5 mg of 
periplasmic proteins per litre were obtained from the periplasmic fraction following incubation of the induced 
pMAL-HO culture at 37°C for 24 hours. This was then purified on a cross-linked amylose column to give 7 
mg of purified fusion protein. 
Sufficient yields of this fusion protein were obtained and the inhibitor showed activity when assayed against 
papain in fluorescent assays and in the gelatin assay. It was also confirmed that this protein acts as an inhibitor 
rather than as a substrate of pa pain. 
The system was, however, unsatisfactory in as much as low yields of inhibitor (0.025 mg) were obtained on 
cleavage with factor Xa. Attempts to optimise the conditions for factor Xa cleavage failed to improve the 
yield. Sufficient purified HO inhibitor was, however, obtained to enable N-terminal sequencing. This 
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The usefulness of this inhibitor as an agent for biocontrol could not be fully assessed by the insect assay that 
was used. A better option would be to use the HO inhibitor protein (rather than the fusion) in biocontrol 
assays. Furthermore, because of the insect's ability to overcome the toxic effects of proteinase inhibitors 
(discussed in chapter 1, section 1.7), these assays should perhaps be: 
1. expanded to include a range of concentrations of inhibitors 
2. conducted in conjunction with other inhibitors such as the serine or aspartic proteinase inhibitors, with 
appropriate controls designed to provide more efficient ways of administering the HO inhibitor. 
In conclusion therefore, the HO inhibitor had been successfully cloned and expresed in the pMAL system. 
However, the yields of 0.025 mg of fusion from one litre of culture were low. To try and improve this yield, 











Chapter 5 Page 110 
CHAPTERS 
Expression of Natural Oryzacystatin I in the pET System 
5.1 Introduction 
The previous chapters have described the synthesis, cloning and expression of the modified hybrid inhibitor. 
However, in order to study this hybrid inhibitor in relation to its two derivative proteins (i.e .. the natural 
chicken and oryzacystatin inhibitors), it was necessary to obtain these two inhibitors. Chicken cystatin is 
commercially available (Sigma) but oryzacystatin on the other hand is not and I had either to express it in a 
genetic vector, or isolate it from rice seeds. I chose the former and was grateful to receive the natural OC I 
gene cloned into the pET-3a plasmid as a kind gift from Dr Lisa Jouanin (Department Of Cellular Biology, 
National Institute for Agricultural Research, Cedex, France). 
The pET system is useful for the expression of foreign proteins. Target genes are cloned under the control of 
the strong bacteriophage T7 RNA polymerase promoter in the host cell. For protein production, a recombinant 
plasmid is transferred to an E. coli host strain, which contains a chromosomal copy of the gene coding for T7 
RNA polymerase. These bacterial hosts are lysogens of bacteriophage DE3, a lambda derivative that has the 
immunity region of phage 21 and which carries a DNA fragment containing the lac! gene, the lacUV5 
promoter, and the gene for T7 RNA polymerase (Studier & Moffatt, 1986). Once a DE3 lysogen is formed, 
the only promoter that will direct transtription of the T7 RNA polymerase gene is the lacUV5 promoter, which 
is inducible by IPTG. Addition of IPTG to the growing culture of the lysogen, induces the production of T7 
RNA polymerase, which in turn transcribes the target DNA in the plasmid (Rosenburg et al., 1987). 
This section therefore, will describe the expression and purification of the OC I protein from the pET system. 
The expressed protein was then used in the kinetic studies and its activity compared with that of the hybrid 
oryzacystatin. 
5.2 Materials and Methods 
5.2.1 Escherichia coli Strains and Culture Conditions 
pET-3a plasmid (Novagen) and pET-3aOC I (Leple et al., 1995) in E.coli strain BL21(DE3) (Novagen) were 
used for these experiments. The cultures were grown in M9ZB media (see Appendix B) at 37°C with vigorous 
shaking and plasmids were maintained by selection in the presence of 100 µg/ml ampicillin. For expression of 
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grown until the A600 reached 0.9 (approximately 5 hours). Expression was induced by the addition of 0.4 mM 
IPTG in the presence of 200 µg/ml rifampicin. The culture was then incubated for a further three hours at 
3 7°C before pelleting the cells. 
5.2.2 Isolation of Total, Soluble Cell Proteins 
Isolation of the soluble, cytoplasmic cell proteins was carried out according to the method of Leple et al. 
(1995). The cells were first pelleted at 5000 rpm for 20 minutes at 4°C and resuspended in 50 mM Tris, pH 
7.5; 0.2 mM NaCl; 2 mM EDTA and 10% glucose. Cells were frozen overnight at -20°C. The following day, 
the cells were thawed and sonicated on ice (3 times for 40 seconds at 100 W) on a Soniprep 150 sonicator. 
This was repeated over 3 minutes and the suspension was centrifuged for 1 hour at 15 000 rpm. The soluble 
supernatant was heated at 65°C for 15 minutes and centrifuged as before to remove the heat-sensitive proteins. 
The supernatant was concentrated at 4°C by pressure ultrafiltration using a Diaflo YM3 membrane (Am.icon 
Corp. Beverly, MA, U.S.A.). 
\ 
5.2.3 Gel Exclusion Chromafography 
For gel exclusion chromatography a Sephadex G25 gel filtration· matrix was used and prepared 
according to the manufacturer's instructions (Pharmacia). Once the column was packed, it was then 
equilibrated in 10 mM Tris, pH 7 .5 before placing 25 ml of the concentrated supernatant over the 
column. Five millilitre fractions were then collected using a :fraction collector, and the A280 of each 5 ml 
fraction was read on a Beckman DU-64 spectrophotometer. Samples were analysed by SDS-PAGE and 
Western blotting (Appendix C). Fractions containing inhibitory activity (assayed as described in Appendix C) 
were pooled and freeze-dried. 
5.2.4 Ion Exchange Chromatography 
Ion exchange chromatography was carried out using DEAE Trisacryl M (Sigma) according to the method of 
Leple et al. (1995). Forty millilitres of the column matrix was packed into a 20 cm x 2.5 cm column according 
to the manufacturer's instructions (Sigma). This was then equilibrated in 8 column volumes of 25 mM Tris-
HCl, pH 7.5. The freeze-dried OC I extract was then dissolved in 30 ml distilled water and placed over the 
column. This was followed with 30 ml of distilled water and then a discontinuous salt gradient from 0.15 to 
0.6 M NaCl was used to elute the proteins (Leple et al., 1995). Following ion exchange, the salt was removed 
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5.2.5 Affinity Purification 
Cm-papain-Sepharose was prepared according to the method of (Anastasi et al., 1983) such that a final 
concentration of 2.3 mg of protein per ml of gel was attained. This was then packed into a column, 2.5 cm x 
10 cm. The column was equilibrated in 50 mM phosphate buffer, pH 6.5, containing 0.5 M NaCl and 0.1 % 
Brij 35 (Anastasi et al., 1983). After absorption of the proteins, the column was washed in this same buffer, 
but with 10% glycerol in place of the Brij 35. Non-specifically bound material was eluted with 50 mM K3P04, 
pH 11.5 containing 0.5 M NaCl and 10% glycerol. The collected fractions were then adjusted to pH 7.4 by 
dialysis at 4°C against 5 mM potassium phosphate buffer, pH. 7.4. 
5.2.6 Polyacrylamide Gel Electrophoresis and Western Blotting 
Samples were prepared for electrophoresis on a 20% SDS-PAGE gel as follows: 
1 ml volumes were removed from E. coli cultures and pelleted by centrifugation in a microcentrifuge at 14 000 
' 
rpm for 5 minutes. Cell pellets were then resuspended in 50 µl sample loading buffer. Immediately before 
loading onto SDS-PAGE gels, samples were boiled for 5 minutes to disrupt the cells. 20 µl of this suspension 
(approximately 30 µg of protein) was loaded. 20% SDS-PAGE gels were prepared as described in Appendix 
C. For Western blotting, proteins were electrophoresed onto nitrocellulose and analysed according to Towbin 
et al. ( 1979) with modifications (Appendix C). OC I antibodies were kindly supplied by Professor Soi chi Arai 
(Department of Agricultural Chemistry, Faculty f Agriculture, University of Tokyo, Japan). 
5.3 Results and Discussion 
5.3.1 Analysis of the Expressed Oryzacystatin I Protein 
Expression was induced by the addition of IPTG (and rifampicin; 200 µg/ml) to a late log phase culture. The 
antibiotic inhibits transcription by the host RNA polymerase and thus reduce~ the backgr9und synthesis of host 
RNA and proteins (Novagen manual). 
One millilitre aliquots were removed from the cell cultures at various times following induction. The 
expression results of the pET-3aOC I are shown in Figure 5.1. The uninduced culture (lane 2), shows almost 
no expression of OC I, whilst lanes 3 - 5, show an accumulation of a 12-kDa protein. 12 kDa is slightly larger 
than the published size of 11,800 kDa for natural OC I as shown by Abe et al. (1987a). However, there is 
often a slight over-estimation of the molecular weight of cystatins when compared with commonly used 
molecular weight marker proteins (Abrahamson et al., 1986). A band size of 12 kDa for OC I has been 
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Figure 5.1: 20% SDS polyacrylamide gel showing the results of expression of pET-3aOC I. Lane 1, 
molecular weight markers (total chicken histones),- lanes 2 - 5, pET-3aOC I at 0, 1, 2, and 3 hours 
















Figure 5.2: Western blot of a 20% SDS polyacrylamide gel. Proteins were detected using antibodies to 
natural OC I. Lane 1, pET-3a uninduced,- lanes 2-4, pET-3a 1,2 and 3 hours post-induction,- lane 5, 
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The identity of this 12-kDa protein was further confmned by western blot analysis using an antibody to natural 
OC I (Figure 5.2). The antibodies bound to a protein of approximately 12 kDa at one, two and three hours 
post-induction (lanes 6 - 8). No bands were seen for the uninduced pET-3aOC I (lane 5), nor for the pET3a 
plasmid only in the uninduced (lane 1) or in the induced cultures (lanes 2 - 4 ). 
5.3.3 Purification of the Expressed QC I Protein by Gel Exclusion Chromatography 
and Ion Exchange. 
Once expression had been optimised, 1 litre cultures of pET-3aOC I were induced, the cells harvested and the 
soluble cytoplasmic proteins were then isolated. Cystatins have been shown to be heat stable (Kondo et al. , 
1990). Thus, as a purification step, cytoplasmic proteins were heated for 15 minutes at 65°C. The heat labile 
proteins were then removed by centrifugation and the heat stable fraction isolated by gel exclusion 
chromatography on a Sephadex 025 matrix. This aimed to remove the high concentrations of salts, glucose 
and rifampicin present in the medium. 
To determine which fractions contained the inhibitor, each 5 ml fraction collected was tested for inhibitory 
activity against papain using the fluorimetric substrate Z-Phe-Arg-AMC (Sigma). Inhibition was determined 
as the percentage decrease in enzyme activity following the addition of 0.1 ml aliquots from the 5 ml fractions. 
Calculations were carried out as described in Appendix C. 
Anastasi et al. (1983) and Keilova and Tomasek (1974) have found that freeze drying of chicken cystatin leads 
to a loss of inhibitory activity. Since such findings were not reported by Leple et al., (1995), and since we 
observed no significant loss in inhibitory activity following freeze-drying, the column fractions were pooled 
and freeze-dried before placing over the ion exchange column as described by Leple et al. (1995). 
For ion-exchange, proteins were eluted using a discontinuous salt gradient according to the method of Leple et 
al. (1995). Peaks were eluted in 5 ml fractions and the A280 of these fractions were read on a Beckman DU-64 
spectrophotometer. The column profile is shown in Figure 5.3 (A). A number of peaks eluted with the 
different molar salt concentrations and aliquots were run on 20% SDS-PAGE gels to check for the presence of 
the inhibitor in the various peaks (Figure 5.3(B)). From the SDS-PAGE gel, the OC I protein was found to 
elute between 0.15 and 0.2 M NaCl. Lane 1 shows the presence of a 12-kDa protein which had previously 
been shown (by Western Blot analysis, section 5.3.1), to be the natural OC I inhibitor. From lanes 2 and 3, it is 
clear that a number of contaminating proteins have been removed. In lane 2, however, a number of other 
protein bands could be seen which eluted at the same time as the OC I protein. Further purification methods 
were therefore necessary to remove these contaminating proteins, although this protein had been used, 















i ~ 2 
I! 
i ~ 







-Absort>ance 280 nm 
· · - ··MNaCI 
10 
1 2 
15 20 25 30 
Test Tube Number 
3 
I., 











Figure 5.3: (A) Column profile of proteins eluted from the ion exchange column (DEAE Trisacryl M) 
equilibrated in 25 mM Tris-Cl, pH 7.5. Proteins were eluted with a discontinuous salt gradient from 
0.15 to 0. 6 M NaCl (indicated by the dotted line). (B) 20% SDS-PAGE gel of fractions eluted from the 
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To further purify the expressed protein use was made of an affinity column. Fractions containing the OC I 
protein from the ion-exchange column (as determined by SDS-PAGE analysis) were dialysed against 5 mM 
phosphate buffer (pH 6.5) to remove the NaCL This was then passed through a column of Cm-papain linked to 
Sepharose 4B. The column was washed with phosphate buffer, pH 6.5 and the bound proteins were eluted by 
changing the buffer pH to 11.5 (Anastasi et al., 1983). The elution profile of the affinity column is shown in 
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Figure 5.4: Affinity chromatography profile of proteins eluted from the affinity column of Cm-papain-
Sepharose. JO ml of proteins were applied to the column equilibrated in buffer (50 mM phosphate 
buffer, pH 6.0; 0.5 M NaCl; 0.1% Brij 35). The column was washed with (50 mMphosphate buffer, pH 
6.0; 0.5 M NaCl; JO% glycerol) followed by elution of the bound protein with 50 mM K3P04, pH 11.0; 
0.5 M NaCl; 10% glycerol (indicated by the arrow). 
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Table 5.1: Purification of the OC I protein from E. coli 
Stage Volume OCI Activity Specific Activity Purification Yield 
(ml) Protein (mg)8 ("units) (U/mg) O/o 
Total Cytoplasmic 40 98.6 62695 636 1 100 
Proteins 
Sephadex Column 55 22 47826.1 2174 3.4 76.3 
Ion Exchange 15 11.4 34168.8 2997.3 4.7 54.5 
Chromatography 
Affinity 10 0.56 22541 40252 63 .3 35.9 
Chromatography 
"Measured as total protein by the Biorad (USA) Protein Assay (Bradford, 1976; Appendix C) 
b 1 Unit is arbitrarily defined as the amount of inhibitor required to reduce the activity of 0.5 µM papain by 
50% under the assay conditions. 
In conclusion, the pET-3aOC I system supplied by Leple et al. (1995) was used successfully to express and 
purify sufficient natural OC I for the kinetic studies. This purified protein was then used in enzyme kinetic 
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CHAPTER 6 
Enzyme Kinetic Studies 
6. 1 Introduction 
In order to define the function of the hybrid inhibitor and to relate this to the activity of the parent inhibitors 
from which it was derived, the appropriate kinetic parameters were measured. The experimental approaches 
that were used for this purpose were taken largely from the literature and were based upon the generally 
accepted assumptions: (a) that cystatin activity is reliably measured by the inhibition of papain-catalysed 
hydrolysis of the synthetic. fluorogenic substrate benzylcarbonylphenylalanyl-arginyl-aminomethylcoumarin 
(Z-Phe-Arg-AMC ; Barrett & Kirschke, 1981 ) (b) that the hybrid inhibitor was a slow. tight-binding inhibitor 
\Vhose interactions v.'ith papain could be defined kinetically by the standard equations for this class of 
inhibitors (Henderson, 1972 ; Cha, 1978; Morrison, 1982); and, (c) that reliable estimates of the kinetic 
parameters can be obtained by regression analysis of progress curves that express the concentration of 
accumulated product (in this case AMC) as a function of time after the addition of pre-incubated mixtures of 
papain and inhibitor to substrate in the reaction cuvette . 
6.2 Materials and Methods 
6.2.1 Enzyme Assay 
Purified papain (EC 3.4.22 .2) was obtained from Boehringer Mannheim and used without further purification. 
Stock solutions of papain were made up in 0.1 M phosphate buffer and stored frozen at - 70°C in 200 µl 
vol um es. A tube was thawed, stored on ice for the duration of the experiment and then discarded. 
Papain activity was measured fluorimetricall y by recording the accumulation of AMC released by the 
hydrolysis of Z-Phe-Arg-AMC as a function of time. A Perkin Elmer .MPF-43A fluorescence 
spectrophotometer. fitted with a temperature-controlled cell holder and a chart recorder was used for this 
purpose. The instrument was standardised with a solution of 0.2 µM 7-amino-4-methylcoumarin (AMC ; 
Sigma) containing the substrate, Z-Phe-Arg-AMC (Sigma) at the concentrations described for the different 
assays. Concentrations were chosen so that the maximum amount of substrate hydrolysis did not exceed 2%. 
Fluorescence was measured at an excitation v.:avelength of 380 nm and an emission wavelength of 460 nm. 
Chart-recordings of fluorescence as a function of time were read manually for linear data or by digitising for 
non-linear data. 











Chapter 6 Page 11 9 
ac ti\ity should be carried out above pH 6.0. preferably at pH 6.8. to prevent the dissociation of inhibitory 
complexes into active enzyme and inhibitor. Assays for inhibitory activity thus involve a compromise between 
the optimal fo r proteolytic activity of the enzyme and stability of the cystatin:enzyme complex. 
6.2.2 Active-Site Titration of Papain with E-64 
Ac ti\·e-site titrations of papain were carried out using the method of Barrett & Kirschke ( 1981 ). Three 
milligrams of E-64 (Sigma) were dissolved in 0.1 ml OMSO and diluted to 1 mM with distilled water. 
Working inhibitor solutions of 1. 2. 3, 4, 5. 6, 7 and 8 µM E-64 were then made. A solution of papain 
(approximately 10 µM) in 0.1 % Brij 35 was used to prepare mixtures comprising: enzyme solution - 25 µl ; 
papain assay buffer - 50 µl and E-64 solutions - 25 µI. These were incubated at 30°C for 30 minutes and 
diluted to 5 ml by the addition of 4.9 ml of 0 .1 % Brij 35 . Ten microlitres of this solution was then assayed for 
residual enzyme activity. The assay buffer was kept as a 4 x concentrated stock solution and diluted. for use. 
to the l x buffer containing 100 mM KHi/Na2 phosphate pH 6 .0 ; 1 mM EOTA; 2 mM OTT. The OTT was 
added freshly on the day of use. 
The result (Figure 6.1) showed that the standardised papain solution had an active concentration of 
8.66 µM. 
6.2.3 Determination of the Km for the Hydrolysis of Z-Phe-Arg-AMC Catalysed by 
Pa pain 
Papain (50 pM) was incubated with the phosphate-assay buffer and 0.1 % Brij 35 at 30°C for 2 minutes. The 
reaction was then started by the addition of various concentrations of Z-Phe-Arg-AMC ranging from 1.5 to 100 
µM and the fluorescence released was measured continuously. Values for K m and V max were derived from 
non-linear fitting of the recorded curve to the Michaelis-Menten equation using the FigP program (Elsevier-
Biosoft . Cambridge . UK). 
6.2.4 Active-s ite Titration of the Inhibitors with Titrated Papain 
Measurement of the inhibitory constant (K i) for the papain:inhibitor' complexes required estimates of the 
reactants. The molarity of the papain solution was determined, as described above, by titration with E-64. The 
standardi sed papain solution was then used to measure the concentration of active inhibitor sites in stock 
solutions as follows: 
Papain (0.3 µM final active concentration; 42 pmoles) was incubated with 70 µl papain assay buffer and 
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This was then diluted to 500 µl and 10 µl were used for the assay. Titrations were performed at a papain/K, 
ratio of > 100. Reactions were started by the addition of Z-Phe-Arg-AMC to a final concentration of 5 ~tM. 
The protein content of the inhibitor solution was then measured using the Bio-Rad protein assay and specific 
ac ti vity (µmoles inhibitory activity/mg protein ) was calculated assuming 1: 1 stochiometry. 
6.2.6 K, Determinations for the Various Cystatins 
For the determination of equilibrium constants, continuous rate assays were carried out using 20 µM Z-Phe-
Arg-AMC. Variable concentrations of inhibitors (80 nM - 240 nM) were used and reactions were started by 
the addition of 20 µl papain (activated in assay buffer at 30°C for 2 minutes) at 8 nM final active 
concentration. A11 experiments were performed under pseudo first order conditions i.e. at a molar ratio of 
inhibitor to enzyme of > 10: 1. 
Apparent K, values (K,(app)) were calculated as the slope of the plot of [I]/1 -V;N 0 ) versus V oN; (Henderson, 
1972). Km values of 63 µM (determined as described in section 6.2 .3) were used to calculate the substrate 
independent K; using the relationship: 
Ki(app) = K; ( 1 + [S]/Km) 
All determinations of V 0 and V; were based on assays with less than 2% hydrolysis and a linear correlation 
coefficient, at steady state, of greater than 0.990. 
For chicken cystatin, the K; value was obtained from estimates of Kon and Karr. Pa pain ( 0 .1 nM) was incubated 
in papain assay buffer at 30°C for 2 minutes in a total volume of 30 µI. The reaction was started by addition of 
the activated papain to the reaction cuvette which contained 10 µM Z-Phe-Arg-AMC and inhibitor (0 .5 nM - 2 
n..~1 ). Values for Kobs· V0 and V, were obtained by curvilinear fitting to the equation: 
where 
[P] = v J + (v 0 - v ;) (1- e -k ob.r ) I k obs . .......... ... .. . •. (Cha, 1976) 
[P] = the concentration of product formed by hydrolysis of the 
substrate 
time 
V 0 initial rate of substrate cleavage 
V; final rate of substrate cleavage 
kobs = the observed pseudo first order rate constant for the reaction of the inhibitor 
with the enzyme 
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6.3 Results and Discussion 
6.3.1 Active-site Titrations of Papain and Inhibitors 
Before commencing the fluorimetric assays, the instrument was calibrated to give a maximum reading with 0.2 
µM AMC. This ensured that no more than 2% of the substrate present was hydrolysed over the assay period 
and that any decrease in the velocity measured was due to the addition of inhibitors and not to substrate 
depletion (Salvesen & Nagase, 1989). 
Linear regression analysis of the data established a conentration of 8.66 µM for the standardised papain 





Figure 6.1: Active-site titration of papain with E-64. Papain was incubated with E-64 for 30 minutes 
at 30 'C and residual 'enzyme activity was detected by continuous fluorimetric assays using 5 µM Z-Phe-
Arg-AMC. Error bars show the 95% confidence limits. 
Inhibitor solutions were then titrated against the standardised papain to determine their active concentrations. 
For the active site titrations of the inhibitors, a papain:Ki ratio of >100 was used since, using an enzyme 
concentration of the same order of magnitude as the K;, gives curvilinear titration curves that do not 
extrapolate to a reliable intersection on the abscissa. Table 6.1 shows the specific activity determined for the 
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Table 6.1: Activity of papain and inhibitors as determined by active-site titration 
,. ~µmoles/mg1rotein 
Chicken Cystatin 0.0692 0.91 
HO Fusion 0.0166 0.86 
HO 0.0153 0.71 
OCI 0.0402 0.45 
3µmoles of active sites of inhibitor per mg of protein determined using the Bio-Rad protein assay. 
bmoles of active sites per mole which assumes purity of the protein added and exact mass 
determination. 
6.3.2 Km Determination 
To determine the Km for Z-Phe-Arg-AMC, I incubated papain (50 pM) with various concentrations of substrate 
(2 .5 - 100 µM) and measured the reaction velocitiy (V0 ) for each substrate concentration ([S]). Values for Km 
and V max were obtained by using the FigP program (Elsevier-Biosoft, Cambridge, UK) to fit the observed 
values for V 0 to the Michaelis-Menten equation: 
V maJS] 
Km+ [S] 









20 40 BO 
Substrate Concentration (µM) 
Figure 6.2: Michaelis-Menten Plot f or papain. 
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A Km value of 63 µM was obtained for the substrate under the assay conditions described in section 6.2.3 
(Figure 6.2). This is similar to the Km values of 60 µM obtained by Lindahl et al. (1992) and 65 µM by Zucker 
et al. ( 1985). 
6.3.3 Determination of Equilibrium Constants (K,) 
A number of different methods have been used to determine the equilibrium dissociation constant (Ki) of 
cystatins and their cognate enzymes. These include the determination of the initial reaction velocities (Vi) 
under presteady state conditions in which activated enzyme is added to a mixture of inhibitor and substrate. 
The results are then fitted (by non-linear regression) to the Cha equation (Cha, 1975). Other methods that have 
been used are those described by Henderson (1972) in which the reaction is started by the addition of enzyme 
to the substrate. The relative steady state velocities before (V 0 ) and after (Vi) the addition of the cystatin 
inhibitor are then used to calculate the apparent Ki value (Ki(appJ)· 
Protocols, such as those used by Bjork et al., 1989; Turk et al., (1996); Lindahl et al. ( 1994 ), that depend upon 
the analysis of pre- and post-steady state reaction velocities are best used when computer-controlled 
experimental systems are avail~ble for the automatic addition of reagents and for monitoring the subsequent 
accumulation of fluorescent product. 
Since I did not have access to the necessary equipment and had, instead, to rely on manual timing of the 
experiment and a strip chart recorder for output, I chose to use the approaches described by Kondo et al. 
( 1990), in which initial reaction velocities are measured in the absence of inhibitor (V 0) and in the presence of 
different concentrations of inhibitor (Vi) after co-incubation with enzyme for a long enough period for 
equilibrium to have been established. 
Each assay took approximately 60 minutes to complete since this period of time was needed before linear 
recordings of V; were obtained. Control incubations, without inhibitor, for 0, 20 and 60 minutes gave similar 
V 0 values for the enzyme. 
The data obtained fot Vi and V0 for the different inhibitors are shov.n in Appendix E. The points in these final 
graphs represent the means of several experimental observations. To ensure that residual enzyme activity 
could be detected at the high concentrations of inhibitor used in these assays the substrate was used at 
concentrations of 25 µM. A lower amount of enzyme (0.8 nM) was used for the HO as there was less inhibitor 
available for assay. Apparent Ki values (K;cappJ) were calculated as the slope of the plot of [I]/1-V;N 0 versus 
V0 N; (Henderson, 1972) and the K; was determined from the relationship: 
Ki(app) = K, ( 1 + [S]/Km). 
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Table 6.2: Ki data for the different inhibitors 
hillll:>itor~ 
. ;.: 
'.Ki(M) ' . 
,.·, 
Chicken Cystatin 5.95 x 10·12 
Oryzacystatin I 1.58 x 10·9 
HO-MBP Fusion 2.89 x 10·9 
HO 3.6 x 10·9 
Analysis of the data (Appendix E) showed considerable variation between the data sets, (i.e. the standard 
deviation at a given inhibitor concentration was greater than the differences between the average points at 
different inhibitor concentrations) so that very large differences in inhibitor concentration were required to 
document significant changes in vi. 
Estimates of Ki obtained for the different oryzacystatin variants (Table 6.2) were slightly higher than described 
in the literature. Represented values for Ki of oryzacystatin range from 7.0 nM to 36.4 nM (Abe et al., 1988; 
Kondo et al., 1990; Arai et al., 1991; Michaud et al., 1994; Urwin et al., 1995). Ki values obtained for HO 
were similar to those observed with the natural OC I. If anything, the natural OC I was a marginally better 
inhibitor. No significant difference was observed between the fused and the free hybrid inhibitors. 
Because chicken cystatin is such a tight-binding inhibitor that does not readily dissociate from the complex, the 
Ki for this inhibitor was obtained from the koff and kon data determined in pre-steady state experiments where 
the enzyme was added to a mixture of the inhibitor and substrate (described in Turk et al., 1996). The data 
were fitted by non-linear least squares regression to the equation: 
(Cha, 1975), where [P] = the concentration of product formed by hydrolysis of the 
substrate 
t = time 
V 0 = initial rate of substrate cleavage 
Vi = final rate of substrate cleavage 
kobs = the observed pseudo first order rate constant for the reaction of the inhibitor 
with the enzyme 
Detailed evaluation and graphic presentation of results (Appendix E) was performed using FigP (Biosoft 
Cambridge). 
kobs was found to be linearly dependent on inhibitor concentration (Appendix E). These observations indicate 
that, under the conditions used, the interactions followed the mechanism E + I = El; i.e., the combination of 












this mechanism, the linear dependence of ~bs on inhibitor concentration is described by: 
kobs = k.1 + k+1[I] 
where k-1 and k+1 represent the 'off' and the 'on' rate constants, respectively. 
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Using the equation it should, theoretically be possible, by plotting kobs as a function of [I], to obtain values for 
both the 'on' and 'off' rate constants - the former as the slope of the curve and the latter as the intercept on the 
coordinate axis. The value that I obtained (9.1 M-1s-2) is similar to that described by Bjork et al. (1990). 
The 'off' rate, however, is so slow that I was not able to get a reliable estimate of the kotrand the derived rate 
for Ki (10-12 M) should be regarded as no better than the upper estimate. Bjork et al. (1990) using a superior 
experimentan system, recorded a Ki of 10-14 M. 
6.4. Conclusions 
The results that I obtained show that the substitution of the N-terminal 21 residues of oryzacystatin for the N-
terminal 15 residues of chicken cystatin did not generate a significantly better inhibitor. In fact, a comparison 
of the inhibitory constants of the hybrid oryzacystatin with the natural component inhibitors showed the HO to 
have a Ki that is similar to the natural OC I and significantly higher than that of the truncated chicken cystatin 
inhibitor. Similar Ki results were seen for the HO and that fused to the MBP. This is in agreement with results 
obtained by Michaud et al. ( 1994 ), Thiele et al. ( 1990) and Kaji et al. ( 1990). 
In terms of the molecular models, these kinetic results suggest that model 1 for the HO inhibitor (Chapter 2) is 
an unlikely structure. Urwin et al. (1995b) showed that Gly10 of OC I was important for maintaining its 
inhibitory activity and that the loss of this residue resulted in an increased Ki· They suggested that the 
importance of this residue lies in the fact that it is involved in a turn formation which brings the Leu9 residue of 
OC I into contact with the proteinase for tighter binding in this region. In model I, however, there is no contact 
between the amino terminus of the HO and papain and hence, from the results described by Urwin et al. 
( l 995b ), one would expect such an inhibitor to have a greatly increased Ki. My results do not support this. 
Since model 2 was found to be improbable, th,e most likely structure for the HO is model 3. In this model the 
amino-terminal contacts of the HO, containing the substituted chicken cystatin N-terminus, makes similar 
contacts with the N-terminal region of papain to the natural chicken cystatin. The importance of the N-
terminal region of chicken cystatin has been demonstrated (Machleidt et al., 1989; Abrahamson et al., 1992; 
Lindahl et al., 1992; Bjork et al., 1994) and loss of the amino-terminal residues Leu7 to Gly9 have resulted in 
large increases in the inhibitory constants of chicken cystatin. The question that therefore. arises is if the N-
terminus does play such an important role, why was there such a small change in the inhibitory constant of the 
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From the results and in answer to this question, the following points can be made: 
1. Urwin et al. ( 1995) showed that deletion of the N-terminal 21 residues from oryzacystatin resulted in 
the inhibitor becoming completely inactive. Abe et al., (1988) who used a similar strategy, (although 
their inhibitor had an additional 15 amino acids at the N-terminus derived from the pUCI8 vector) 
found no change in the inhibitory capabilities of the molecule. These results, as well as those shown 
here. suggest that a pre-requisite for inhibitory activity of the inhibitor is the presence, in this area. of 
residues that provide some contact with the proteinase. In this way, the N-terminus may help to pilot 
the molecule over the active site of the enzyme and thus, as long as there are no residues in the amino 
terminus that provide steric hindrance with papain, a degree of inhibition is obtained. Although not 
determined in this project, there may in fact be differences in the association and dissociation constants 
between the natural and hybrid rice inhibitors. 
2. Shibuya et al. (1995) have shown that changes in the N-terminus can affect the positioning of the first 
hairpin loop which has been shov.n to be important in the cystatins for conferring inhibitory activity 
(Abrahamson et al., 1987; Abe et al., 1988; Turk & Bode, 1991). Furthermore, Bode et al. (1988) 
showed that interactions occur not only between the cystatin and the proteinase but also between the 
different cystatin loop regions (for example, Gln53 of chicken cystatin forms a H-bond with Gly9 of the 
N-terminus). Although I was not able to show (through molecular modelling) any changes in the 
interactions of the different loops of oc I by replacing the N-terminus with that of chicken cystatin, it 
must be remembered that the OC I part of this modelled molecule was based on the structure of stefin 
B and there may be slight differences to the actual OC I inhibitor. Thus the interaction of the 
substituted region and the two binding loops of the HO may have been different from that of the 
natural chicken cystatin and this could have been responsible for the increased Ki of the HO. This is 
particularly important since chicken cystatin has a different sequence (i.e. QLVSG as opposed to 
QVVAG). Shibuya et al. (1995) showed that the contacts between the cystatin binding loops are 
essential and any changes may affect the association constant and hence the Ki. I agree with Urwin et 
al. (1995), Machleidt et al (1995) and Shibuya et al. (1995) who suggest that the inhibitory regions of 
cystatins do not act independently but all contribute to the inhibitory capabilities of the inhibitor. 
3. Many of the effects of mutations on the K/s have been the result of significant changes .in the 
properties of the substituted amino acid residues. For example, in experiments with stefin B, changes 
in the K; were observed when ionic residues such as glutamine replaced Cys3. In my case, however, 
substituted amino acid residues were all very similar in the form of their hydrophobics and charges, 
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4. It has been suggested that binding of the N-terminus in family II cystatins compensates for less 
favourable contacts made in the other hairpin loops such as the QL VSG region of chicken cystatin 
(Machleidt et al., 1989). The results I obtained with the HO indicate that the N-terminus in the family 
I cystatins may not be as important as in the family II cystatins, since substitution of the whole N-
terminal region of OC I for the chicken N-terminus did not significantly change the inhibitory constant 
from that of the natural inhibitor. 
5. Finally, experiments in which the N-terminus of stefin B was replaced by the N-termini of cystatin C 
or kininogen (Jerala, 1994), yielded protein whose ·activity was largely unaffected as far as papain and 
cathepsin L were concerned. Inhibition of cathepsin H by these hybrids, however, was considerably 
weaker than that of the natural stefin. Since only the inhibitory effects against papain were 
investigated in this project, it would be interesting to determine the effect of such a substitution on 
other cysteine proteinases such as the cathepsins. 
Thus in summary, the interactions between the three binding loops appear to be important for inhibitory 
activity of the cystatins, particularly in the family II cystatins. The flexible N-terminus being responsible for 
the positioning of the cystatin over the active site residues of the cysteine proteinase. 
In terms of biocontrol, this inhibitor was shown to be slightly less effective an inhibitor of papain than the 
natural inhibitor. To improve its inhibitory capabilities for use in plants, therefore, one would need to study 
other substitutions such as those in which other loop regions of chicken cystatin were introduced as mentioned 
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Appendix A 
Expression of the Hybrid Oryzacystatin in the Yeast Pichia 
pastoris 
A. 1 Introduction 
The production of the HO gene as a fusion product in bacteria was successful in that a large amount of 
biologically active fusion protein was produced. Cleavage of the fusion with factor Xa, however, gave poor 
yields of liberated inhibitor, so it was decided to explore other expression systems. To this end, the hybrid 
inhibitor was expressed in a yeast system. The yeast Saccharomyces cerevisiae has often been used for the 
expression of foreign genes for the advantages that yeast offers over other expression systems i.e: 
• The organisms can be grown rapidly and to high cell density (Bucknolz & Gleeson, 1991 ). 
• The production of proteins in yeast often leads to higher levels of heterologous protein expression than in 
bacterial systems. 
• Yeasts are eukaryotes and hence their intracellular environment is often more suitable for the correct 
folding of eukaryotic proteins. 
The low yields of expressed proteins and difficulties in secreting some proteins in Saccharomyces have, 
however, led to the use of alternative yeast expression systems. One of these is Pichia pastoris developed by 
Invitrogen, San Diego. The Pichia pastoris expression system was used in this study. The following sections 
give a brief review of this yeast expression system and discuss the expression results. 
A.1.1 Pichia pastoris as an Expression Host 
Pichia pastoris is a methylotrophic yeast that is capable of using methanol as its sole carbon source. It has 
been used successfully by a number of groups to produce recombinant proteins (Cregg et al., 1987; Clare et 
al., 1991; Scorer et al., 1993) and often produces higher yields of expressed protein than many other yeast 
expression systems. 
The first step in the metabolism of methanol by this yeast is the oxidation of methanol to formaldehyde using 
molecular oxygen and the enzyme alcohol oxidase (AOXJ). This reaction generates formaldehyde and 
hydrogen peroxide. To avoid toxicity of the latter, methanol metabolism takes place in the peroxisome which 
sequesters these toxic by-products.from the rest of the cell (Ellis et al., 1985). The AOXJ enzyme has a poor 
affinity for oxygen and so the yeast compensates by generating large amounts of this enzyme. It is the A OXJ 
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There are two genes in P. pastoris that code for alcohol oxidase - AOXJ and AOX2 (Cregg et al., 1989). The 
AOXJ gene is responsible for the vast majority of alcohol oxidase activity in the cell, and in methanol grown 
cells the AOXJ gene message represents approximately 5% of the total poly A+ RNA levels (Cregg et al., 
1993 ). The A OXJ promoter is under the control of both a general carbon catabolic repression/ derepression 
mechanism and a C-specific induction mechanism (Johnston, 1987). In this system, growth on glucose 
represses transcription, even in the presence of the inducer, methanol. Hence, before induction, this yeast is 
grown on glycerol as the carbon source. The second functional alcohol oxidase gene, AOX2, encodes a protein 
that is 97% identical to and has almost the same specific activity as AOXJ (Cregg et al., 1993). Clones lacking 
the AOXJ gene grow much slower on methanol and this allows for the isolation of Muts strains (Cregg et al., 
1989; Koutz et al., 1989). The reason these transformants can grow on methanol is because of the second 
alcohol oxidase gene, AOX2, which provides a less efficient source of alcohol oxidase (Cregg et al., 1987). 
A.1.2 Heterologous Protein Secretion In Pichia 
The goal in this case, and with many other expression systems in Pichia pastoris, was secretion of the foreign 
protein into the media. This has the advantage in that Pichia secretes very low levels of its own native proteins 
and so it provides a first step in the purification of the protein of interest. 
The pPIC9 vector, which is used for secretion of foreign proteins in this yeast, was used in this study (Figure 
A.1). This expression vector contains the Saccharomyces cerevisiae pre-pro-a-mating factor leader sequence 
which is responsible for directing the secretion of several proteins from the cell (Clare et al., 1991). It is a 13-
residue peptide that is secreted by cells of the a-mating type and functions by acting on cells of the opposite 
mating type to promote efficient conjugation. This leads to the formation of diploid cells (Brake et al., 1984). 
For the processing of this pre-pro-a-factor signal peptide a number of different proteolytic activities are 
required (Clare et al., 1991). For example, the glycosylated pro-a-factor is cleaved firstly by an 
endoproteinase that cleaves on the carboxyl side of the Lys-Arg sequence (Figure A.2). This endoproteinase is 
encoded by the K.EX2 gene and is used in conjunction with the a-factor leader sequence to direct the secretion 
of small peptides (Clare et al., 1991). An investigation into the properties of this endoproteinase (Clare et al., 
1991) has shown it to be a membrane-bound, calcium-dependent serine protease which is homologous to 
subtilisin and other related proteases. Since the inhibitor being cloned was a cysteine proteinase inhibitor and 
not a serine proteinase inhibitor, cloning of this HO protein into a vector containing this protease was not 


















Figure A.J: Map of the pPIC9 vector showing the muliple cloning site and positions of the AOXJ and 
His 4 genes. S, a-factor sign.al sequence. 
mRNAAOXl 
5' end (773) a.F start 
773 ... ···-·········· 917 AAAAACAACTAATTATTCGAAGGATCCAAACG ATG AGA TTT CCT TCA ATT TTT ACT 
Met ARG Phe Pro Ser Ile Phe Thr 
973 GCA GTT TTA TTC GCA GCA TCC TCC GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT 
Ala Val Leu Phe Ala Ala Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp 
1033 GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA GGG GAT TTC 
Glu Thr Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe 
1093 GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTT ATA AAT ACT 
A:sp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr 
Xhol ,J.. 
1153 ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA TCT CTC GAG AAA AGA GAG GCT GAA 
Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser Leu Glu Lys Arg Glu Ala Glu 
*SnaBI Eco RI Avril Notl stop mRNAAOXl 
1213 GCT TAC GTA GAA TTC CCT AGG GCG GCC GCG AAT TAA 3'end (1418) 
Ala Tyr Val Glu Phe Pro Arg Ala Ala Ala Asn ... TTCGCCTTAGACATGACTGTT ......... -.. TTGTCA 
Figure A.2: The pP IC9 promoter and multiple cloning region. The KEX2 cleavage site ( J) and the pre-
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Preliminary cleavage of the signal sequence by the KEX2 gene product occurs between arginine and 
glutamine in the sequence Glu-Lys-Arg* Glu-Ala-Glu-Ala where * is the site of cleavage. The STE13 
gene product then further cleaves the Glu-Ala repeats. This STEJ 3 gene encodes a membrane-bound, heat-
stable di-peptidylaminopeptidase which is responsible for removal of Glu-Ala sequences after the signal 
cleavage site (Romanos et al., 1992). The a-factor signal sequence, the cleavage sites and the mllitiple 
cloning site of pPIC9 are shown in Figure A.2. 
Secreted proteins are often glycosylated. However, an advantage of Pichia over Saccharomyces, is that Pichia 
does not hyperglycosylate. Thus, although both S. cerevisiae and P. pastoris have mainly N-linked 
glycosylation of the high-mannose type, the length of the oligosaccharide chains added post-translationally to 
proteins in Pichia is much shorter than those added in S. cerevisiae (i.e. 8-14 in Pichia as opposed to 50-150 in 
S. cerevisiae; Tschopp et al., 1987). Furthermore, S. cerevisiae core oligosaccharides have terminal 1,3 glycan 
linkages whereas P. pastoris does not. It is believed that the 1,3 glycan linkages in glycosylated proteins 
produced from S. cerevisiae are primarily responsible for the hyper-antigenicity that makes them particularly 
unsuitable for therapeutic use (Cregg et al., 1993). This is predicted to be less of a problem for glycoproteins 
generated in P. pastoris since these resemble the glycoprotein structure of higher eukaryotes (Cregg et al., 
1993). 
The recognition site for glycosylation is Asn-X-Ser/Thr (Brake, 1990). This sequence is not present in the HO 
sequence and hence glycosylation was not considered to be a problem in secretion of this protein. 
A.1.4 Recombination and Integration in Pichia 
Pichia pastoris has no stable episomal vectors and so those used for transformation into the yeast are 
integration vectors. Integration into the genome has the advantage in that it confers stability through meiosis 
(Romanos et al., 1995). There ~e three ways in which the vector expression cassette can be inserted into the 
yeast genome, depending on the restriction enzymes used to linearise the vector. This is illustrated in Figure 
A.3 and is described in more detail below. 
(A) The vector is cut with Bgill 
Digestion with Bgill produces a :fragment with ends homologous to the 5' and 3' ends of AOXJ. On 
transformation, these are then targeted to transplace into the AOXJ locus (Figure A.3 (A)). The chromosomal 
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(B) The vector is cut with Sac! 
A second method of integration is to linearise the vector with Sac!. This targets integration by a single cross-
over event into the AOXJ locus (Figure A.3 (B)). The AOXJ gene remains intact in this case, and the resultant 
clones have the Mut phenotype. Multiple insertions by repeated single cross-overs can also occur. 
CC) The vector is cut with Stu! 
Linearising the vector with Stu! targets integration into the chromosomal his4 locus by a single cross-over 
mechanism (Figure A.3 (C)). These transformants are again Mut and multiple integrations can occur. 
Thus in summary, the gene of interest is cloned into the multiple cloning site of the vector, this vector is then 
integrated, in one of the above ways, into the yeast genome. 
A.2 Materials and Methods 
A.2.1 Yeast Strains 
P. pastoris, GSl 15 (his4; Cregg et al., 1995), S1'1Dl 168 (his4, pep4; Invitrogen, San Diego, USA) were used 
as host strains for the expression of the HO in yeast. E. coli strain DH5a was used for the plasmid pPIC9 
(Invitrogen, San Diego, USA) and pPIC9-HO constructions and propagations. 
A.2.2 Cloning of the Hybrid Oryzacystatin Gene in Pichia pastoris 
All molecular biology methods were carried out according to the methods of Sambrook et al. (1989). 
Restriction enzymes were from Boehringer Mannheim. The insert was removed from the pUC18 vector by 
cutting with the restriction enzymes PvuIT and HindIIJ. and gel purified as discussed previously (section 3.3.5). 
For cloning into the SnaBI site of the pPIC9 vector, the HindIIJ. site was blunt-ended using Kienow 
(Boehringer Mannheim). This 282-bp fragment was then cut with SnaBI and cloned behind the AOXJ 
promoter in pPIC9 (Figures Al and A.2). Transformation into the E. coli host DH5a was carried out using the 






















I Cut with Stul f single crossover into HIS 4 
AOXl 
Cut with Sad 
single crossover integration into 
AOXJ 
HIS4 Chr 
Figure A.3: The 3 models of chromosomal integration of pPIC9 into the P. pastoris genome. (A) 
transplacement of the expression cassette into AOXl; (B) transplacement of the whole vector into 
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A.2.3 Preparation of DNA for Transformation into the Yeast Strain GS115 
The recombinant pPIC9 vector (pPIC9-HO) was linearised with Bgill according to the manufacturer's 
instructions (Boehringer Mannheim), run on a 1 % agarose gel and the uppermost-band excised and purified 
using the GENECLEAN kit according to the manufacturer's instructions (Bio 101 ). The concentration and 
purity of the DNA was determined by scanning the DNA at a wavelength of 220 nm to 310 nm on a Beck.man 
DU-64 spectrophotometer. 
A.2.4 LiCI Transformation Procedure and Electroporation 
The transformation of the Bgill cut fragment into P. pastoris was as outlined in the Pichia manual (Invitrogen, 
San Diego), with slight modifications. The yeast strains were grown until the A600 reached 1.2. Cells were 
centrifuged at 5000 rpm for 10 minutes, the cell pellet washed in 100 ml of distilled water, dissolved in 100 ml 
ofLiCl transformation buffer (0.1 M LiCl; 1mMEDTA;0.01 M Tris-Cl, pH 7.4) and incubated at 30°C for 45 
minutes. 1.25 ml of a 2 M DTT stock solution was then added and the cells were incubated at 30°C for a 
further 15 minutes before pelleting at 5000 rpm for 10 minutes. Cells were washed several times in 30 ml of 
ice cold 1 M sorbitol and the final pellet was resuspended in 0.5mlof1 M sorbitol. 
For electroporation, 10 µg of DNA was added to 40 µl of yeast cells and electroporated using a Bio-Rad 
GenePulser at 1.5 kV, 25 µF and 400 ohm. Immediately after delivery of the high voltage pulses, 1 ml of ice 
cold 1 M sorbitol was added and 200 µl aliquots were then spread onto RDB plates (Appendix B). Plates were 
incubated at 30°C for three to five days, or until colonies appeared. 
A.2.5 Screening for Recombinant Clones 
Transformation of the GSl 15 (or SMD1168) strain using the Bgill fragment favours recombination at the 
AOXI locus (Cregg et al. , 1993). The His+ transformants from the RDB plates (used to identify His+ 
transformants) were therefore patched onto minimal methanol (MM) and minimal dextrose (MD) plates 
(Appendix B). The Mut phenotype of the recombinant Pichia was then identified by visual screening for the 
absence of normal growth on the methanol-containing plates. This was then further verified by inoculating the 
clones into MD and MM broth (Appendix B). 
A.2.6 Isolation of Chromosomal DNA 
Yeast cells were grown to stationary phase in 10 ml YPD (1 % yeast extract, 2% peptone, 2% glucose) medium 
at 30°C. Cells were then pelleted at 3000 rpm for 5 minutes and the pellet washed in distilled water. Cells 
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SDS; 100 mM NaCl; 1 mM EDTA; 10 mM Tris-Cl, pH 8.0) and 200 µl of a phenol/chloroform/-
isoamylalcohol mix at a ratio of25:24:1. To this 0.3 g of acid-washed glass beads (Sigma) were added. This 
was vortexed until 90% of the cells were broken (the extent of the cell breakage was determined using a Zeis 
Standard WL Microscope). 200 µl of TE (1 0 mM Tris; 1 mM EDTA, pH 8.0) was then added and the cells 
centrifuged in a micro-centrifuge at 14 000 rpm for 5 minutes. The aqueous layer was then transferred to a 
fresh 2 ml eppendorf tube and chromosomal DNA was precipitated with 100% ethanol. Following 
centrifugation, the pellet was resuspended in TE with the addition of 30 µl of a 1 mg/ml RNAse A solution 
(prepared according to Sambrook et al., 1989). This was incubated at 37°C for 10 minutes. 10 µl of 4M 
ammonium acetate and 1 ml 100% ethanol were added and the DNA again precipitated by centrifugation. The 
DNA pellet was then washed in 70% ethanol, and resuspended in 100 µl TE. The concentration and purity of 
the DNA was tested by scanning the DNA as described in section A.2.3 above. 
A.2.7 PCR Analysis of Pichia lntegrants 
Amplification of this chromosomal DNA (isolated as described in section A.2.6) was carried out using the 5' 
A OXJ and 3' A OXJ sequencing primers (Invitrogen, San Diego). A typical PCR reaction was as follows: 
10 x PCR buffer (Promega) 5 µl 
Chromosomal DNA ( 1 µg) 5 µl 
100 mM dNTPs (25 mM each; Boehringer Mannheim) 
20 pmoles 5' AOXJ primer 
20 pmoles 3' AOXJ primer 
Sterile water 




to 50 µl 
0.25 µl 
An average cycle consisted of a "hot start" of 2 minutes at 94 °C. This was followed by a denaturation step at 
93°C for 20 seconds, an annealing step of 50°C for 30 seconds and an extension step of 72°C for 1 minute. 
After 30 cycles, a final extension step of 5 minutes at 72°C was used. Following PCR, the aqueous phase was 
removed and electrophoresed on a 0.8% agarose gel stained with ethidium bromide for visualisation of the 
PCR bands. 
A.2.8 Large-Scale Protein Expression: Media Composition and Culture Conditions 
Yeast cells containing the cloned gene, or the pPIC9 vector only, were pre-cultivated in 10 ml YPD (1% yeast 
extract, 2% peptone, 2% glucose) medium at 30°C for 24 hours. This pre-culture was then inoculated into a 5 
litre Erlenmeyer flasks containing 500 ml minimal medium (13.4 g/l yeast nitrogen base without amino acids, 
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about 10 7 cells/litre) reached saturation ( 48-72 hours), they were harvested by centrifugation and resuspended 
in 500 ml of minimal medium containing 0.5% (v/v) methanol in place of the glycerol. The incubation was 
continued for a further 7 days, during which time additional methanol (5 ml/litre) was added every 24 hours. 
Cells were harvested by centrifugation, and the supernatant kept. The supernatant was then concentrated by 
ultracentrifugation on an amicon P6 membrane (Amicon Inc., USA). Protein concentrations in yeast media 
were determined using the Bio-Rad assay (Bradford, 1976; Appendix C). 
A.2.9 SDS-Polyacrylamide Gel Electrophoresis (SOS-PAGE) 
SDS-PAGE was performed according to Laemmli (1970) as described (Appendix C). 
A.3 Results and Discussion 
A.3.1 Subcloning into the Yeast Expression Vector pPIC9 
The pPIC9 vector, described in section A.1.3, was used as the cloning vector for the HO insert. The 
synthesised HO insert was removed from the pUC18 vector rather than from pMAL because restriction sites 
present in pUC18 enabled the coding sequences for the HO to be removed without including vector sequences, 
and cutting with PvuII generated a blunt-ended site at the beginning of the gene which could then be cloned 
into the blunt-ended SnaBI site of the yeast vector. 
The insert was therefore removed from pUC18 using Pvull and HindITI. The HindITI site on the insert was 
then blunt-ended by filling in with dideoxy-nucleotide-tri-phosphates using the enzyme Klenow (Boehringer 
Mannheim). The insert was cloned into the SnaBI-linearised pPIC9 and transformed into E. coli strain DHSa 
using the method of Chung and Miller ( 1988). 
Positive clones were identified by PCR screening using the 5' and 3' AOXJ primers (Invitrogen, San Diego). 
PCR products were then electrophoresed on 1 % agarose gels and clones carrying the HO insert were identified 
as an increase in the banding size from 494-bp (control, pPIC9 only) to 779-bp (pPIC9 + HO). 
Since both the vector and the insert were blunt-ended, it is possible for the gene to be inserted into the vector in 
either orientation. To determine which clones had the correct orientation, these 'positive' clones were 'mini-
prepped' (Sambrook et al,. 1989) and the DNA mapped by digesting withXhoI. 
Seven out of the ten positive clones selected contained the correct orientation. Two of these were 'maxi-
prepped' and sequenced to confirm that: 
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• the ATG was in the proper context for eukaryotic translation initiation 
• the HO sequence was correct. 
However, because the distance between the 5' and 3' AOXl primers was so large (741-bp), it was never 
possible to sequence the 5' -HO sequence. Hence, a second primer was designed using the 'Primer' computer 
programme and the following primer sequence was generated. This primed close to the multiple cloning site 
of pPIC9: 
5' AAATACTACTATTGCCAGC 3' 
Once the sequence of the HO and the correct reading frame for the secretion signal had been confirmed, the 
vector was linearised with Bgill for transformation. This generated a fragment that was able to displace the 
chromosomal AOXJ gene by double-crossover recombination (transplacement; see Figure A.3) and, as 
opposed to cutting at other restriction sites (Stu! and Sad), generates the highest frequency of multi-copy 
integrants (Romanos, 1995). 
A.3.2 Transformation of pPIC9-HO into GS115 and Screening of Recombinants 
In order to target the BglII linearised fragment to the AOXJ gene locus in the chromosome, the pPIC9-HO 
DNA was mixed with the LiCl yeast transformation mix. This was then electroporated and the transformants 
selected for histidine prototrophy (His+) on RDB plates (Appendix B). This is possible because the GS115 
yeast strain, a histidine rich autotroph, has been made defective in histidinol dehydrogenase. The pPIC9 
vector, however, contains the his4 gene and thus serves as a selectable marker for transformation. 
As shown in Figure A.3 , correct insertion of the fragment should result in the deletion of the entire AOXJ gene. 
Such alcohol oxidase disruption mutants (Mut8) grow slowly on methanol. The reason these transformants can 
grow on methanol at all is due to the presence of the second alcohol oxidase gene, AOX2, which provides a 
less efficient source of alcohol oxidase (Cregg et al., 1987). 
144 His+ transformants were plated onto MM and MD for determination of their Mut phenotype. However this 
screening was not conclusive as the yeast tended to grow slowly. It was thus difficult to see the difference 
between slow growth and the even slower growth expected for the Muts transformants. The phenotype of 
clones suspected to be Mut8 were thus confirmed by inoculating into MD and MM broth (see Appendix B) in 
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Figure A.4: Screening for the Muf phenotype using MM and MD broth. The positive control (for the 
Muf phenotype) was a strain in which the AOXJ gene had been replaced and expressed the albuman 
gene while the negative control (for the Muf phenotype) was a strain which had the AOXJ gene and 
which expressed the f3-galactosidase gene (both supplied by Invitrogen, San Diego). 
Of the His+ transformants only 8% were Muts. This indicates that in the majority of cases the transforming 
DNA integrates without AOXJ disruption. Similar results have been found by other researchers (Clare et 
al., 1991; Sreekrishna et al., 1989). 
To confirm the phenotypes at the genetic level, PCR was then carried out using the 5' and 3' AOXJ primers. 
To do this, genomic DNA was isolated from the Pichia transformants (both Mut+ and Muts) as well as from 
appropriate controls. Ten microlitre samples from each PCR reaction were then run on 0.8% agarose gels 
(Figure A.5). The differences between Muts and Mut phenotypes on the genetic level can easily be identified. 
Lane 6 (pPIC9 only) shows the presence of a single 494-bp band which is the size of the pre-pro a - factor and 
the multiple cloning region (see Figure A.2). In lane 5, the GSl 15 shows the presence of a 2.2 kb band which 
is the size of the AOXJ gene. From the Pichia transformants in lanes 1-4, it can be seen that lanes 1,3 and 4 
contain the insert as there is an 779-bp (size of pPIC9 region+ HO) band present. Of these, only lane 1 is 
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Figure A.5: 0.8% agarose gel showing the results of PCR amplification of chromosomal DNA from 
transformants. Lanes 4 - 7, Pichia transformants; 3, GSl 15 PCR product; 2, pPIC9 only; 1, molecular 
weight marker, lambda DNA digested with Hind!!! and EcoRI. 
A.3.3 Screening for High Levels of Expressed Protein. 
Cregg et al. (1993) have shown that independently isolated P. pastoris strains transformed with the same 
expression vector routinely display a range of product levels. Tbis clonal variation has been observed even 
with clones containing the same number of expression cassettes (Cregg et al. , 1993). Thus, in order to 
determine which clones give the best product expression levels, it is necessary to screen a significant number 
of transform.ants. 
A small-scale expression study was therefore carried out. For this test, 10 ml cultures of a number of both 
Mut5 and Mut+ clones, containing the insert, were grown to an OD of 17 (8 .5 x 108 cells/ml). The optical 
density of the medium at 600 nm (OD600) was used to estimate the cell density, assuming that 1 OD600 is 
equivalent to 5 x 107 cells/ml. Once this OD was reached, the cells were placed in 10 ml minimal media 
containing methanol in 100 ml volume Erlenmeyer flasks for a further 2 days. Extracts of the cell medium, 
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In all the clones tested the levels of HO in the culture medium were found to be < 0.001 µg/ml in the YNB 
minimal medium. There was also no difference between the Mut and the Muts strains (results not shown). 
Similar results were obtained with all other clones tested. The lack of expression could be due to a number of 
reasons, for example: 
• The flasks used in this expression may have been too small for adequate aeration. This is a critical 
requirement for Pichia expression, as dissolved molecular oxygen is necessary for growth in methanol (J. 
M. Cregg, personal communication). 
• Induction in methanol was only carried out over 48 hours. This may not have been sufficient for large 
scale production of the inhibitor. 
• Richer medium containing yeast extract and peptone may be better for expression. Clare et al. ( 1991) 
showed that yeast induced in rich media produced higher levels of mouse epidermal growth factor than 
yeast grown in minimal media. 
From the above results, it was clear that the culture conditions for growth of the yeast needed to be fully 
optimised. 
A.3.4 Optimisation of the Culture Medium for Expression 
The first step in the optimisation process involved a study of different media. Often different media may be 
optimal depending on the particular protein being expressed. For example, Clare et al. (1991) found yields of 
mouse epidermal factor to be higher in richer media (B!\.1MY) than minimal media (Appendix B), however, 
they found that proteolytic degradation of their expressed protein was less of a problem in the minimal media, 
especially if supplemented with casamino acids. Hence, it was decided to test a range of transformants in 
BMGY media (Appendix B). This rich medium contains yeast extract and peptone. Transformants were 
grown as 100 ml volumes in 1 litre Erlenmeyer flasks to provide good aeration. Cultures were grown in this 
BMGY medium containing glycerol at 30°C until a large cell density of about 8.5 x 108 cells/ml (17 OD units) 
was obtaip.ed. Cultures were then resuspended in fresh volumes of the same medium, but containing 0.5% 
methanol instead of glycerol as the sole carbon source. Aliquots were withdrawn on each day to determine the 
extent of HO production by SDS-PAGE. However, an analysis of the results showed similar low levels of 
expression to that observed in minimal media. 
Romanos ( 1995) observed that heterologous secretion is more demanding than intracellular expression and is 
not guaranteed to work. Sometimes the secretory pathway can be blocked due to malfolding of the protein 
(Romanos et al., 1992). Thus, to determine whether such a breakdown in the secretary system had occurred in 
this case, the cellular fraction was analysed. Extracellular and intracellular protein preparations were extracted 
according to the method of La Grange (1995). Proteins retained in the periplasmic space were also isolated by 
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had occurred. However, SDS-PAGE analyses of the cellular and periplasmic fractions showed no HO protein 
(results not shown). 
A further· point to note, however, was that any HO protein expressed was observed on day 1 of expression in 
methanol. None or very little HO protein was detected in the medium beyond day 2. It appeared therefore, 
that the low yields could be a result of proteolysis. Romanos (1995) observed proteolysis to be a common 
problem in the expression of many proteins in yeast. Proteolysis rather than a lack of oxygen was considered 
the most likely problem since: 
• no 'fermentation odours' were detected in the yeast culture which might indicate anaerobic metabolism 
• no increase in protein yield was seen even if molecular oxygen was bubbled into the culture vessel. 
There are a number of options available to minimise protein degradation. Clare et al. (1991) demonstrated that 
the yield of mouse epidermal growth factor could be improved by firstly, adding 1 % casamino acids to the 
medium, and secondly, by buffering the YNB medium to pH 6.0 using a phosphate buffer (Clare et al., 1991). 
Proteolysis of human immunodeficiency virus type I envelope glycoprotein, on the other hand, was minimised 
by maintaining a low pH (Scorer et al., 1993). 
In this study, proteolysis of the HO inhibitor was observed even though the cells were cultured in buffered 
medium (pH 6.0) containing the peptide components of yeast extract and peptone. The addition of 3% 
casamino acids to either medium did increase the amount of HO produced (results not shown), but a decrease 
in the protein concentration with time was still observed (Figure A.7). 
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Figure A. 7: Yeast strain GSJ 15 carrying the pPIC9-HO integrated plasmid was grown for 6 days. 
Aliquots of the media were removed on each day, the A600 was read and after pelleting the cells, the 
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Whether this proteolysis was occurring during or after secretion into the yeast medium was not clear. Human 
albumen (Bathurst et al., 1987) andAspergi1lus glucoamylase (Innis et al., 1985) which were secreted from S. 
cerevisiae, have been shown to be processed by the KEX2 protease during secretion. P. pastoris, as mentioned 
previously (section A.1.2), also possesses an analogue to KEX2 protease during secretion (Buckholz and 
Gleeson, 1991). This KEX2 protease of S. cerevisiae exhibits a substrate specificity toward the carboxyl sides 
of Lys-Arg, Arg-Arg and Pro-Arg sequences (Mizuno et al., 1989). These cleavage sites are not, however, 
present in the HO sequence. Thus, if the substrate specificity of the KEX2 homologue of P. pastoris is 
identical to that of KEX2 of S. cerevisiae, unknown protease(s) rather than the KEX2 homologue must be 
responsible for the breakdown of the protein product. 
A.3.5 Approaches to Reduce Proteolysis 
Romanos et al. (1992) have reported that the proteolysis of some secreted products could be reduced by using 
the protease-deficient strain SMDl 168 i.e. deficient in a gene (PEP4) that is homologous to protease A in S. 
cerevisiae. I therefore decided to try this option. 
By using YNB medium that had been buffered to pH 6.0 and supplemented with 3% Casamino acids, secreted 
HO levels were increased to approximately 0.055 µg/ml. These levels are still disappointing, partic:ularly since 
levels of expression of some proteins in this yeast system have been as high as 4 g/l as in the case of human 
serum albumin (Barr et al., 1992). Discussions with others at a Pichia expression conference in San Diego, 
California, indicated that not all proteins could be expressed in Pichia and in such cases, other expression 
systems should be considered. Other possible reasons for the poor expression levels are outlined below: 
The use of a fermenter might have been better for large scale production. Romanos et al, (1991) found 
that due to oxygen limitation, P. pastoris shake-flask inductions are often sub-optimal when compared to 
fermenter inductions. 
-
2 A second problem could be RNA truncation. Some consensus sequences considered to be a problem in S. 
cerevisiae (which may be similar in P. pastoris), include (TAG) .. (T rich) .. TA(T)GT .. (A + T rich) .. TTT 
(Zaret and Sherman, 1984) and TTTTTATA (Henikoff and Cohen, 1984). Scorer et al, (1993) found 
termination to be a problem when attempting to express the HIV-1 envelope glycoprotein in yeast. This 
protein had AT-rich consensus sequences similar to the problematic TTTTTATA sequence. The HO 
sequence also contains many AT runs, for example: 151. •••••••••••••• 160 
5' TTTATTATTT 3' 
3 The HO gene codon usage had been optimised for expression in bacteria rather than yeast. According to 
Hadfield et al. (1983), a major factor influencing translational efficiency in the expression of foreign 
genes in yeast, is codon usage. To determine whether the codon usage for the HO gene was sufficient for 
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The CBI is a measure of directional codon bias towards the use of 25 out of the 61 possible codons for the 
20 amino acids. It measures the occurrence of any of the 25 optimal codons in a gene sequence. This 
reaches a maximum value of 1.0 in a gene with extreme codon usage. If all the possible codons for amino 
acids are used equally, the CBI value is 0.0. A negative value indicates the occurrence of very few 
optimal codons in a specific gene (Sharp & Cowe, 1991 ). The codon bias for the HO gene in yeast was 
0.311. This is not optimal for yeast (W.H. van Zyl, personal communication), and hence the presence of 
the minor codons may have resulted in limited translation owing to the demand placed upon rare tRNAs, 
thus resulting in low concentrations of recombinant HO protein. Temporary but specific pauses during 
polypeptide elongation have been attributed to secondary structure formation on mRNA. These 
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Appendix B : Media, Buffers and Solutions 
8.1 Bacterial Media 
B.1.1 Luria-Bertani Medium (LB) 
Bacto-tryptone 10 g 
Yeast Extract 5g 
NaCl 5g 
Sterilise by autoclaving 
For Luria agar media, add agar to L5% before autoclaving. 
B.1.2 M9ZB Media 
Bacto-tryptone 10 g 
Glucose 40 g 
MgS04,7H20 20 g 
KH2P04 30 g 
~Cl 10 g 
Na2HP04 60 g 
NaCl 50 g 
pH to 7.2 
B.2 Yeast Media 
B.2.1 RDB Plates 
Dissolve 186 g sorbitol and 20 g agar in 700 ml of water and autoclave. When cool the medium is maintained 
at 45 °C and a prewarmed mix of the following solutions are added: 
100 mls 20% Dextrose 
100 mls 10 x YNB (13,4% yeast nitrogen base with ammonium sulphate and without amino 
acids) 












l 0 mls 100 x amino acids* 
88 ml sterile water 
* 100 x Amino Acids 
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Dissolve 500 mgs each of L-glutamic acid, L-methionine, L-lysine, L-leucine, and L-isoleucine in 100 mls of 
water. Filter sterilise and store at 4°C. 
B.2.2 YPD 
10 g yeast extract 
10 g peptone 
100 ml 20% Glucose stock solution 
Distilled Water to 1000 ml 
B.2.3 Minimal Methanol (MM) Media 
1.34% YNB 
4 x 10-5 % biotin 
0.5% methanol 
B.2.4 Minimal Dextrose {MD) Media 
1.34% YNB 
4 x 10-5 % biotin 
1% dextrose 
To make plates, 15 g/l agar is added to the above solutions 
B.2.5 BMGY 
1 % yeast extract 
2% peptone 
100 mM potassium phosphate, pH 6.0. 
1.34% YNB 
4 x 10-5 % biotin 
1% glycerol 
B.2.6 BMMY 
1 % yeast extract 
2% peptone 
100 mM potassium phosphate, pH 6.0. 
1.34% YNB 
4 x 10-5 % biotin 
0.5% methanol 
B.2.7 Minimal Media for Large Scale Protein Expression 
1.34% YNB 
4 x 10-5 % biotin 
100 mM potassium phosphate, pH 6.0. 












8.3 Enzyme Assay Solutions 
B.3.1 4 x Papain Assay Buffer 
350 mM KH2P04 
50 mM Na2HP04 
4mMEDTA 




2 mM DTT (Dithiotbreitol) is added just before use. 
B.3.2 0.1°/o (m/v) Brij 35 
0.5 g Brij 35 
Distilled water to 500 ml 
B.3.3 1 mM Substrate Solution 
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Dissolve 1 mg Z-Phe-Arg-AMC in 1.5 ml DMSO (Dimethyl sulphoxide ). Stock solutions were aliquoted and 
stores at -20 C. Solutions were thawed for use and diluted to working concentrations 
B.3.4 20 µM Substrate Stock Solution 
Stock substrate solution (100 µl) was diluted to 5 ml with distilled water. Solutions were discarded after use. 
B.3.5 10 mM E-64 Stock Solution 
E-64 (3.8 mg) was disoolved in 100 µl DMSO and diluted to 1 ml with distilled water. This stock solution 
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APPENDIX C : General Techniques 
C. 1 10% Non-denaturing Polyacrylamide gel electrophoresis · 
Non-denaturing polyacrylamide gels were nm using a Hoefer SE600 vertical slab electrophoresis unit (Hoefer 
) 
Scientific Instruments, San Fransisco, USA). 
Acrylamidea 33.3 
10 x TBEb 20 
10% Ammonium persulphate 0.7 
TE MED 0.035 
Distilled Water to 100 mls 
a30% Acrylamide stock solution 
• 29 g acrylamide 
• 1 g N, N' -methylenebisacrylainide 
blO x TBE (i 1) was made as follows: 
• 216 g Tris-base 
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C.2 SOS Polyacrylamide gel electrophoresis (SOS-PAGE) 
Discontiriuous SDS-PAGE was done according to the method of Laemmli (1970), using a Hoefer SE600 
vertical slab electrophoresis unit (Hoefer Scientific Instruments, San Fransisco, USA). Gel spacers were 1.5 
mm thick. 
Component ;··. Millilitres · 
. 
13% Resolving Gel 
30% Acrylamide (as above) 20 
1.25 M Tris, pH 8.8 12.5 
10% SDS 0.5 
10% Ammonium persulfate 0.5 
TE MED 0.02 
Distilled Water to 50 mls 
6.7% Stacking Gel 
30% Acrylamide 1.7 
0.375 M Tris, pH 6.8 1.25 
10% SDS 0.1 
10% Ammonium persulfate 0.1 
TE MED 0.01 
Distilled Water to 10 mls 
SDS-PAGE tank and loading buffers were as described by Laemmli (1970) 
C.3 Western Blotting 
For the Western blotting assay, proteins were transferred by the electroblotting procedure to a nitrocellulose 
filter (Amersha.m International) according to the method of Towbin et al., (1979). Electrotransfer was carried 
out using a Hoeffer Transphor (TE 42) unit in transfer buffer (0.196 M glycine, 0.025 M Tris, and 20% 
methanol, pH 8.3) at constant voltage (20 V) for 6 hours at 4°C. Once blotted and dried, the nitrocellulose 
membrane was then blocked in phosphate buffered saline (1 x PBS; phosphate buffered saline) containing 
4,5% milk powder for 1 hour at room temperature. The primary antibody was then added (at dilutions as 
indicated in the relevant sections). Incubation was for 1 hour at room temperature. The blot was then washed 
three times in wash solution (1 x PBS + 0.5% Tween 20). The primary antibody was detected with a 
secondary antibody conjugate (goat anti-rabbit IgG conjugated to alkaline phosphatase; Sigma), at a 1/5000 
dilution. The membrane was washed again with three 10 minute washes in 1 x PBS containing 0.5% Tween 
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substrates, BCIP and NBT (Sambrook et al., 1989). Colour was allowed to develop, in the dark, at room 
temperature and stopped by washing the nitrocellulose membrane in deionised water. 
C.4 Biorad Protein Assay 
Protein concentrations were determined according to the instructions in the Bio-Rad Laboratories manual 
which is based on the method of Bradford (1976). Two standard curves were prepared in triplicate using BSA 
fraction V (Boehringer Mannheim.) as the protein standard. Microgram dilutions of this BSA were made and 
the volume made up to 800 millilitres with distilled water or the buffer the protein to be determined was 
dissolved in. To this was added 200 µl BioRad dye reagent concentrate. The tubes were then mixed by 
vortexing and incubated at room temperature for 20 minutes. The OD595 was then read against the reagent 
blank (water+ dye reagent). The OD595 versus the standard concentrations was then plotted and the regression 
curve (y=mx+c) was determined using the computer software package Microsoft Excel for Windows 95 
(Microsoft, USA). 
C.5 Inhibitory Assays of Column Fractions 
Assays for inhibitory activity were carried out using the fluorimetric substrate Z-Phe-Arg-NHMec as described 
by Barrett and Kirschke (1981). 200 pM papain was incubated with papain assay buffer (87.5 mM KH2P04, 
12.5 mM Na2HP04, 2 mM DTT, 4 mM EDTA, pH 6.8) and water (in the case of the control samples) or 20 µl 
of column samples, for 20 minutes at 30°C. For all assays percent inhibition was expressed as a percentage 
using the equation: 
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APPENDIX E: Kinetic Data 
E.1. Active-Site Titrations 
E.1.1 Papain Active site Titration 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average 
Cone. Vo 
(µME-64) 
Vo ri Vo fL Vo r ·-
0 8.02 X 10-H 0.9999 8.13 x 10-8 0.9992 8.18 x 10-8 0.9999 8.11 x 10-8 
1 6.84 x 10-8 0.9974 7.26 x 10-8 0.9999 6.55 x 10-8 0.9999 6.88 x 10-8 
2 6.24 x 10-8 0.9998 6.34 x 10-8 0.9992 6.08 x 10-8 0.989 6.23 x 10-8 
3 4.93 x 10-8 0.9996 5.21x10-8 0.9999 5.27x10"8 0.9994 5.14x 10-8 
4 4.22 x 10-8 0.9998 4.19 x 10"8 0.9949 4.47 x 10-8 0.9997 4.29 x 10-8 
5 3.15 x 10-8 0.9986 3.54 x 10"8 0.999 3.57 x 10"8 0.9937 3.42 x 10-8 
6 2.78 x 10"8 0.999 2.58 x 10-s 0.9974 2.35 x 10"8 0.9989 2.57 x 10-8 
7 1.55 x 10-8 0.9986 1.35 x 10-8 0.9952 1.43 x 10-8 0.9934 1.44 x 10-8 



























Figure E.1: Standardisation of papain by titration with E-64. A solution of papain (JO µM) was 
prepared from the commercial product and titrated with E-64 as described in section 6.2.2. The 
extrapolated linear regression curve intercepted the abscissor at a point corresponding to a papain 
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E.1.2 Chicken Cystatin Active-Site Titration 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average Stddev 
Cone. Vo 
(ng Vo r2 Vo Vo 
Chicken) 
0 1.14 x 10-1 0.9997 1.11 x 10-' 0.9999 1.13 x 10-/ 0.9999 1.13 x 10-1 0.002 
100 9.24 X 10-H 0.9992 9.54X10-H 0.9997 9.66 X 10-H 0.9998 9.48 X 10-H 0.002 
200 7.4 X 10-H 0.9997 7.06 X 10-H 0.9995 7.38 X 10-H 0.9999 7.28X10-H 0.0019 
300 5.64 X 10-H 0.9999 5.89 X 10-H 0.9997 5.66 X 10-H 0.999 5.73 X 10-H 0.00013 
400 3.99 X 10-H 0.9990 3.66 X 10-H 0.9992 3.98 X 10-H 0.9999 3.88 X 10-H 0.0002 
500 2.22 X 10-H 0.9999 1.22 X 10-H 0.9985 1.04 X 10-H 0.9999 1.28 X 10-H 0.0002 
600 1.59 X 10-H 0.992 1.21X10-H 0.999 1.03 X 10-H 0.9999 1.28 X 10-H 0.003 









50 100 150 200 250 300 350 400 450 
ng Chicken CystaUn added 
Figure E.2: Active-site titration of chicken cystatin using E-64 standardised papain. Papain was 
incubated with chicken cystatin for 30 minutes at 30 'C and residual enzyme activity was detected by 
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E.1.3 Oryzacystatin I Active-Site Titration 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average Std dev 
Cone. Vo 
(µg OCI) 
Vo r2 Vo r2 Vo rz 
0 7.44 X 10-s 0.9997 7.08X10-s 0.9969 7.01X10-s 0.9981 7.17 X 10-s 0.003 
200 5.69 X 10-s 0.9992 5.94 X 10-s 0.9998 5.97 X 10-s 0.9997 5.87 X 10-s 0.0016 
400 4.4 X 10-s 0.996 4.36 X 10-s 0.9997 4.38 X 10-8 0.9995 4.38 x I 0-8 0.0002 
600 3.11 X 10-s 0.9992 3.12 X 10-s 0.9993 3.4 X 10-s 0.9992 3.11X10-s 0.0017 
800 1.42 X 10-s 0.9994 1.4 X 10-s 0.9992 1.53 X 10-s 0.9995 1.45 X 10-s 0.9994 











100 200 300 400 500 600 700 800 800 
ng of OC I protein added 
Figure E.3: Active-site titration of OC I against E-64 standardised papain. Papain was incubated 
with OC I for 30 minutes at 30 't:' and residual enzyme activity was detected by continuous fluorimetric 
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E.1.4 Fusion Active Site Titration 





Vo r Vo r Vo r' 
0 8.37 X 1o·H 0.9981 8.49 X 10·H 0.9998 9.31X10·H 0.9998 8.72 X 10·H 0.0051 
500 6.85 X 1o·H 0.9973 6.53X10·H 0.9995 7.02 X 10·H 0.9984 6.8 X 10·H 0.002 
1000 5.34 X 1o·H 0.9988 5.73 X 10·H 0.9954 6.32 X 1o·H 0.9977 5.79X10·H 0.005 
1500 3.64 X 10·H 0.9998 3.42 X 1 O~H 0.9996 3.48 X 10·H 0.9995 3.64 X lQ"H 0.0011 
2000 2.71 X 10·H 0.9999 2.66 X 1o·H 0.9999 2.84 X 10·H 0.9997 2.74 X 10·H 0.0009 












0 200 400 600 800 1000 1200 1400 1600 
ng HO-MBP added 
Figure E.4: Active-site titration of HO-MBP fusion against E-64 standardised papain. Papain was 
incubated with the fusion for 30 minutes at 30 ~ and residual enzyme activity was detected by 
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E.1.5 Hybrid Orvzacystatin (Cut with Fxa) Active Site Titration 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average Std dev 
Cone. Vo 
(nMHO) 
·- __ ...;.. . -· 
Vo r.l Vo ri Vo ri 
0 9.48 x 10·• 0.9997 9.41 x 10·• 0.999 9.35 x 10·• 0.9998 9.41x10·• 0.0006 
500 7.93 x 10·• 0.9996 7.9 x 10·• 0.9997 7.60x10·• 0.9993 8.06x10-" 0.0018 
1000 6.21 x 10·• 0.9999 5.57x10·• 0.9991 6.17 x 10·• 0.999 5.98x10·• 0.0035 
1500 4.09 x 10·• 0.9999 4.26 x 10-" 0.9997 3.6 x 10·• 0.9989 3.98 x 10-• 0.0034 
2000 2.88 x 10·· 0.9998 2.79 x 10-• 0.9999 2.61 x 10·• 0.9996 2.76 x 10·• 0.0014 
2500 6.9 x 10-~ 0.9979 1.1 x 10-~ 0.9968 1.04 x 10·· 0.9968 9.49 x 10-~ 0.0022 











0 500 1000 1500 2000 2500 
ng HO added 
Figure E.5: Active-site titration of HO against E-64 standardised papain. Papain was incubated with 
HO for 30 minutes at 30 CC and residual enzyme activity was detected by continuous.fluorimetric assays 
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E.2 Determination of Km and Vmax Values for Papain 
c Experiment 1 · Experiment 2 Experiment 3 Average Stddev 
Vo 
Vo r ·vo r Vo r·l 
1.5 2.53 x 10-• 0.998 2.73 x 10-• 0.999 2.68 x 10-• 0.994 2.64 x 10-1 0.01 
3.75 4.20x10-s 0.999 3.83 x 10-" 0.998 3,71 x 10-· 0.998 3.77x10·• 0.0025 
7.5 1.23 x 10·7 0.999 1.24 x 10-7 0.999 1.21x10-/ 0.999 1.23 x 10-/ 0.0016 
15 3.12 x 10·1 0.999 3.03x10·1 0.999 2.94 x 10-' 0.999 3.03x10-1 0.0092 
22.5 4.64 x 10"7 0.999 4.32 x 10"7 0.999 4.54 x 10-7 0.999 4.5o x 10-1 0.016 
30 6.36 x 10-1 0.999 6.01x10-1 0.999 5.81x10-1 0.999 6.08 x 10-1 0.02 
45 6.65 x io-I 0.999 7.25 x 10-7 0.999 6.86 x 10·1 0.999 6.92 x 10-1 0.03 
75 8.16 x 10-1 0.999 8.01x10-1 0.999 7.98x 10·' 0.993 8.05x10-
1 0.009 
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E.3 Determination of Equilibrium Constants (Ki) 
E.3.1 Data For K1 Determination of the Hybrid Protein 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average 
Cone. Vo 
(nMHO) Vo r" Vo r" Vo t' 
0 2.03x10·9 0.9999 1.42 x 10·9 0.9999 1.95 x 10·9 0.9999 1.49 x 10·9 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average 
Cone. Vi 
(nMHO) Vi r2 Vi r2 Vi ri 
8 3.46 x 10·11 0.9998 2.98 x 10-11 0.9997 3.22 x 10·11 0.9995 3.22 x 10·11 
16 3.56 x 10·11 0.9998 2.81x10·• 1 0.9991 3.72 x 10-11 0.9993 3.38 x 10"8 
24 3.47 x 10·11 0.9993 3.23 x 10-11 0.9991 3.26 x 10·11 0.9998 3.32x10·11 
32 3.22 x 10·11 0.999 3.09 x 10·11 0.9992 3.26 x 10·11 0.9991 3.19 x 10·11 














4.66 x 10·9 
Std dev 
2.40 X 1o·IZ 
4.83 X 10·IZ 
1.310 X 10·U 
8.89x10-Jj 
1.68 x 10· 1 ~ 
4.10E+01 4.20E+01 4.30E+01 4.40E+01 4.50E+01 
VJV1 
4.60E+01 4.70E+01 4.80E+01 4.90E+01 



























Experiment 1 Experiment 2 Experiment 3 Average 
Vo 
Vo r' Vo r' Vo r 
8.14 x 10-" 0.999 8.15xlo- 0.998 8.01 x IO-" 0.999 8.10 x 10·" 
11 
Experiment 1 Experiment 2 Experiment 3 Average 
Vi 
Vi r' Vi r Vi r' 
6.96x10·11 0.999 6.78 x 10·11 0.998 7.08 x 10·11 0.999 6.94x10·11 
6.88 x 10·11 0.999 6.73 x I0-11 0.999 6.1x10·11 0.996 6.57 x 10·11 
6.46 x I0-11 0.999 6.96 x 10·1• 0.999 6.26x10·11 0.999 6.56 x 10·11 
6.31x10· 11 0.999 5.97 x 10·11 0.998 6.5 x 10·• 1 0.991 6.26 x 10·11 















1.39 X 10-IZ 
2.06 x 10·11 
3.61x10·12 
2.69 x 10-12 
1.39 x 10·11 
1.15E+02 1.20E+02 1.25E+02 1.30E+02 1.35E+02 1.40E+02 
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E.3.3 Data For Ki Determination of Oryzacystatin I 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average Stddev 
Cone. Vo 
(nMOCI) Vo r1 Vo r1 Vo fl 
0 4.03x10·11 0.999 4.25 x 10·11 0.999 4.3 x 10·11 0.999 4.2 x 10·11 1.41 x 10·10 
Inhibitor Experiment 1 Experiment 2 Experiment 3 Average Std dev 
Cone. Vi 
(nMOCI) Vi r:t Vi r' Vi r:t 
20 4.03 x 10·11 0.997 3.96 x 10"" 0.999 3.71x10"" 0.998 3.9 x 10-ll 1.67 x 10·1< 
40 3.46 x 10-" 0.999 3.89 x 10-" 0.999 3.75 x 10"" 0.999 3.7 x 10-11 2.19 X 10-u 
60 3.71x10-11 0.999 3.39 x 10·11 0.998 3.16 x 10-" 0.997 3.42 x 10"" 1.63x10"1" 
80 3.23 x 10·11 0.999 2.97 x 10-11 0.999 3.11 x 10·11 0.999 3.09 x 10·11 9.89 x 10-IJ 
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0.00E+OO 5.00E-10 1.00E-09 1.50E-09 2.00E-09 2.50E-09 
Chicken cystatin (M) 
Figure E.10: Plot of kobs versus inhibitor concentration for chicken cystatin. 
